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Introduction 
THE HINT RESEARCH GROUP 
It is now well accepted that the role of newly 
developed drugs used in the clinical management 
of patients needs to be evaluated in properly designed 
randomised clinical trials. In 1980, the Interuniversity 
Cardiology Institute of the Netherlands initiated the 
Holland Interuniversity Nifedipine/metoprolol Trial 
(HINT). The objective of this randomised, double-
blind, multicentre trial was to evaluate the effec-
tiveness of nifedipine (a calcium antagonist) and 
metoprolol (a beta blocker) in preventing recurrence 
of ischaemia or progression to myocardial infarction 
in patients suspected of having unstable angina at 
hospital admission, a topic which at that time had 
not been well investigated. The trial was designed to 
follow cardiologic practice as closely as possible. In 
particular, patients were entered as soon as unstable 
angina was suspected at hospital admission, without 
waiting for enzyme assessments to exclude evolving 
myocardial infarction. 
The first patient was enrolled on 1 February 1981. 
On 30 October 1984 patient enrolment was discon-
tinued because an interim analysis suggested that the 
risk of myocardial infarction was higher in patients 
assigned to nifedipine than in patients treated with 
the other trial medications. The main findings have 
been published previously[11• This supplement of the 
European Heart Journal provides a more detailed 
report. 
In chapter 1 the pathophysiology of unstable 
angina pectoris is delineated. Special attention is 
given to new insights developed since 1980. An 
overview of anti-anginal drugs is provided. In addi-
tion, strategies and concepts in patient management 
in unstable angina are sketched. Principles of inter-
vention research are outlined in chapter 2. It is 
stressed that the objective of a clinical trial is to obtain 
a valid and precise estimate of the magnitude of the 
treatment effect(s) at issue. The requirements for 
validity of methodology are formulated. Further-
more, the concept of scientific generalization is 
touched upon. In chapter 3 eligibility and patient 
enrolment in HINT are described. A profile of 537 
randomised patients who satisfied the eligibility cri-
teria in terms of descriptive baseline characteristics is 
given. In chapter 4 the trial regimens and methods of 
data collection are described. The occurrence of 
recurrent ischaemia or myocardial infarction within 
the first 48 hours is documented for each trial 
medication group separately. In addition, findings of 
subsequent angiography are presented. Chapter 5 is 
concerned with data analysis. A short introduction 
to data analysis is provided. The need to use risk 
summarization in the assessment of baseline com-
parability is stressed. Stratified analysis is employed 
to obtain estimates of the treatment effects that have 
been adjusted for incomparability in baseline risk. 
Subgroup analyses to identify subgroups of patients 
in whom different treatment effects may be operating 
are described. The study organization is the subject of 
chapter 6. The various committees and their responsi-
bilities and functioning are described, as is the 
organization within the Clinical Centres and the 
Coordinating Centre. Special attention is paid to data 
management and quality control. Chapter 7 docu-
ments monitoring of the ongoing trial. Full details 
on the interim reports on treatment effects are 
provided. In chapter 8 recent evidence from clinical 
trials in the treatment of patients with prolonged 
anginal pain at rest is reviewed. A general discussion 
of the HINT findings in the light of practice today is 
provided in chapter 9. 
Reference 
[I] Early treatment of unstable angina in the coronary care 
unit: a randomised, double-blind placebo-controlled 
comparison of recurrent ischaemia in patients treated 
with nifedipine or metoprolol or both. The HINT 
Research Group. Br Heart J 1986; 56: 400--13. 
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1 Unstable angina pectoris 
J. G. P. TussEN, M. L. SrMOONs, P. J. DE FEIJTER, P. G. HuGENHOLTZ AND J. LussEN 
Angina pectoris 
The term angina pectoris was first used by William 
Heberden, who described the characteristics of the 
syndrome in a report published in 1772rll_ He wrote: 
There is a disorder of the breast, marked with strong and 
peculiar symptoms, considerable for the kind of danger 
belonging to it, and not extremely rare, of which I do not 
recollect any mention among medical authors. The seat of 
it and sense of strangling and anxiety with which it is 
attended, may make it not improperly be called angina 
pectoris. 
Those who are afflicted with it, are seized while they are 
walking, and more particularly when they walk soon after 
eating, with a painful and most disagreeable sensation in 
the breast, which seems as if it would take their life away if 
it were to increase or to continue: the moment they stand 
still, all this uneasiness vanishes. In all other respects the 
patients who are at the beginning of this disorder are per-
fectly well, and in particular have no shortness of breath, 
from which it is totally different. 
As described by Heberden, angina pectoris was a 
symptom complex; there was no implied association 
with the heartr21. It was C. H. Parryr3l who first 
proposed in 1799 that the pain was due to the heart 
being provided with a blood supply less than it 
required, particularly on exerciser41 • Today, the term 
is still used to describe a symptom, but one which 
is thought to be the consequence of myocardial 
ischaemia r2l_ A transient and reversible inadequacy 
of the coronary circulation gives rise to that type of 
chest pain known as angina pectorisr21 . The stimulus 
to the pain is thought to originate from the myo-
cardium becoming ischemic. If the reduction in coron-
ary blood flow is so severe as to cause death of an 
area of the myocardium, the pain is usually more 
severe and prolonged [21_ 
Anginal pain has four major attributes: its char-
acter, its location, its relation to exercise, and its 
duration [21. Anginal pain usually conveys a sense of 
strangling; other adjectives include 'constricting', 
'burning', 'sharp'. Many patients deny actual pain 
but refer only to a sense of discomfort or tightness of 
the chest. The site of the pain is usually retrosternal 
but radiation is common, in particular to the left arm. 
Angina pectoris is usually provoked by exertion but 
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may also be induced by emotion, anger, or cold 
environment. Most attacks are short-lived, dissipat-
ing after cessation of the precipitating activity. 
In most patients, angina pectoris can be identified 
by analyzing the symptoms related by the patient. 
The fact that the pain of angina is not uniform and 
that other entities can mimic it makes the differentia-
tion of other disorders from angina pectoris at times 
difficult. It is well known that certain emotional, 
· gastrointestinal, pulmonary, and non coronary cardio-
vascular conditions may also produce chest pains that 
resembles angina. In most of these disorders angina 
pectoris can be excluded by a careful history and 
physical examination. Yet, considerable skill on the 
part of the physician is required to identify the par-
ticular variety of chest pain that is caused by myo-
cardial ischaemia. 
Angina pectoris as described above may be con-
sidered a causally defined disease entity-for the 
defining criterion hinges on myocardial ischaemia as 
the cause of the chest pain. From the practical point 
of view, however, angina pectoris must be considered 
a clinical syndrome, the diagnosis of which is based 
on the presence of a variety of clinical symptoms. 
In fact, no well-defined series of nosographic 
characteristics defining angina pectoris is available. 
Thus, the diagnostic reasoning in establishing angina 
pectoris contains interrelated elements of pattern 
recognition, causal reasoning, and probabilistic 
thinking. 
Attacks of angina pectoris are commonly provoked 
by effort or emotional stress. But angina pectoris may 
also occur at rest without an apparent precipitating 
cause. Angina pectoris (of effort) is said to be stable 
when there has been no change in the frequency, 
duration, or precipitating factors during the preced-
ing 60 daysr51. All other presentations of angina 
pectoris are subsumed under the heading 'unstable 
angina'. 
The most frequently recognised underlying cause 
of myocardial ischaemia (and thereby of angina pec-
toris) is obstructive coronary atherosclerosis. But it 
may also be caused by nonatherosclerotic cardiac 
disease such as severe aortic valve disease, hyper-
tension, or even congenital disorders. Furthermore, 
vasoconstriction of the larger coronary vessels, 
whether or not superimposed on an atherosclerotic 
© 1987 The European Society of Cardiology 
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plaque, may also cause myocardial ischaemia. 
Finally, a decrease in arterial oxygen content, which 
can result from anaemia or pulmonary dysfunction, 
may precipitate myocardial ischaemia. 
The remainder of this chapter is concerned with 
atherosclerotic coronary heart disease-that is, coron-
ary atherosclerosis and its clinical manifestations. 
Pathophysiology of atherosclerotic coronary heart 
disease 
PATHOLOGY OF CORONARY ATHEROSCLEROSIS 
Coronary atherosclerosis is a pathological con-
dition of the coronary arteries characterised by 
abnormal lipid and fibrous tissue accumulation in the 
vessel wall with resulting disruption of the vessel 
architecture and function r5l. These atheromatous 
lesions or atherosclerotic plaques have a necrotic 
centre of fatty debris-the atheroma--covered by a 
fibrous cap. The density and thickness of the 
overlying cap may vary considerably. These focal 
plaques may become thick and encroach upon the 
lumen of the coronary artery. In addition, the fibrous 
cap may rupture, which may lead to ulceration of the 
necrotic core. platelet aggregation, and fibrin deposi-
tion (thrombus formation). The thrombus itself is 
biologically unstable. Lysis. fragmentation, pro-
gression to an occlusive thrombus, or incorporation 
lie ahead r6- 9 l. Plaque rupture may also cause vaso-
constriction either mechanically or chemically via 
vasoconstrictive substances released from aggregated 
platelets at the rupture siter6 · 10l. 
There are currently at least two schools of thought 
regarding the initiating factors in the formation of 
coronary atherosclerosis r111. The first believes in the 
endothelial injury theory where a minor lesion on the 
endothelial surface leads to adherence of platelets and 
subsequently to smooth muscle cell proliferation P 21 . 
In this concept the platelets play a primary role in the 
initiation of the atherosclerotic process. The other 
school of thought believes that atherosclerosis and 
thrombosis are, initially at least, separate disorders 
and that the initiating factor in atherosclerosis is the 
deposition of excess lipids in the vessel wall r13l. As 
the lesion grows into the atherosclerotic plaque, a 
rupture in the latter can lead to haemorrhage which 
in tum provokes rapid aggregation of platelets and 
thrombosisr6 · 14l. In both concepts it is believed that 
the smooth muscle cell is at the heart of the reactive 
connective tissue proliferation in the subintimal cells 
of the media [151 . As Becker pointed out recently. no 
unifying theory can at present be offered, but it is 
clear that the 'classical' atherosclerotic lesion or 
plaque remains a major end pointP 5l. 
While aetiology of coronary atherosclerosis re-
mains to be clarified, but a number of predisposing 
factors have been identified: a family history, hyper-
lipidaemia, hypertension, smoking of cigarettes, dia-
betes mellitus, and obesity. 
CORONARY BLOOD FLOW AND MYOCARDIAL ISCHAEMIA 
The coronary circulation is capable of autoregula-
tion-flow increases with augmented oxygen demand 
and falls with reduced demand. This adjustment is 
achieved by means of appropriate alterations in 
coronary vascular resistance. The major determinants 
of myocardial oxygen demand are heart rate, wall 
stress, and contractility. Wall stress of the left 
ventricle is determined by left ventricular systolic 
pressure, left ventricular end-diastolic volume, and 
wall thickness. The determinants of oxygen supply 
are heart rate, aortic diastolic pressure, left ventri-
cular end-diastolic pressure, and coronary vascular 
resistance (tonus and diameter). In addition, oxygen 
supply depends on haemoglobin concentration and 
on arterial oxygen saturation, which is determined by 
lung function. 
Coronary atherosclerosis may lead to a progressive 
narrowing of the coronary lumen to the degree that 
blood flow to the myocardium is impeded. In addi-
tion, thrombotic processes which occur at the site 
of a ruptured plaque may further reduce or even 
obstruct coronary blood flow. Myocardial ischaemia 
occurs when coronary blood flow is unable to meet 
the myocardial demand for oxygen and nutrients. 
The consequences of myocardial ischaemia include, 
besides anginal pain, metabolic and electrophysio-
logical changes, cessation oflocal myocardial contrac-
tion, and sometimes ventricular failure. Myocardial 
ischaemia initially causes metabolic changes in the 
affected cells characteristic of reversible injury: res-
toration of arterial flow and oxygenation prevents cell 
death and allows the affected cells to begin function-
ing again. Prolonged or severe myocardial ischaemia 
causes irreversible injury to the affected cells: the cells 
die and cannot be salvaged by re-oxygenation. The 
term myocardial infarction is therefore used to indi-
cate necrosis of a portion of heart muscle as a result 
of inadequate blood supply[2l_ The occlusion of a 
coronary artery by thrombus (i.e. coronary throm-
bosis) usually causes myocardial infarction, although 
prolonged mild ischaemia may also cause myocardial 
infarction. 
CLINICAL MANIFESTATIONS 
Coronary atherosclerosis may lead to a variety of 
syndromes which can affect the same patient at 
different times. These are stable angina pectoris, 
unstable angina pectoris, acute myocardial infarc-
tion, cardiac failure, arrhythmia, and sudden death 
(not necessarily in that sequence) l2 1_ 
Patients may have coronary atherosclerosis which 
is not sufficiently severe to impede coronary blood 
flow. Such patients usually have no symptoms. Also, 
in more gradually developing atherosclerosis col-
lateral flow may become so extensive that major 
symptoms do not develop. However, if coronary 
atherosclerosis has progressed to a degree that coron-
ary flow reserve is critically limited, myocardial 
ischaemia (and angina as its clinical counterpart) 
consistently develops when a sudden increase in 
myocardial oxygen demand exceeds the capacity of 
the coronary artery to supply blood. Removal of 
factors causing increased myocardial oxygen demand 
(exercise or emotional stress) eliminates myocardial 
ischaemia within minutes and prevents irreversible 
injury to the heart muscle. The absence of anginal 
complaints or the presence of stable, exercise induced 
angina characterise the clinically stable phase of 
atherosclerotic coronary disease. 
Sudden critical changes in the degree of flow ob-
struction originating from the atherosclerotic lesion 
may precipitate acute syndromes interrupting the 
phase of clinical stability. Changes in flow obstruc-
tion that only affect coronary flow reserve manifest 
themselves in changes in the level of exertion at which 
angina occurs (the anginal threshold). If the change 
in flow obstruction prohibits further support of the 
resting metabolism of the myocardium, myocardial 
ischaemia and chest pain, either of the anginal type 
or typical for myocardial infarction, will occur with-
out being provoked by exertion. Also, myocardial 
ischaemia may occur without causing a sensation of 
chest pain-this phenomenon is referred to as silent 
ischaemia. 
Plaque rupture or endothelial ulceration followed 
by platelet aggregation or a thrombotic process are 
generally considered pivotal factors in sudden 
changes in the degree of flow obstruction and hence 
in the conversion from clinical stability to clinical 
instabilityl6- 9 l_ The formation of a partial occlusive 
thrombus on the site of a ruptured plaque could be 
the basis for a sudden decrease of myocardial oxygen 
supply with angina at rest or a dramatic decrease in 
anginal threshold as its clinical counterpartl16- 19l_ As 
stated before, the degree of flow obstruction and its 
duration (together with the amount of collateral flow) 
Unstable angina pectoris 5 
determine the extent of irreversible injury (necrosis) 
induced in the myocardium at risk. Timely lysis of a 
partially occlusive thrombus would imply a return to 
stability without myocardial infarction. Occlusive 
thrombus formation (not followed by timely lysis) or 
prolonged severe partial occlusion will lead to acute 
myocardial infarction r20 -21 l_ Incorporation of a 
partial occlusive thrombus in the plaque could lead 
to further but slower progression of coronary athero-
sclerosis with stable angina at a lower threshold as its 
clinical manifestation r9 J_ Recurrent episodes of 
thrombus formation and thrombus disintegration 
could be the basis of recurrent episodes of angina 
or of ischaemic myopathyl61_ Fragmentation of the 
thrombus can lead to sudden death [GJ_ Finally, 
vasoconstrictive phenomena, either through platelet 
activation or otherwise, also play a role in the pre-
cipitation of clinical instabilityP 9-221_ 
Newly developed angioscopes have allowed direct 
in vivo examination of the endothelial surface of the 
coronary artery during unstable coronary syndromes. 
Sherman and co-workers observed ragged, ulcerated, 
haemorrhagic endothelium and acute thrombi in the 
pain related coronary artery in patients with unstable 
angina who underwent coronary surgery because 
pharmacologic management had failed l231. Com-
parable endothelial lesions were not seen in patients 
with stable .syndromes. These observations suggest 
that instability of the plaque makes some athero-
sclerotic lesions more susceptible to thrombosis and 
vasoconstriction than others. The severity of the fixed 
atherosclerotic lesion seems to be a major deter-
minant for the ultimate outcome of the thrombotic 
process. Progression to an occlusive thrombus or 
plain spasm (i.e. abnormal vasoconstriction leading 
to complete occlusion) could occur more easily when 
the vascular lumen is already critically reduced by 
severe atherosclerosis, especially if the remaining 
lumen is eccentric l24l_ 
Methods used to identify acute clinical syndromes due 
to atherosclerotic coronary heart disease 
The physician utilizes the patient's history, the 
reaction to treatment, the physical examination, and 
certain laboratory techniques to identify acute clinical 
syndromes due to atherosclerotic coronary disease. 
Each of the diagnostic tools has value but each 
method has its own imperfectionsl5l_ 
It is a physician's skill to elicit and to interpret 
a patient's history accurately. On the other hand, 
history as a diagnostic method has its limitations. 
Take as an example patients who deny symptoms 
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because they cannot cope with the consequences or 
patients who exaggerate symptoms for self gain. 
The physical examination may be helpful in diag-
nosing acute myocardial infarction (signs of acute 
heart failure, vegetative symptoms, severe perspira-
tion). It may also play a role in identifying a non-
coronary cause for the chest pain. On the other hand, 
it must be emphasized that the patient with angina 
pectoris usually exhibits no abnormalities on physical 
examination [51. 
The information gained from the electrocardiogram 
is valuable if serial electrocardiograms recorded 
during and after chest pain are available. The value 
of the resting electrocardiogram by itself is limited if 
no electrocardiograms recorded during chest pain 
are available. ST-segment displacements or T-wave 
inversions occurring during chest pain are character-
istic of myocardial ischaemia. Transient abnormalities 
usually point towards reversible ischaemia, persisting 
severe ST -segment displacements towards irreversible 
ischaemia. On the other hand, prolonged myocardial 
ischaemia may occur without electrocardiographic 
changes. Changes in the QRS-complex characteristic 
of myocardial infarction usually appear within 48 
hours of onset of myocardial infarction. However, 
these characteristic changes can be absent, particul-
arly in small infarctions. 
The technique of measuring the activities of cardiac 
enzymes in the blood is used to diagnose myocardial 
infarction. Cardiac enzymes are released from 
irreversibly injured myocardial cells into the circula-
tion during a period of several hours or possibly days 
after onset of myocardial infarction. It takes a few 
hours before the enzymes appear in the circulation in 
sufficient amounts to become detectable after 
ischaemia has brought irreversible damage on the 
myocardium rz 51. As no instantaneous techniques for 
the determination of enzyme levels are routinely 
available, an additional laboratory delay is unavoid-
able. As a result, enzymatic confirmation of myo-
cardial infarction usually becomes available not until 
eight hours or more after its onset. Therefore, enzy-
matic detection of myocardial infarction plays a key 
role in the retrospective assessment of episodes of 
clinical instability, but enzyme values are of little 
· importance in the early differentiation between 
reversible and irreversible ischaemia. 
The syndrome of unstable angina pectoris 
Unstable angina as defined above comprises all 
clinically unstable manifestations of coronary athero-
sclerosis in which myocardial ischaemia causes only 
reversible injury to the myocardium. Other terms 
such as impending myocardial infarction, threatened 
myocardial infarction, acute coronary insufficiency, 
or the intermediate coronary syndrome have been 
used in this context. Unstable angina has become the 
currently preferred term, connoting the instability of 
the clinical situation [261. 
The syndrome of unstable angina encompasses a 
wide variety of distinct clinical presentations. Three 
different categories are usually distinguished: (1) 
angina of effort of recent onset; (2) angina of effort 
with a changing pattern, usually progressive; (3) 
angina at rest rz 71. Within the category of angina 
at rest several subcategories can be identified, such 
as variant angina, refractory angina, postinfarction 
angina. The term variant angina, originally proposed 
by Prinzmetal, is used to describe angina at rest 
associated with transient ST -segment elevation in the 
electrocardiogram in patients with normal exercise 
tolerancer281. Patients in whom attacks of angina at 
rest repeatedly occur in spite of (vigorous) pharmaco-
logic treatment are referred to as having refractory 
anginar291. The term postinfarction angina is 
adopted when patients develop unstable angina 
during the recovery phase after myocardial infarc-
tion. Each of the above (sub)categories may be 
viewed as a separate syndrome. 
Angina at rest may appear de novo or may occur 
in a patient with stable or progressive angina of 
effort. There may be single or there may be multiple 
episodes, lasting from minutes to one hour. ST-
segment depression or ST-segment elevation may be 
observed in the electrocardiogram during an attack. 
In addition, it may produce T-wave inversions in the 
electrocardiogram that require hours or even days to 
return to normal. Notwithstanding Conti's definition, 
the term 'unstable angina' is also often used to refer to 
episodes of prolonged (more than 15 minutes) anginal 
pain at rest, with accompanying ST-segment or 
T-wave changes in the electrocardiogram r26 ·301. 
Some authors still refer to this specific condition as 
the 'intermediate coronary syndrome' r31 1. It forms a 
subcategory of Conti's third category and may also 
include Prinzmetal's syndromef27 ·281. 
Current anti-anginal drugs 
In the treatment of angina pectoris a distinction 
must be made between the treatment to eliminate 
acute chest pain and maintenance treatment to pre-
vent episodes of angina pectoris or to diminish their 
frequency. 
Treatment of acute chest pain starts with limitation 
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Table 1.1 Influence of oral nitrates, oral beta blockers, and oral calcium antagonists on myocardial oxygen consumption and 
oxygen supply 
Decrease oxygen consumption Increase oxygen supply 
Decrease Decrease Decrease Increase 
Decrease syst blood LV end- Decrease coronary diast blood 
heart rate pressure diast vol Contractility resistance pressure 
Nitrates + + 
Beta blockers + + 
Nifedipine + 0 
Verapamil + + 
Diltiazem + + 
syst, systolic; LV, left-ventricular; diast, diastolic, vol, volume; 
+, a salutary effect on the oxygen balance; 
0, no effect on the oxygen balance; 
-, a detrimental effect on the oxygen balance. 
of those factors and conditions which initiated the 
attack, aided in some patients by sedation. If chest 
pain persists, it can be relieved by the sublingual use 
of nitrates (glyceryl trinitrate or isosorbide dinitrate) 
or by a capsule of nifedipine. Opiates are usually 
needed to relieve the pain associated with more severe 
ischaemia, suspected to be of acute myocardial in-
farction. 
Episodes of anginal pain may also be prevented by 
readjustment of the factors determining oxygen 
consumption and oxygen supply. Nitrates, beta 
blockers, and calcium antagonists, either alone or in 
combination, are advocated as being useful in this 
context. Their influences on oxygen consumption and 
oxygen supply of the heart muscle are summarized in 
Table 1.1. 
Nitrates increase the venous capacitance, causing 
pooling of blood in the peripheral veins. Myocardial 
oxygen demand is attenuated by the ensuing reduc-
tion in left ventricular end diastolic volume (preload) 
and systemic blood pressure (afterload) [321. Nitrates 
may also diminish coronary vasomotor tone, which 
improves coronary perfusion and increases oxygen 
supplyr331 . The most important side effects are 
headaches and orthostatic hypotension, but palpita-
tions, reflextachycardia and nausea may also occur. 
Sublingual glyceryl trinitrate is rapidly absorbed from 
the sublingual mucosa. Its onset of action occurs 
within minutes, with maximal effects at three to 15 
minutes, while little residual activity remains at 20 to 






the drug prophylactically prior to an activity that is 
known to precipitate angina pectoris. Glyceryl tri-
nitrate in ointments and in transdermal therapeutic 
systems (plasters) for topical applications may be 
an important addition to the available anti-anginal 
agents for some patientsr341 . Intravenous glyceryl 
trinitrate is now being used in coronary care units 
to eliminate recurrent episodes of ischaemia. Long-
lasting anti-anginal effects may also be obtained from 
oral slow release preparations of nitrate esters, such 
as isosorbide dinitrate. High oral doses have to be 
given to overcome the rather extensive first pass liver 
metabolism r331 . Isosorbide mononitrate, a metabol-
ite of isosorbide dinitrate, is characterised by more 
favorable pharmacokinetic properties[35•36l. 
However, continuous long-term use of nitrates, in 
particular of glyceryl trinitrate, may cause toler-
ance, which offsets anti-anginal effects in certain 
patientsr371 . 
Beta blocking agents antagonise the actions of 
catecholamines on the beta receptors by competitive 
inhibition. Beta blockade reduces the oxygen demand 
by reducing heart rate and blood pressure and de-
pressing contractilityr321 . To be effective a resting 
heart rate of 55-60 beats min-1 must be achieved [321. 
Beta blockers are contra-indicated in patients with 
signs of cardiac failure, obstructive lung dysfunction, 
bradycardia, or conduction disorders. Cardioselective 
beta blockers carry a smaller risk for bronchocon-
striction than nonselective beta blockers. A system-
atic comparison of the efficacy of the numerous beta 
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blockers currently available in the management 
(unstable) angina has not been performed r38l. Beta 
blockade may cause cardiac failure. Side effects of 
beta blockers include cold distal limbs, impotence, 
and occasionally intermittent claudication, gastro-
intestinal dysfunction, hallucinations, coronary 
artery spasm, and Raynaud's syndrome. 
Calcium antagonists represent a heterogeneous 
group of vasodilating drugs which share the ability 
to inhibit the transmembrane influx of ca:lcium in all 
types of muscle cells. The most popular calcium 
antagonists are nifedipine, verapamil, and diltiazem. 
Although the three drugs share the same principle, 
they vary in their potency to affect the different 
components of the cardiovascular system r39l. The 
calcium antagonists have a direct action on the 
smooth muscle of certain arteries, depending on the 
specific compound. They inhibit or relieve coronary 
spasm and produce dilation of coronary arteries 
including both large and small arteries as well as col-
lateral vessels, thereby causing an increased cardiac 
blood supplyr4o-.4fJ_ Furthermore, dilatton of the per-
ipheral arteriolar bed reduces vascular resistance and 
systemic blood pressure and thus the afterload to the 
heartr411. Calcium antagonists may also decrease 
contractilityr421 . In contrast to nifedipine, which may 
cause an increase in heart rate, verapamil and diltia-
zem usually lead to a reduction in heart rater431 . 
When considered at a cellular level, it can be argued 
that all calcium antagonists will confer protection 
to the myocardium against the deleterious effect of 
ischaemia by slowing excessive calcium influx, by 
blocking early catecholamine release, by avoidance 
of high-energy phosphate break-down with suppres-
sion of attendant loss of purine derivativesr44.45l. 
However, it was recently stressed that cardiopro-
tective effects of calcium antagonists were only 
observed in animal preparations when the drugs were 
given before the ischemic condition had been estab-
lished, and that, as a logical consequence, similar 
effects may only be expected in clinical practice under 
similar circumstances, in particular that fewer benefits 
should be expected when calcium antagonists are 
given after onset of ischaemia r451• Adverse effects 
are those of all peripheral vasodilators: flushing, 
headache, pretibial oedema. Aggravation of angina 
can occur in some patients, an effect possibly related 
to arterial hypotension in combination with reflex 
tachycardia or to coronary steal r43l. 
Apart from the afore mentiOned mam mechanisms 
each drug has a host of ancillary pharmacologic 
properties. For instance, nitroglycerine, beta block-
ers, and calcium antagonists are claimed to have mild 
anti-aggregatory effects on platelets[38·47l. It, 
however, appears difficult to judge the relevancy of 
these properties in the clinical situation. 
Thrombolytic agents, platelet aggregation inhibit-
ing drugs, and anticoagulants appear to be an alterna-
tive or additional approach to the current drug 
treatment of unstable angina, especially in view of 
recent patho-physiologic insightsr9 l. The first may 
lyse intracoronary thrombi, the second may inhibit 
platelet aggregation at the site of a ruptured plaque, 
and the third may prevent intracoronary thrombosis. 
Management of patients with acute chest pain 
INITIAL MANAGEMENT AND DIFFERENTIATION 
When examining a man for illness in his cordia, he has 
pain in his arms, in his breast, on the side of his cardia ... it 
is death which approaches him. 
The Ebers papyrus, 3000 BC 
One will never know whether the ancient Egyptian 
suffered from acute myocardial infarction or from 
unstable angina. One thing is certain, even to date, 
patients with the symptoms described above represent 
a problem in deciding whether a myocardial infarc-
tion has occurred or may still be averted by timely 
intervention r481 . 
Patients developing abrupt persistent chest pain 
without a precipitating cause usually seek help of a 
physician (the patient's general practitioner or a 
physician at the mobile coronary care unit, at the 
emergency room or at the coronary care unit itself). 
Treatment of chest pain is usually started without a 
diagnosis being made. The available medications 
include sublingual or intravenous glyceryl trinitrate, 
nifedipine, fentanyl, or opiates. If an acute cardiac 
problem is suspected, the general practitioner, if 
involved, usually refers the patient to hospital. 
In the hospital an early (provisional) diagnosis is 
made after relief of chest pain, if still present. The 
patient's reaction to pain treatment, the interview, 
and electrocardiography are the diagnostic tools 
available to the physician. Each one is indispensible 
to identify myocardial ischaemia (either reversible or 
irreversible) as the (presumed) cause of the chest pain. 
Three diagnostic categories are available, each reflect-
ing the physician's perception of the nature of the 
ischaemia: (I) suspected acute myocardial infarction, 
i.e. irreversible ischaemia; (2) suspected unstable 
angina, i.e. reversible ischaemia (3) probably no 
angina, i.e. no acute ischaemia. Each diagnostic 
category has its own therapeutic consequences. 
Patients are identified as sustammg acute myo-
cardial infarction ( 1) if severe chest pain has persisted 
for more than 30 minutes, in particular if opiates 
need be given to eliminate chest pain; (2) if vegetative 
symptoms or signs of overt cardiac failure have 
appeared; or (3) if typical electrocardiographic 
abnormalities persist or worsen. The task in early 
management is (I) to relieve pain, dyspnoea, and 
anxiety; (2) to provide continuous monitoring and 
prompt treatment of life-threatening arrhythmias, if 
they should occur; (3) to salvage as much of the 
jeopardized myocardium as possible; and (4) to treat 
left heart failure, if present. As myocardial infarction 
is usually caused by complete occlusion of a (major 
branch of a) coronary artery, thrombolytic treatment 
has become the first therapeutic option if the occlus-
ion is thought to have occurred within the last four 
to six hoursr49l. There is now substantial evidence 
that treatment with streptokinase (intravenously but 
especially intracoronary) may be useful [50- 531. 
Treatment with recombinant tissue-type plasminogen 
activator seems promising[54-56l. In addition, there 
is overwhelming evidence that early beta blockade 
marginally reduces early mortality in patients with 
uncomplicated myocardial infarction [57 · 581. 
Patients are identified as having unstable angina 
(I) when chest pain did not last for more than 30 
minutes and had ceased spontaneously or could 
rapidly be relieved by glyceryl trinitrate; and (2) if 
the electrocardiogram shows signs of reversible 
myocardial ischaemia. Further management is de-
scribed below. 
Patients with chest pain of the anginal type without 
further evidence for myocardial ischaemia or coron-
ary atherosclerosis and patients with severe but as 
yet unexplained chest pain are usually kept in the 
hospital for further observation while therapeutic 
measures are deferred until symptoms reappear or 
until exercise testing or angiography is performed. 
Appropriate measures are taken if the chest pain can 
be attributed to a non-cardiac cause (e.g. peptic ulcer, 
oesophagitis, or gall stones) or to a noncoronary 
cardiac cause (e.g. aortic stenosis). 
FURTHER MANAGEMENT OF PATIENTS WITH UNSTABLE 
ANGINA 
After initial pain relief the aims of early treatment 
in patients identified as having unstable angina at 
hospital admission are the prevention of recurrent 
ischaemia or progression to myocardial infarction 
and the restoration of a stable clinical condition. As 
electrocardiography and severity of chest pain have 
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limited sensitivity for irreversibility of myocardial 
injury, chest pain initially impressing as unstable 
angina may in fact originate from evolving myo-
cardial infarction, which might be an important 
consideration in the determination of further manage-
ment. 
It is generally agreed upon that patients with un-
stable angina should be admitted to a coronary care 
unit to provide continuous monitoring and prompt 
treatment of life-threatening complications, if they 
should occurr591 . Bed rest, reassurance, and sedation 
may go a long way in reducing the determinants of 
myocardial oxygen demand[ 261 . It is now common 
practice to intensify and optimize pharmacologic 
treatment first, in an attempt to stabilize the acute 
ischaemic symptomsr26 ·30l. (The process of stabiliz-
ing the symptoms is often referred to as 'cooling off' 
unstable angina.) Nitrates, beta blockers, calcium 
antagonist may be useful in this respect by readjust-
ment of factors determining oxygen demand and 
supply. As the main mechanisms are different, 
combination of these drugs may be advantageous. 
Some authors recommend to increase drug treatment 
stepwise, guided by symptoms and haemodynamics 
of the patient, for instance according to the scheme 
provided by Simoons (Table 1.2)[601. Others recom-
mend that triple treatment be the rule with intra-
venous nitrates used as necessaryr31l. Treatment 
with heparin may also be beneficial. The role of early 
intravenous fibrinolytic treatment in this condition 
has not (yet) been delineated. Whether benefits out-
weigh the albeit small risks of severe bleeding 
complications (including cerebro-vascular accidents) 
remains to be established. 
Table 1.2 Step-up approach in the treatment of unstable 
angina after hospital admission 
In all patients: 
Rest, sedation, correction of hypertension, anaemia. etc. 
Additional pharmacologic treatment: 
2 
3 







Further invasive treatment: 
4 Urgent coronary angiography, and depending on its 
interpretation angioplasty or surgery, and if neces-
sary intra-aortic balloon pump 
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MANAGEMENT OF PATIENTS WITH REFRACTORY SYMP-
TOMS 
It is generally agreed upon that refractory angina 
(i.e., persisting symptoms in spite of intensive pharm-
acologic treatment) forms an indication for urgent 
coronary angiographyl26 ·30•6 1.621 . If the angio-
graphic appearance suggests that a thrombus is pre-
sent at the symptom related segment, thrombolysis · 
may be attempted. If the symptom related lesion 
appears suitable for angioplasty or bypass grafting, 
that intervention is usually performed as soon as 
possible. If the intervention cannot be performed at 
short notice, the intra-aortic balloon pump can be 
used for temporary stabilization of patients awaiting 
further interventions. 
The inoperable refractory patient has a grave 
prognosis. In addition to continuing and optimiza-
tion of the medical treatment, the physician can only 
offer support and symptomatic relief with analgesics 
as needed r261 . 
MANAGEMENT AFTER STABILIZATION OF SYMPTOMS 
A symptom free interval of 48 hours (in the ab-
sence of enzyme rises) is generally considered a token 
of restored clinical stability. It creates room for 
further diagnostic work-up and the determination of 
a long term treatment strategy. The initial months 
following hospital admission for unstable angina are 
a period of high risk of recurrence of symptoms, 
infarction, or death, in particular in patients with ST-
segment depression l31 1. After this period the risks 
are substantially reduced and become comparable to 
those of patients with stable angina l631. 
Treatment aims in unstable angina patients after 
stabilization of symptoms are: (1) to prevent new 
episodes of unstable angina, myocardial infarction, 
or sudden death; (2) to alleviate symptoms of stable 
angina, if present: (3) to slow down progression of 
coronary atherosclerosis. 
To begin with, patients should be encouraged to 
stop smoking, to attain a normal weight, and to 
achieve a normal blood pressure. 
It is common practice to perform coronary angio-
graphy in most patients, except in elderly patients 
who are not candidates for surgery or in patients with 
an isolated episode of chest pain without recurrence. 
The knowledge gained from the angiogram can be 
helpful in selecting appropriate treatment. The 
majority of patients are found to have atherosclerotic 
coronary lesions, the severity of which determines 
long term prognosis. Angioplasty or bypass surgery 
seems indicated as a measure to improve prognosis, 
particularly in younger patients with advanced 
coronary lesions (even in the absence of severe 
symptoms)l21 . Exercise testing or continuous electro-
cardiographic monitoring may help to identify 
patients at high risk, in whom revascularization 
procedures may be indicated r64•631 . In other 
patients one may consider to continue and optimize 
pharmacologic treatment first and to offer angio-
plasty or bypass surgery when recurrent severe 
symptoms persist or develop. If normal or minimally 
diseased vessels are found, increased coronary vaso-
motor tone can be considered the cause of the un-
stable episode, provided that objective evidence of 
ischaemia has been obtained. Patients with this 
condition usually have a good prognosisl65 •661. 
Nitrates, beta blockers, and calcium antagonists 
are known to be efficacious in avoiding symptoms 
of stable angina, if they should occurl33•39•671. 
Beta blockers may also be considered in the absence 
of these symptoms because of their established 
role in reducing mortality after myocardial infarc-
tion l68 ·691. Todays insights in the pathophysiology 
of unstable angina suggest a major role for antithrom-
botic treatment in the prevention of long-term 
complicationsl91. However, treatment with full-dose 
anticoagulation has not (yet) adequately been in-
vestigated. Beneficial effects of acetyl salicylic acid 
have been observed in large secondary prevention 
studies f?O. 711 when the drug was given after the 
acute episode. 
TEMPORAL ASPECTS TO THE DIFFERENTIATION BETWEEN 
UNSTABLE ANGINA AND ACUTE MYOCARDIAL INFARC-
TION 
Wulff has pointed out that a diagnosis is not an 
end in itself-it is a mental resting-place for prog-
nostic considerations and therapeutic decisions rn1. 
Early differentiation between (suspected) acute myo-
cardial infarction and (suspected) unstable angina 
may have considerable therapeutic consequences, for 
instance in regard to the institution of thrombolytic 
treatment or emergency revascularization proced-
ures. As these measures may not be deferred until a 
final, definitive diagnosis is made, the treating phys-
ician must make a provisional, early diagnosis based 
upon the often scanty information available at pre-
sentation. This is a momentary (or instantaneous) 
diagnosis in the sense that it reflects the physician's 
opinion on what is going on in the coronary arteries 
and myocardium of the patient at that particular 
moment. Revision of the diagnosis may occur 
repeatedly, either because new information (enzyme 
values, details of the patient's history) becomes 
available or because the clinical course takes a tum 
(e.g. the occurrence of new apparently uncontrollable 
chest pain). 
Once the clinical condition of the patient has stabil-
ized (after a pain free interval of 48 hours), the 
treating physician may look backward and evaluate 
the preceding episode of clinical instability, with a 
view towards further treatment. Usually, tlie episode 
as a whole is labelled. The most important categories 
are (confirmed) myocardial infarction, (confirmed) 
unstable angina, chest pain of known noncoronary 
origin, chest pain with unknown cause. It is custom-
ary to designate all episodes of chest pain at rest 
accompanied by electrocardiographic changes but 
without subsequent enzyme rises as episodes of 
'unstable angina', even if the patient initially pre-
sented as acute myocardial infarction. Likewise, a 
patient initially diagnosed as having unstable angina 
is said (in retrospect) to have sustained myocardial 
infarction when subsequent enzyme values were 
found to be raised. 
As a consequence, the differentiation between 
myocardial infarction and unstable angina has an 
important temporal aspect and should be approached 
from the point of view of early diagnoses (with a 
view to treatment of the acute illness) and late (retro-
spective) diagnoses (with a view to long-term second-
ary preventive treatment). The consequences of this 
distinction for the interpretation of findings from 
clinical trials are discussed in chapter 8. 
Concepts underlying the design of IDNT 
The present trial-the Holland Interuniversity 
Nifedipinefmetoprolol Trial (HINT)-was designed 
in the late seventies and initiated in 1981. At that 
time it was felt that the relative effects of the various 
pharmacologic treatments in the early phase of un-
stable angina had not been sufficiently studied [7 31 . 
While the restoration of a stable clinical condition 
within 48 hours in combination with the prevention 
of acute myocardial infarction was perceived as the 
primary goal of early pharmacologic treatment, it 
was unclear which compound or combinations there-
of would be superior. 
Pathophysiologic insights at that time were domin-
ated by the concept of flow reduction due to fixed 
atherosclerotic lesions on which variable obstructions 
due to spasm or increased vasomotor tone were 
superimposed r74• 751 . The idea was that all forms of 
unstable angina were in between two extremes: (I) 
classic stable angina resulting from a severe fixed 
atherosclerotic lesion which caused chest pain 
already at very slight exertion (95% obstruction, 5% 
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spasm) and (2) severe spasm in the near absence of a 
fixed stenosis resulting in Prinzmetal's syndrome 
(95% spasm, 5% obstruction) (Fig. 1.1). Long-acting 
nitrates were supposed to be effective over the whole 
range. Beta blockers, and ultimately bypass surgery, 
were believed to be most effective if a fixed stenosis 
was the dominating factor. Calcium antagonists were 
supposed to be most effective if spasm or increased 
vasomotor tone was the dominating factor. There-
fore, in the presence of a mixture of increased coron-
ary vasomotor tone and a fixed lesion a com-
bination of a beta blocker and a calcium antagonist 
might be useful. It followed from this that the thera-
peutic choice between a beta blocker and a calcium 
antagonist should depend on the treating physician's 
perception of the underlying pathophysiology. As it 
was virtually impossible to assess the mix between 
spasm and fixed lesions in the individual patient 
(especially without angiography), a growing tendency 
emerged to commence treatment with triple treat-
ment: nitrates, beta blockers, and calcium antagon-
ists. In view of possible haemodynamic interactions 
and of the impossibility to judge the effects of the 
drugs separately, a step wise approach guided by the 
symptoms and haemodynamic condition of the 
patient was considered preferable. 
In view of the above considerations, it was decided 
that the effect of a beta blocker and a calcium 
antagonist, either alone or in combination, in the 
early treatment of suspected unstable angina de-
served investigation in a large scale randomised 
clinical trial. Long-acting nitrates were left out from 
the trial comparison. They would be available as 
back-up treatment in case of persisting symptoms. 
As many clinicians then believed (and still do today) 
that emotional and physical rest is most essential in 
the treatment of unstable angina, a comparison with 
placebo was considered justified. Of the possible beta 
blockers metoprolol was chosen mainly because of 
its long action and fixed dosage scheme. Of the 
calcium antagonists nifedipine was chosen because 
of its outspoken spasmolytic effect on the coronary 
arteries and because of promising findings in non-
randomised studiesr40•761 . Another important 
consideration was the willingness of the manu-
facturers of these drugs to sponsor the trial in part. 
. Patients who develop unstable angina while 
already on maintenance treatment with a beta 
blocker, must be considered a failure of beta 
blocker treatment. The addition of nifedipine to the 
regimen was a therapeutic option worthy of further 
investigation-for one might argue that among other 
factors enhanced vasoconstriction might be the 
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Figure 1.1 Causes of the various forms of unstable angina as they were perceived at the time when 
HINT was designed (1980): 'The therapeutic approach to the various forms of unstable angina depends 
on the clinician's awareness of the underlying pathophysiology. If a 'fixed' stenosis is suspected, the 
first choice of treatment will be quite different than when spasm is the most likely cause of the symptoms. 
Most cases will lie in between and therefore require individual assessment of the situation in order to 
achieve optimal choice of treatment' (PTCA-percutaneous transluminary coronary angioplasty). 
dominant factor in these patients. A comparison with 
placebo seemed ethically justifiable by the same 
argument as above. 
Thus, a clinical trial was designed in patients with 
unstable angina at hospital admission--that is, after 
an episode of prolonged ( > 15 min) chest pain at rest 
due to reversible ischaemia as perceived by the treat-
ing physician after relief of chest pain. In patients 
not on previous maintenance treatment with a beta 
blocker, treatment with nifedipine, metoprolol, or 
the combination was compared to treatment with 
placebo in its capacity of restoring clinical stability 
within 48 hours. In patients on previous maintenance 
treatment with a beta blocker the effect of nifedipine 
was compared to that of placebo, whilst beta block-
ade was continued. 
General outline of the trial design of HINT 
Patients admitted to a coronary care unit after one 
or more episodes of chest pain at rest were screeq.ed 
for inclusion in the trial. The inclusion criteria 
required elimination of existing chest pain by sub-
lingual glyceryl trinitrate and ST segment or T-wave 
changes on the electrocardiogram suggestive for re-
versible ischaemia. For patients admitted to hospital 
after spontaneous relief of chest pain, the inclusion 
criteria required either an abnormal resting electro-
cardiogram or other evidence of atherosclerotic heart 
disease. The exclusion criteria comprised signs and 
symptoms of acute myocardial infarction, known 
extracardiac cause of myocardial ischaemia, the usual 
contra-indications for nifedipine or beta blockers, 
and previous maintenance treatment with nifedipine. 
All patients received usual medical care--that is, 
bed rest, sedation, and electrocardiographic monitor-
ing. Patients not on previous maintenance treatment 
with a beta blocker were randomly assigned to 
receive either double placebo, nifedipine plus meto-
prolol placebo, metoprolol plus nifedipine placebo, 
or both drugs. Patients on previous maintenance 
treatment with a beta blocker were randomised to 
receive either nifedipine or placebo, whereas their 
beta blockade was continued. Trial medications were 
started as soon as possible after relief of chest pain. 
They were continued for at least 48 hours unless 
contra-indications developed. 
Trial medications were compared as to percentage 
of patients who developed acute myocardial infarc-
tion or who experienced recurrent myocardial 
ischaemia within 48 hours of randomisation. Acute 
myocardial infarction was established if enzyme 
values were raised over twice the upper limit for 
normal. Recurrent myocardial ischaemia was 
inferred from the recurrence of chest pain with ST-
segment or T-wave changes. The clinical course of 
each patient was documented and independently 
reviewed by a panel of experts with a view to estab-
lish whether myocardial infarction or recurrent 
ischaemia had taken place. 
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Introduction 
It was P. C. A. Louis who already in 1835 urged 
that future evaluations of treatment should use the 
'numerical method', which had served him so well in 
denouncing the practice of blood letting in inflam-
matory disease[l 1• Although the interest never com-
pletely vanished in the intervening period, the need 
to devise objective ways to evaluate medical interven-
tions found renewed interest in the 1930s and 1940s. 
In those days the need to evaluate different treat-
ments in groups of patients with comparable prog-
nosis treated in different ways was clearly recognised 
as was the need for blind evaluation [21. The concept 
of randomisation as a device for treatment allocation 
was introduced by Fisher to agricultural experi-
mentation in 1923 [31. Although random treatment 
allocation had been applied before in clinical experi-
ments, the 1948 Medical Research Council trial on 
the use of streptomycin in the treatment of pulmon-
ary tuberculosis is generally considered as pioneering 
work in the development of the multicenter random-
ised clinical trial as treatment evaluation method [4 1. 
From the beginning of medicine physicians have 
found cures that with the passage of time have 
proven to be useless. In contemporary medicine it 
has become accepted that medical interventions are 
critically evaluated in the clinical setting before being 
introduced to clinical practice. Pathophysiologic and 
pharmacologic insights, usually the result of basic 
research, engender a hypothesis (or a theory) that a 
certain clinical intervention may be efficacious in a 
certain disease. Clinical investigators subsequently 
design and conduct clinical studies in order to investi-
gate clinical usefulness of the intervention. The ran-
domised clinical trial has become the paradigm for 
the latter [S1. 
The clinical trial: a measurement device for therapeutic 
effects 
In clinical practice it is not sufficient to just know 
that a certain therapeutic intervention 'works' or 
'does not work'. Treatment decisions ultimately hinge 
on weighing the magnitude of the expected thera-
peutic benefit against possible adversary effects and 
against costs. Consequently, a clinical trial must be 
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viewed as a device to measure treatment effect (i.e., 
expected therapeutic benefit) and not as a means of 
assessing whether a treatment effect exists or does 
not. 
Viewing a clinical trial as a measurement device 
provides firm guidance in planning and carrying out 
a trial and in interpreting its findings as well. Con-
sequently, the objective of a clinical trial should be 
stipulated in quantitative terms. As an example, the 
objective of a trial of beta blockers in suspected acute 
myocardial infarction is to 'estimate the percentage 
mortality reduction' rather than 'to determine whether 
mortality is reduced', the latter being a qualitative 
statement. It is noted that the above principles im-
plies the inherent specification of a quantitative 
measure of treatment effect as the object of measure-
ment. 
As regards a measurement device in general, it is 
first and foremost necessary to identify the object 
of measurement. Secondly, behaviour in terms of 
measurement errors need be considered. For the 
latter, a distinction is usually made between systematic 
and random error. 
As noted above, the object of measurement in a 
clinical trial is a treatment effect. As a rule, treatment 
effects can only be meaningfully expressed in relative 
terms-that is by relating disease outcome under one 
treatment to that under another treatment, the latter 
serving as reference. More specifically, a treatment 
effect is characterized by three elements: (1) the treat-
ments to be compared; (2) the disease entity for which 
treatment effect assessment is required; and (3) the 
disease outcome, i.e. that aspect of the clinical course 
that one intends to influence. 
Accuracy of a measurement device refers to lack of 
systematic error. A device is said to be accurate if it 
has the property that the value obtained by measure-
ment equals the underlying true value on the average. 
The principles of clinical trial design derive from the 
need to avoid systematic error in measuring treat-
ment effects. A trial that may be expected to yield 
accurate measurement of the treatment effect under 
study is said to be internally valid. 
Precision of a measurement device refers to lack of 
random variation. An accurate measurement device 
is useless if the influence of random error is so 
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extensive that the measured value may substantially 
deviate from the underlying true value. Thus, such 
random error must be avoided so that the value 
obtained by measurement can be expected to be 
reasonably close to the true underlying value. Pre-
cision in a clinical trial primarily depends on the size 
of the compared treatment groups. 
In the following sections the design elements which 
specify the object of measurement in a clinical trial 
and the design features that bear on accuracy and 
precision are discussed in more detail. 
Design elements 
TREATMENTS 
In a clinical trial the interest usually centers around 
one specific treatment. In many instances the treat-
ment of interest is pharmacologic in nature, but also 
other interventions such as surgical treatments or 
therapeutic strategies may be studied. The treatment 
of interest is called the index treatment. It is con-
trasted to another treatment for comparison: the 
reference treatment. A newly developed drug may be 
contrasted to a placebo, a standard drug, or the 
absence of treatment. A surgical treatment is usually 
compared to the best available 'conservative' treat-
ment. The choice of the reference treatment depends 
on the particular situation and is guided by considera-
tions of internal validity (see further below). 
DISEASE ENTITY 
The inclusion and exclusion criteria of a trial must 
be viewed as the defining characteristics of the disease 
entity of interest. They specify the disease entity to 
which the treatments may be applied. According to 
Wulff, diseases are abstract categories in arbitrary 
classifications of patientsr61. However, abstract does 
not imply vagueness-the definition of the disease 
entity can (and should) be very specific. 
The inclusion and exclusion criteria by themselves 
do not define a group of patients. The investigator 
must devise a recruitment scheme to obtain a group 
of patients to represent the disease entity. The recruit-
ment scheme ties the selection of patients to a particu-
lar place (hospital, city, country) and to a particular 
time (period of patient accrual). 
The HINT inclusion criteria, which are described 
in chapter 3, expressly define the syndrome of un-
stable angina (prolonged anginal pain at rest). The 
trial was carried out in Dutch patients presenting 
with this syndrome at one of the 11 participating 
hospitals between 1981 and 1984. Treatment effects 
as observed in these patients are of interest insofar as 
they provide a means to learn about treatment effects 
in unstable angina in general. The specificity of the 
definition of unstable angina as presented in chapter 
3 applies to the (particularistic) patient group and to 
to the (abstract) disease entity as well. The disease 
entity as defined in HINT not only refers to a particu-
lar syndrome (unstable angina) but also to a specific 
phase in its development (i.e. as diagnosed immedi-
ately after relief of chest pain after admission to 
hospital). 
The great majority of diseases present a clinical 
spectrum varying from mild to severe symptoms. The 
diagnostic characteristics themselves do not define the 
clinical spectrum. Tertiary referral centres see a dis-
proportionate large proportion of high risk patients 
and, therefore, a clinical spectrum that can be quite 
different from what would have been obtained if the 
same criteria had been applied in the setting of a 
general practice[71. The inclusion and exclusion 
criteria of a clinical trial define the disease entity to 
be studied, but various features of the recruitment 
procedure ultimately determine the clinical spectrum 
of the disease eventually studied. The baseline profile 
(as described by the distribution of baseline charac-
teristics) and the clinical course in the reference group 
are essential additional descriptors of the clinical 
spectrum of the disease that is represented by the 
admitted patients. 
OUTCOME 
In every clinical trial treatment effects are invariably 
measured in terms of certain disease outcomes. The 
definition of the outcome is a major concern in the 
design of a study. In most clinical trials the outcome 
of interest is an (untoward) clinical event which may 
or may not occur over a fixed period of time (the 
outcome event). For example, in trials comparing 
secondary preventive measures after myocardial in-
farction one might choose death within two years as 
the outcome event. The outcome event in HINT is 
'recurrent ischaemia or myocardial or myocardial 
infarction within 48 hours'. 
With the outcome event specified, its occurrence 
can be identified for each individual patient. The 
proportion of patients who have developed the out-
come event characterizes the occurrence in the whole 
group. The outcome is not necessarily the occurrence 
of an ali-or-none event observed over a fixed follow-
up period. For example, if the concern is with blood 
pressure, the change in diastolic blood pressure over 
the treatment period would constitute the outcome 
in individual patients. The mean or median change 
in diastolic blood pressure would characterize the 
outcome in the whole group. 
Internal Validity 
Internal validity implies accurate effect measure-
ment within the context of the clinical trial itself. 
Internal validity hinges on three issues: (1) Does the 
treatment comparison truly reflect the comparison of 
interest? (2) Are other factors which might influence 
the outcome equally distributed between the treat-
ment groups? (3) Is the observation of the outcome 
identical between the treatment groups? 
The conventional methods to achieve internal 
validity are: (1) the use of a placebo or sham treat-
ment as reference treatment-to assure comparability 
of extraneous effects; (2) the use of random treatment 
assignment-to assure comparability of groups; (3) 
the use ofblinding-to assure comparability of inform-
ation rsJ. These methods need not be used in all 
instances. Understanding of the rationale, however, 
provides guidance in designing an internally valid 
study. 
COMPARABILITY OF EXTRANEOUS EFFECTS 
The choice of the reference treatment is guided by 
an express understanding of what aspect of the index 
treatment is to be studied. In the assessment of drugs 
the attention is usually on the effect of the agent 
(chemical substance) itself. Possible placebo effects 
must be considered extraneous to the comparison at 
issue. Consequently, the drug is compared to placebo 
in order to eliminate (extraneous) placebo effect from 
the comparison. As regards surgery, one usually 
intends to compare the strategy of surgery with a 
strategy of conservative treatment. In this context, 
extraneous effects are irrelevant to the comparison. 
No sham operation is needed in the reference group. 
The need for a placebo treatment thus originates 
from the investigator's perception of what aspects of 
the index treatment must be considered extraneous 
to the comparison at issue. 
COMPARABILITY OF GROUPS 
The data will reflect the effect of the index treat-
ment relative to the reference treatment only insofar 
as the two groups of patients are comparable. Com-
parability in this sense means that the expected occur-
rence of disease outcomes is the same for the compared 
groups had they been given the same treatment. The 
groups are required to have comparable prognosis. 
If no specific assignment scheme would have been 
devised (that is, in a nonexperimental study), com-
parability of groups is compromised by the treating 
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physician's preference to assign the more seriously 
afflicted patients to the favoured or to the most 
intensive treatment. Perceived high risk or poor prog-
nosis tends to constitute an indication for interven-
tion f91. In the context of a nonexperimental study, 
patients selected for different treatments have by 
definition different indications. Hence they cannot 
be expected to have comparable prognosis. This 
phenomenon (usually referred to as confounding by 
indication) poses major and often insurmountable 
difficulties to nonexperimental evaluation of efficacy. 
To achieve comparable groups, the investigator must 
devise an assignment scheme in advance that com-
pletely eliminates (intended or unintended) selection 
of patients into preferred treatment groups. Today, 
random allocation of patients to treatments is widely 
accepted as the method of choicer10•111. It renders 
treatment assignment completely unpredictable and 
beyond control of the treating physician. 
Systematic assignment schemes (e.g. in which every 
other patient is assigned to the index treatment) or 
schemes based on patient characteristics (e.g. based 
on the day of birth) implies that the treating physician 
knows the treatment assignment of a particular 
patient in advance. This prior knowledge may affect 
the physician's decision regarding entry or not, and 
treatment assignment becomes liable to manipulation. 
Systematic treatment assignment must therefore be 
rejected. A treatment assignment procedure based on 
randomisation but implemented in such a way that 
the physician has access to the randomisation code 
before the patient is definitively (and irrevocably) 
entered into the trial has the same deficiency. 
In a double blind comparison of pharmacologic 
treatments a system of pre-packed medications to be 
issued sequentially to patients as they are entered 
into the trial usually suffices. In an open comparison 
of, for example, surgical treatment with continued 
pharmacologic treatment a system of registration by 
telephone upon which the next treatment assignment 
is issued is mandatory. The frequently used so-
called envelope method usually provides no safe-
guard against manipulation. 
Even procedurally flawless random assignment of 
treatments does not necessarily produce comparable 
groups of patients owing co random variation. As a 
consequence, comparability of prognosis remains a 
major concern in data analysis. A further discussion 
on this topic is provided in chapter 5. 
COMPARABILITY OF INFORMATION 
Information regarding outcomes in individual 
patients must be obtained in a way that is identical 
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for the treatment groups. The conventional way to 
assure comparability of outcome information has 
been blinded data collection. It is an essential feature 
of trials involving outcomes subject to interpretative 
observation. An alternative would be to choose a 
'hard' outcome criterion, e.g. death within seven days 
of randomisation. This outcome does not allow any 
subjectivity from the observer, provided that inform-
ation over the whole risk period for all patients is 
obtained. However, even if a 'hard' outcome is 
selected, blinding of the patient or the treating 
physician may be indicated to maintain comparability 
of extraneous effects, in particular with regard to 
prescription of additional treatment. 
Precision 
Observed effects in a clinical trial are subject to 
random variation. If the study is replicated in the 
same context, other treatment effects will be observed. 
Random variation is that part of the outcome one 
cannot predict. In the context of a clinical trial it 
originates from (1) the process of randomisation itself 
and (2) random events occurring during follow-up of 
individual patients. Precision pertains to random 
variation in the observed effect estimate. 
The primary way to reduce the influence of random 
variation on the observed effect estimate (i.e. to 
increase precision) is to enlarge the size of the study. 
It is stressed that increased precision is only relevant 
if the trial design warrants internal validity. 
It is a prevalent belief that required size of the 
treatment groups can be determined in advance by 
statistical methods. Indeed, given certain quantities 
one can calculate the required study size statistically. 
The basic line of thought underlying these calcula-
tions and the actual formulas can be found else-
where[ll-IJJ_ The apparent exactness of these calcu-
lations creates the impression that the calculated 
study size is the optimal study size. This impression 
is delusive. Firstly, the study size is calculated from 
arbitrarily chosen statistical quantities, which include 
the level and the power of the test but also expected 
outcome occurrences, which are generally speaking 
unknown. Secondly, the calculations are extremely 
sensitive to these underlying assumptions: a small 
change in expected outcome occurrences may have a 
considerable impact on the required size. With all 
these arbitrary decisions and estimates, the number 
arrived at by calculation from formulas is subject to 
considerable manipulation. Thirdly, statistical size 
calculations are not based on any optimality criterion 
weighing the advantage of greater precision against 
the costs of performing a larger triaL In fact, the cost-
benefit problem is insoluble, as the impact of even 
the most promising trial is unpredictable: t:me cannot 
know in advance how many patients will benefit from 
the trial findings. Fourthly, the calculations do not 
take account of other available evidence. As a result, 
one is left to choose the study size judgmentally in 
the light of one's best (intuitive) understanding of 
precision, costs, and a surmise of the utility of the 
result [BJ_ 
Generalization 
Generalization may be viewed as the specification 
of a 'law of nature' which is believed to underlie the 
observations. For instance, from the many trials 
measuring the effect of beta blockers in acute myo-
cardial infarction, one may infer the following 'law 
of nature': 'Beta blockers in suspected acute myo-
cardial infarction reduce one-week mortality by 19% '. 
This statement does not only pertain to the patients 
that were entered into the particular trials. Rather, it 
confers a notion about a treatment effect in an abstract 
disease entity (suspected acute myocardial infarction, 
no contra-indication for a beta blocker). Scientific 
generalization is a process of abstraction from time-
and space-specific empirical measurement of a treat-
ment effect in a group of patients to a treatment 
effect in an (abstract) disease entity. Scientific general-
ization is not specific to medical research. It pertains 
to all branches of science. It has puzzled scientists 
and philosophers of science as well for centuries and 
is still not completely understood[IOJ_ 
Scientific generalization in the context of clinical 
trials is judgmental as to which characteristics of the 
trial patients are relevant to generalization. As an 
example, from a clinical trial in men, one might 
generalize the results to women if gender is considered 
to be irrelevant to the treatment effect-a judgement 
based on knowledge about the likely mechanism of 
action and its relation to the patient's gender. 
Scientific generalization (in the research setting) 
should not be confused with statistical generalization 
from sample to sampled population in sample surveys. 
Statistical generalization (e.g. in an opinion poll) does 
not go beyond the temporal and spatial constraints 
of the sampled population. For this reason it cannot 
be considered the basis for scientific generalization. 
As a matter of fact, if scientific generalization were 
simply a matter of statistical generalization, there 
would be no application to humans of results obtained 
from animal research [IOJ_ 
The relevance of a particular trial is ultimately 
determined by its potential for generalization: findings 
should support conclusions about the therapeutic 
benefit to be expected in a defined clinical indication 
which can be recognised in day-to-day clinical 
practice. A further discussion on this aspect of 
generalization is provided in the introductory notes 
to chapter 8. 
Ethical aspects 
The design and conduct of a clinical trial are 
fraught with ethical dilemmas. The general ethical 
requirements of clinical research have been formu-
lated in the Declaration of Helsinki issued by the 
World Medical Association. It is widely accepted that 
patients must be fully informed of their participation 
in a trial and of the possible consequences and that 
participation may take place only after consent has 
been given. 
A first premise is that it is unethical to conduct an 
experiment that is poorly designed or carried out. 
Further, a trial protocol is only ethically justifiable 
if under present knowledge there is no established 
explicitly better treatment available outside the proto-
col. Also, the treatment alternatives should be equally 
acceptable. In each clinical trial there is a potential 
conflict between the needs of the individual patient 
who requires treatment at that moment and the needs 
of future patients who might benefit from the re-
search efforts to identify better treatments. Each 
trial requires a careful weighing of the needs of the 
individual against those of the collective. On the 
other hand, a patient entering a randomised trial 
with balanced allocation to either of two treatment 
regimens has a chance of one half of receiving the 
better treatment, a guarantee that cannot always be 
given in ordinary clinical practice. 
The epidemiologic perspective of clinical trials 
Clinical research may be viewed as applied medical 
science, or as the scientific link between biomedical 
science (basic research) and clinical practice ( examin-
ation and treatment of the individual patient). The 
goal of all scientific research in medicine is to expand 
existing knowledge on disease and health in humans. 
The medical scientist, just like the physicist, seeks to 
expand knowledge of nature. In medical science, how-
ever, the quest for knowledge is not a goal in itself 
but derives from the desire to prevent diseases and 
to improve their treatment. This principle is, of 
course, very prominent in clinical research, but it 
applies to basic research as well. 
In contrast to basic research, which is concerned 
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with the functioning of the human organism in disease 
and health, clinical research deals with the occurrence 
of states and events of medical concern among patients 
under medical care. This facet has given rise to the 
concept and discipline of clinical epidemiology. The 
more traditional epidemiology studies the occurrence 
of an outcome or a health event (e.g. atherosclerotic 
coronary heart disease) in relation its determinants 
(e.g. cholesterol) in man. Likewise, the forcus of 
clinical epidemiologic research is on the relation 
between an outcome (e.g. recurrence of myocardial 
ischaemia) and a determinant (e.g. treatment with a 
calcium antagonist) among patients (e.g. patients 
admitted to hospital for unstable angina). 'Deter-
minant' is used to indicate a characteristic on which 
the outcome depends, e.g. in the sense that cholesterol 
may 'determine' the occurrence of atherosclerotic 
heart disease, or that recurrence of ischaemia is 'deter-
mined' by the treatment that is used. 
A multitude of medical sciences and areas of 
practice embody epidemiologic problems. There-
fore, epidemiology does not constitute a field of 
knowledge per ser8l. Cardiovascular epidemiologic 
research, whether clinical, etiologic, or preventive, is 
research within the field of cardiology. The adjective 
epidemiologic relates to the form of the research 
problem: the occurrence of an outcome (or health 
event) in relation to one or more determinants in 
man. The form of the epidemiologic research problem 
is common to all fields of clinical medicine. The 
principles of studying the occurrence of illness and 
related states and events in man constitute what may 
be termed theoretical epidemiologyr8 l. Other terms 
that might be used are the theory of applied medical 
science, the theory of clinical research. 
Epidemiology as a research discipline distinguishes 
two types of studies: experimental and nonexperi-
mental. In an experimental study the investigator 
deliberately manipulates a condition in order to learn 
about its effect on outcome. Epidemiologic experi-
ments have their roots in the concepts of scientific 
experimentation (e.g. in physics and agricultural 
science). When experiments are not feasible, non-
experimental studies (i.e. studies without artificial 
manipulation of the determinant) are designed to 
emulate what might have been learned had an experi-
ment been conducted [101. Epidemiologic research, 
whether experimental or non-experimental, is by 
definition empirical. It is based upon systematic 
collection of observations on the phenomena of 
interest in a defined group of individuals. The term 
'observational' to indicate a nonexperimental epi-
demiologic study must be considered a misnomer. 
22 J_ G. P. Tijssen and J. Lubsen 
Thus, a clinical trial may be defined as a scientific 
experiment with patients as subjects. In a scientific 
experiment the scientist varies one factor under other-
wise controlled circumstances, in order to ascertain 
what effect variation in that factor would have on 
the outcome of interest. In physical sciences the 
scientist usually can control all other factors that 
would affect the outcome. Complete control of other 
factors affecting the outcome cannot be achieved in 
the setting of clinical medicine, but techniques such 
as placebo treatment, randomisation, and blinding 
are available to establish conditions for valid experi-
mentation. 
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Design and methods 
INITIAL SCREENING OF PATIENTS 
At admission to hospital men and women under 71 
years of age in whom unstable angina was suspected 
were screened for inclusion before the results of the 
enzyme measurements were known. Chest pain (if 
present) was treated according to a standardized 
protocol (see below). Eligibility was assessed only 
after relief of chest pain. Eligibility could also be 
assessed when chest pain developed after admission 
to hospital. No logbook of screened but eventually 
rejected patients was kept. 
TREATMENT OF ANGINA PAIN 
. ~hest pain was treated with sublingual glyceryl 
tnmtrate (maximum two 1·0 mg doses) and if it per-
sisted for more than five minutes with an intravenous 
injection of glyceryl trinitrate (maximum 1 mg in 10 
ml 5% glucose) or fentanyl (0·05 mg). Electrocardio-
grams were recorded before treatment was started 
between each of the above steps, and after relief of 
pain. Blood samples were obtained after relief of 
pain. If chest pain could not be relieved by these 
treatments, a provisional diagnosis of suspected acute 
myocardial infarction was made, and further measures 
were left to the discretion of the treating physician. 
At the time when the trial was started, the study 
protocol had no provision for the intravenous in-
jections. The patient should chew one 10 mg dose of 
nifedipine if chest pain was not relieved by sublingual 
glyce~yl trinitrate. From 1 January 1982 nifedipine 
was disallowed, and the study protocol required intra-
:enou~ injections with glyceryl trinitrate or fentanyl 
If sublmgual glyceryl trinitrate failed to relieve chest 
pain. 
ELIGIBILITY 
T_o qualify for admission to the trial the presence 
of ~Ither ?fthe following was required: (1) a chest pain 
episode m the hospital accompanied by a varying 
patte~ of ST-segment or T-wave chang(!S suggesting 
rev~rs1ble ~yocardial ischaemia; (2) a history of 
typical angma at rest or during light activity occur-
ring within 12 hours of admission and lasting more 
than 15 minutes combined with either ST-segment or 
T-wave abnormalities, a documented history ofmyo-
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cardia! infarction or unstable angina, or at least 50% 
narrowing of a major coronary artery observed at 
earlier angiography. 
Patients who did not qualify at hospital admission 
were included on the basis of the above criteria when 
chest pain subsequently developed, provided that 
available enzyme values were below twice the local 
upper normal limit. 
If chest pain was not relieved by the above treat-
ments or if the patient impressed otherwise as sustain-
ing acute myocardial infarction, the patient qualified 
as yet when serial enzyme measurements showed that 
myocardial necrosis was absent, provided that chest 
pain had subsided and that no time limits were 
exceeded . 
Patients were not included if a contra-indication 
for treatment with a beta blocker or nifedipine was 
present (clinically overt heart failure, heart rate below 
50 beats min- 1 , or systolic blood pressure < 100 
mmHg) or if an indication for treatment with a beta 
blocker or nifedipine was present (heart rate over 120 
beats min- 1 or systolic blood pressure > 170 mmHg 
and diastolic blood pressure > 110 mmHg). Also 
excluded were patients with a possible noncoronary 
cause of angina pectoris, such as anaemia (haemo-
globin < 6· 5 mmol I-1 ), conduction abnormalities 
other than bundle branch block, congenital or 
valvular heart disease, cardiomyopathy, serious pul-
monary disease. Patients with new Q-wave formation 
in the electrocardiogram or with acute myocardial 
infarction within the last week were not included. In 
addition the following exclusions were applied: 
maintenance treatment with nifedipine, age over 70, 
s~rio~s noncardiac disease, and previous participa-
tion m HINT. 
If patients had high heart rate or high blood 
pressure immediately after admission to hospital, 
enrolment should proceed but heart rate and blood 
pressure were required not to exceed the above limits 
just before randomisation. 
INFORMED CONSENT 
It was the responsibility of the treating physician 
to inform possible participants of the trial and to ask 
consent. The information was intended to give each 
participant a thorough understanding of the purpose 
and the nature of the trial, the cooperation required, 
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and any side-effects possibly associated with the trial 
medication regimens. The benefits the patient might 
derive from the trial and the impact possibly emerging 
from the trial were explained. It was clearly pointed 
out that the patient might be treated with placebo, 
but also that placebo treatment might emerge as the 
most favorable treatment in the trial. It was expressly 
stated that the patient was completely free to refuse 
and that if he did so he would receive standard treat-
ment with the same degree of care. It was also pointed 
out that the trial medication consisted of four-hourly 
doses, so that awakening during the night in order to 
take medication was necessary. 
To assist the treating physician, a sample consent 
form was made available. Only oral consent was 
required. If possible, relatives of the patients attended 
the information and consent session. If no relatives 
were available, consent was asked in the presence of 
a nurse. If the patient desired some time for reflection, 
this was granted. The informed consent procedure 
was approved by the institutional review boards of the 
participating Clinical Centres. Modifications required 
by the institutional review board were applied in the 
centres concerned. These included, amongst others, 
that an information pamphlet was handed over to 
possible participants. 
The consent also included permission for the 
Coordinating Centre to gather information on the 
clinical course for the sole purpose of scientific re-
search. Whether the consent also included permission 
for subsequent coronary angiography depended on 
the angiography policy in the Clinical Centre. If 
angiography was part of the diagnostic routine, per-
mission for angiography was asked in the context of 
this routine. If this was not the case, permission to 
perform angiography was incorporated in the consent 
for the trial. 
LATE EXCLUSIONS 
The informed consent procedure and administrative 
procedures of admission to hospital sometimes caused 
a considerable delay, in which conditions could have 
changed. It was required that all criteria still applied 
at randomisation and that no more than 12 hours had 
elapsed since the last episode of chest pain. In par-
ticular, a patient was as yet excluded if signs of acute 
myocardial infarction had developed before the start 
of trial medication: renewed chest pain that could 
not be relieved as described above, new Q-wave form-
ation on the electrocardiogram, enzyme rises over 
twice the local upper limit for normal. (There was no 
need to wait until enzyme values were returned from 
the laboratory, but already available measurements 
were taken into account). If the treating physician 
came to the conclusion that the clinical condition of 
the patient had deteriorated too much, the patient was 
also excluded. 
START OF TRIAL MEDICATION 
As soon as eligibility was established and informed 
consent was obtained the following was undertaken: 
(I) an electrocardiogram was recorded (the baseline 
electrocardiogram), (2) blood samples were obtained 
(for the determination of enzyme concentrations, 
chemistry, haematology, plasm levels of nifedipine 
and metoprolol), (3) baseline measurements of heart 
rate and blood pressure were taken, in duplicate ten 
minutes apart. Thereupon, trial medication, which 
was available at the coronary care unit in pre-packed 
sequentially numbered boxes, was started without 
further delay. The moment of randomisation was 
defined as the moment when the first dosage of trial 
medication was taken. 
Definition of the IDNT cohort 
The enrolment procedure as carried out in the 
Clinical Centres has yielded a cohort of patients to be 
followed onwards from randomisation. To promote 
clarity of data description and data analysis, all enrol-
ments were retrospectively grouped as 'unassess-
able', 'improper', or 'proper'. The grouping was 
applied by the Classification Committee (see chapter 
6) based upon pre-randomisation data only. 
An enrolment was grouped as unassessable if any 
of the following applied: (1) loss of all or most of 
the electrocardiograms; (2) inability to identify the 
moment of randomisation-an uncertainty margin 
not greater than one hour was allowed; (3) inability 
to identify the randomisation number for a particular 
patient. Second enrolments were also counted in this 
category. 
Enrolments in which the inclusion protocol had 
been unequivocally violated were grouped as im-
proper under the following headings: (1) misinter-
pretation of recent history: a delay of more than 12 
hours between the last attack of chest pain and ran-
domisation, duration of chest pain at home less than 
15 minutes, angina of effort only, misidentification 
of previous maintenance treatment with a beta 
blocker; (2) overlooked exclusion criteria: too old, 
hypertension, bradycardia, recent myocardial in-
farction, unequivocal electrocardiographic signs of 
evolving acute myocardial infarction; (3) use of un-
allowed medications before randomisation, either to 
treat anginal pain (chewing a capsule nifedipine, 
opiates) or otherwise (an infusion of glyceryl trini-
trate, intravenous beta blockade); (4) persisting chest 
pain at randomisation; (5) miscellaneous. A protocol 
violation constituted entry of an ineligible patient. 
This was mostly a matter of mismanagement of the 
trial protocol, often obvious and clearly preventable 
but sometimes of a more subtle kind. Take as an 
example a patient who qualified for admission on 
the basis of transient ST-segment changes during an 
episode of chest pain after hospital admission. Con-
sent was granted after a delay of two hours. In 
keeping with the instructions, the nurse recorded an 
electrocardiogram just before start. The electrocardio-
gram showed distinct new Q-wave formation: an ex-
clusion criterion had eventually been overlooked. 
The remaining patients (i.e., those with assessable 
records, without unequivocal violations of the admis-
sion protocol) were grouped as proper; they constitute 
the HINT cohort 
Central review of the electrocardiograms 
The Classification Committee reviewed all pre-
randomisation electrocardiograms to ascertain the 
required ST -segment or T -wave changes or abnor-
malities. 
For patients enrolled on the basis of purported ST-
segment or T -wave changes during pain the Classifica-
tion Committee could either (I) confirm the (required) 
ST-segment or T-wave changes; (2) acknowledge 
steady ST-segment or T-wave abnormalities; or (3) 
deny any ST-segment or T-wave abnormality. If only 
one electrocardiogram recorded during pain was 
available, changes could by definition not be estab-
lished. The case was then classed under (2) or (3) of 
the above. 
For patients enrolled on the basis of a recent history 
of chest pain at home and additional evidence for 
atherosclerotic coronary heart disease the Classifica-
tion Committee ascertained the evidence: ST-segment 
or T-wave abnormalities, previous myocardial in-
farction as evidenced from hospital case notes or Q-
waves on the electrocardiogram, previous episodes 
of unstable angina as evidenced from hospital case 
notes and serial electrocardiograms, or angiographi-
cally shown narrowings of the coronary arteries 
reported at earlier angiography. 
The goal of the Classification Committee's review 
was to put the enrolments in order for data present-
ation and data analysis. Consequently, the review of 
the Classification Committee did not necessarily 
follow the momentary reasoning of the treating physi-
cian when the patient was admitted. Take as an ex-
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ample a patient who came to the emergency room 
after an attack of chest pain at home which had 
subsided spontaneously before arrival at the hospitaL 
The admission electrocardiogram showed T-wave 
inversion in V 3 and V 4 . The treating physician 
(rightly) decided that the patient was eligible for 
immediate enrolment However, the electrocardio-
gram showed no ST -segment or T -wave changes 
when the patient subsequently developed renewed 
chest pain during the consent procedure. The patient 
was classified on the basis of the later in-hospital 
attack of chest pain, and the (required) ST-segment 
or T-wave changes were not confirmed. 
The Classification Committee took a mild posture 
when assessing ST-segment or T-wave changes or ab-
normalities. Minute changes or abnormalities suf-
ficed. No complete return to normality after relief of 
chest pain was required. If worsening ST -segment or 
T-wave abnormalities unequivocally pointed towards 
evolving myocardial infarction, the enrolment was 
grouped as improper. 
Also, the presence of Q-waves greater than 0-03 
seconds or Q-wave equivalents (R-wave > 0-03 
seconds in V 1 and R/S-ratio greater than unity in 
V 2 ) on pre-randomisation electrocardiograms was 
ascertained. 
Definition of recorded baseline characteristics 
CLINICAL HISTORY 
The presence of angina pectoris prior to admission 
to hospital was scored in: (I) no angina pectoris, (2) 
angina pectoris of effort present for less than four 
weeks, (3) angina pectoris of effort present for more 
than four weeks with gradual acceleration during the 
last few days or weeks, (4) stable angina pectoris of 
effort present for more than four weeks, without any 
acceleration prior to the presenting episode of angina 
at rest. 
Previous myocardial infarction was ascertained 
from clinical case notes and from the presence of Q-
waves on the admission electrocardiogram. Results 
of previous angiography were recorded from angio-
graphy reports. The left main, the left anterior 
descending, the circumflex, and the right coronary 
artery were scored as diseased if the report made 
mention of a narrowing of at least 50% in the artery 
itself or in any of the main branches (first or second 
diagonal for the left anterior descending artery, first 
to third marginal branch for the circumflex artery, 
descending posterior for the right coronary artery-
irrespective of its origin). The most recent angiogram 
was used. An artery with a bypass was scored as 
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diseased. In addition, previous bypass surgery was 
recorded. Medications being taken prior to admission 
to hospital were recorded in the following categories: 
beta blockers, long-acting oral nitrates, oral antico-
agulants, diuretics, cardiac glycosides, antiarrhythmic 
drugs, calcium antagonists other than nifedipine, 
platelet aggregation inhibiting drugs, antihypertensive 
drugs. Furthermore, medications being taken for pain 
relief after hospital admission but before randomis-
ation were recorded in the following categories: sub-
lingual glyceryl trinitrate, an intravenous injection 
with glyceryl trinitrate or fentanyl. 
TIME DELAYS 
The pain free interval was defined as the time 
elapsed between pain relief after the last episode of 
chest pain and randomisation. The pain free interval 
represents the period over which the patient has been 
clinically stable. 
The moment of qualification was taken as the 
moment when eligibility could have been established, 
i.e. for patients with in-hospital episodes of chest pain 
with ST-segment or T-wave changes: after the last 
episode of chest pain with ST -segment or T -wave 
changes; for patients with in-hospital episodes of 
chest pain without ST-segment or T-wave changes: 
after the last attack of chest pain; for patients without 
in-hospital episodes of chest pain: the time of admis-
sion to hospital. The· randomisation delay was defined 
as the time elapsed between qualification and random-
isation. The randomisation delay represents the delay 
due to the informed consent procedure and further un-
necessary delays between qualification and random-
isation. 
The hospital delay was taken as the time interval 
between hospital admission and randomisation. 
PRE-RANDOMISATION ELECTROCARDIOGRAPHY 
For each patient two electrocardiograms recorded 
before randomisation were singled out for further 
analysis: an electrocardiogram recorded in the 
absence of pain (the baseline electrocardiogram) and 
an electrocardiogram made during pain (the pain 
electrocardiogram), the latter only for patients with 
pain while in hospital. 
The last pre-randomisation electrocardiogram 
obtained in the absence of pain was taken as the 
baseline electrocardiogram. If no electrocardiogram 
recorded in the absence of pain was available, an 
electrocardiogram made after substantial diminution 
of pain was taken as baseline electrocardiogram. 
When only electrocardiograms made during unabated 
chest pain were available, the baseline electrocardio-
gram was considered not available. 
The pain electrocardiogram was selected by one 
cardiologist as the electrocardiogram made during 
pain that most clearly presented the abnormalities 
that were typical for myocardial ischaemia. The car-
diologist was blinded to the patient's trial medication 
assignment. Electrocardiograms made while chest 
pain was still untreated were preferred. The pain 
electrocardiogram was not available for patients 
admitted on the basis of a chest pain episode at 
home. 
Both electrocardiograms were submitted for sys-
tematic coding of abnormalities. If the coding tech-
nician decided that an electrocardiogram could not 
be coded owing to the poor quality of the electro-
cardiogram, it was, if possible, replaced by another 
electrocardiogram. The electrocardiograms were 
coded for the Minnesota coder1l, the cardiac in-
farction injury scorer2 l, and a specially developed ST-
segment scorer3 l. The latter recorded (amongst other 
things) the maximal amount ofST-segment depression 
and the maximal amount of ST -segment elevation in 
the following four groups of leads: infero-posterior 
(leads II, III, aVF), anterior (leads VrV5 ), V2 (lead 
V2 only), and lateral (leads I, aVL, V6 ). The coding 
was in the following categories: none, 0·01-0·04 mV, 
0·05-0·09 mV, 0·10-0·19 mV, 0·20-0·50 mV, 0·51 mV 
or more. The scores were declared missing (1) if the 
electrocardiogram was not available, (2) if the electro-
cardiogram was illegible (and could not be replaced 
by a suitable legible one), or (3) if any of the 
Minnesota codings rendered the ST -segment un-
defined (codes 6-4-l, 7-1-1, 7-2-1, 7-4, or 9-8-1). 
Several electrocardiographic baseline characteris-
tics were derived from the codes. The main principle 
was to describe abnormalities present on the baseline 
electrocardiogram and changes in the pain electro-
cardiogram relative to the baseline electrocardiogram. 
Separate codes were used to indicate that the baseline 
or the pain electrocardiogram was missing. The latter 
circumstance is of clinical relevance because this 
would occur if the patient had arrived at the hospital 
after chest pain had subsided. The presence of ST-
segment depression of at least 0·1 m V on the baseline 
electrocardiogram was based upon the maximal ST-
segment depression coded for the four groups ofleads. 
The presence of ST -segment elevation on the baseline 
electrocardiogram was defined analogously. More ST-
segment depression during pain was considered to be 
present if the ST-segment coding for any of the four 
groups of leads was in a higher category at pain than 
at baseline. More ST-segment elevation during pain 
was defined analogously. These variables were de-
clared missing (I) if the pain electrocardiogram was 
missing, (2) if its ST-segment was undefined, (3) if 
the baseline electrocardiogram was missing, or (4) if 
its ST-segment was undefined. 
HEART RATE AND BLOOD PRESSURE 
Two measurements of heart rate and of systolic 
and diastolic blood pressure were scheduled for each 
patient. Baseline values for heart rate and for blood 
pressure were taken as the average of the two measure-
ments, provided that they were not more than fifteen 
minutes apart. Otherwise, the last measurement of 
heart rate and systolic and diastolic blood pressure 
was taken as the baseline value. If more than four 
hours had elapsed between the last measurement and 
randomisation or if there were no measurements at 
all, the baseline values were considered missing. 
ACTIVITIES OF CARDIAC ENZYMES 
Blood samples for measurements of activities of 
creatine kinase or its ME-isoenzyme and glutamic 
oxaloacetic transaminase were obtained at least once 
(and preferably shortly) before randomisation. All 
enzyme determinations were performed locally and 
were subsequently related to local normal values. 
They are expressed as a percentage of the local upper 
limit for normal. (Values over 200%-that is, 
activities over twice the local upper limit for 
normal-are referred to as significantly raised.) 
The last enzyme values obtained before random-
isation were taken as the baseline values for the 
above enzymes, provided that had been obtained no 
longer than six hours before randomisation. Post-
randomisation values were never taken as baseline 
value. 
Description of the HINT cohort 
RESPECTIVE CATEGORIES OF ENROLMENT 
Thirty enrolments were classified as unassessable. 
In three patients all electrocardiograms were missing. 
The moment of randomisation could not be identified 
in four patients. For two patients the randomisation 
number could not be identified. There were seven 
second enrolments. Fourteen patients developed a 
contra-indication after they had provisionally been 
assigned a randomisation number but before trial 
medication was actually started. 
Between 1 February 1981 and 30 October 1984, 668 
patients with assessable records were enrolled in 11 
Clinical Centres. Not all Clinical Centres participated 
over the whole accrual period. Table 3.1 shows the 
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Table 3.1 Patient accrual per clinical centre 
Patients entered 
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contribution per Clinical Centre. Figure 3.1 shows 
patient accrual over time. 
Table 3.2 shows the occurrence of unequivocal 
violations of the enrolment protocol in 131 patients. 
The Classification Committee decided that fourteen 
patients showed unequivocal explicit signs of evolving 
myocardial infarction on pre-randomisation electro-
cardiograms. In some patients more than one protocol 
violation occurred. The remaining 537 patients were 
eligible and thus constitute the HINT cohort. 
PROFILE OF THE HINT COHORT 
Table 3.3 shows the baseline values for the activities 
of the cardiac enzymes. Twenty-two patients had 
significantly raised baseline values for at least one 
cardiac enzyme (a value greater than 200%). In 
another three patients significantly raised enzyme 
values were registered, but these were considered 
of noncardiac origin: raised activities of glutamic 
oxaloacetic transaminase in one patient who was an 
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Table 3.2 Patients in whom an unequivocal violation of 
the admission protocol occurred 
Patients with violation of admission protocol 
Misinterpretation of recent history 
> 12 hours pain free 
Pain< 15 min 
Angina of effort 
Previous beta blockade 






Overt signs of heart failure 
Conduction abnormalities 
Valvular heart disease 
Serious pulmonary disease 
Recent myocardial infarction 
Evolving myocardial infarction* 
Previous maintenance nifedipine 
Unallowed medications 
To treat chest paint 
Infusion of glyceryl trinitrate 
Other 



























* Unequivocal signs of evolving myocardial infarction on 
pre-randomisation electrocardiograms. 
t These include opiates and chewing a capsule of nifedipine. 
In some patients more than one protocol violation occurred. 
alcoholic and two measurement errors. These enzyme 
values are not included in Table 3.3. The HINT 
cohort is described for patients with pre-random-
isation myocardial infarction and those without 
separately. 
Of the 515 patients without pre-randomisation 
myocardial infarction 177 (34%) were on previous 
maintenance treatment with a beta blocker. They 
are further described for the two groups defined by 
previous maintenance treatment with a beta blocker 
separately. 
Table 3.4 shows the results of the central review of 
pre-randomisation electrocardiography. The treating 
physician's judgement on the presence of (qualifying) 
ST-segment or T-wave changes was confirmed in 80% 
of the patients without pre-randomisation myo-
cardial infarction admitted on the basis an in-hospital 
episode of chest pain with accompanying electro-
cardiograms; in 7% of these patients the Classifica-
tion Committee found no abnormalities at all. ST-
Table 3.3 Baseline values for the activities of three selected 
cardiac enzymes 
Cardiac enzymes 
CK MB-CK GOT Maximum 
(N = 353) (N = 252) (N = 488) (N = 520) 
< 100%* 310 (88%) 224 (89%) 450 (92%) 448 (86%) 
100-150% 19 (5%) 7 (3%) 23 (5%) 32 (6%) 
150-200% 10 (3%) 7 (3%) 12 (2%) 18 (3%) 
>200% 14 (4%) 14 (6%) 3 (!%) 22t (4%) 
CK, creatine kinase: MB-CK, ME-isoenzyme of creatine 
kinase; GOT, glutamic oxaloacetic transaminase; Maximum. 
maximum of these three enzymes; 
* Activities at baseline are expressed as percentages of the 
local limit for normal. 
t These 22 patients (4%) had a pre-randomisation myo-
cardial infarction, which was not known when the patient 
was randomised. 
In 17 patients, no pre-randomisation enzyme values were 
available. 
segment or T-wave abnormalities at baseline were 
confirmed in 72% of the patients without pre-
randomisation myocardial infarction enrolled on the 
basis of an episode of chest pain at home; in 15% 
other evidence of atherosclerotic coronary heart dis-
ease was available; in the remaining 13% no further 
evidence for atherosclerotic coronary heart disease 
was available. 
Table 3.5 shows selected demographic clinical base-
line characteristics of the patients of the HINT 
cohort. The vast majority of HINT patients was of 
the male gender and between 50 and 65 years of age. 
The majority of patients had a history of angina 
pectoris, but not of previous myocardial infarction. 
Among the patients on previous maintenance treat-
ment with a beta blocker there was a (relatively) 
higher prevalence of previous angina pectoris and 
previous myocardial infarction; angiography and by-
pass surgery had also been performed more often in 
these patients. 
Table 3.6 shows medications being taken before 
hospital admission. Previous maintenance treatment 
with a beta blocker consisted mostly of metoprolol 
or propranolol. Long-acting nitrates were being taken 
by 100 patients (19%). Antiarrhythmic drugs or 
cardiac glycosides were taken by only a few patients. 
Diuretics were being taken by 100 patients (19%), 
mostly for hypertension. Table 3.6 also shows medica-
tions given for pain relief prior to randomisation. 
Sublingual glyceryl trinitrate sufficed in almost all 
patients. 
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Table 3.4 Review of pre-randomisation electrocardiographic abnormalities by the 
Classification Commillee 
Pre-randomisation MI Previous beta blockade 
Yes No No Yes 
(N = 22) (N = 515) (N = 338) (N = 177) 
Pain ECGs available 19 319 210 109 
ST-T changes confirmed 17 (90%) 254 (80%) 172 (82%) 82 (75%) 
Steady ST-T abnormalities 2 (10%) 41 (13%) 21 (10%) 20 (18%) 
No ST-T abnormalities 0 (0%) 24 (7%) 17 (8%) 7 (6%) 
Pain ECGs not available 3 196 128 68 
Resting ST-T abnormalities 2 (67%) 141 (72%) 90 (70%) 51 (75%) 
Other evidence of ACHD 1 (33%) 29 (15%) 18 (14%) 11 (16%) 
Neither of the above 0 (0%) 26 (13%) 20 (16%) 6 (9%) 
MI, myocardial infarction; ECGs, electrocardiograms; ST-T, ST-segment or T-
wave, ACHD, atherosclerotic coronary heart disease. 
Pain electrocardiograms (i.e. electrocardiograms recorded during chest pain) were, 
generally speaking, only available for patients with chest pain while in hospital. 
Changes refer to ST-segment or T-wave changes between electrocardiograms 
obtained during pain and electrocardiograms obtained after relief of chest pain. 
Table 3.7 shows the pain free interval, the random-
isation delay, and the delay in the hospital. Trial 
medication was started after a pain free interval of 
less than one hour in 26% of patients and in a further 
37% after an interval of between one and three hours. 
In 68% of patients there was an (unwanted) delay of 
more than one hour between qualification and ran-
domisation. Only 12% of patients were randomised 
within one hour of hospital admission. 
Table 3.8 shows characteristics from the (pain free) 
baseline electrocardiogram. ST-segment codings were 
not available in 22 patients: in five patients no codable 
pre-randomisation baseline electrocardiogram was 
available, in 8 patients only (one) electrocardiogram 
made during pain was available, and in nine patients 
ST-segments were undefined because of Minnesota 
code incompatibilities (e.g. a bundle branch block). 
ST -segment depressions of at least 0·1 m Vat baseline 
were present in 98 patients (18%), ST-segment eleva-_ 
tions of at least 0·1 m V in 109 patients (20% ). 
Table 3.9 shows electrocardiographic baseline 
characteristics from the pain electrocardiogram. ST-
segment codings during pain were not available in 
199 (37%) patients, because they had not suffered 
chest pain while in hospital; in another 17 patients 
(3%) ST-segment codings were not available owing 
to illegibility of pain electrocardiograms or to 
Minnesota code incompatibilities. ST-segment de-
pressions of at least 0· I m V on electrocardiograms 
made during pain were present in 127 patients (24%); 
similar ST-segment elevations in 72 patients (13%). 
The codings of the ST -segment on the baseline electro-
cardiogram could be compared to those on the pain 
electrocardiogram in 308 patients (57%): more ST-
segment depression occurred in 169 patients (31 %), 
more ST-segment elevation in 107 patients (20%), 
whereas more ST -segment depression in some leads 
and more ST -segment elevation in other leads 
occurred in 53 patients (10%). 
Table 3.10 shows baseline values for heart rate and 
blood pressure. Heart rates were lower for patients 
on previous maintenance treatment with a beta 
blocker in comparison to those not on beta blockers. 
Blood pressures were approximately equal for these 
groups of patients. 
Discussion 
According to one widely accepted definition 
patients who have recent onset (effort) angina, wor-
sening angina, or angina at rest are classified as 
having unstable angina provided there are no signs 
of acute myocardial infarction rs1. It is generally 
recognised that the differential diagnosis of such cases 
may be difficult and that myocardial infarction may 
already have occurred or may be about to occur. In 
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481 (93%) 321 (95%) 160 (90%) 
34 (7%) 17 (5%) 17 (10%) 
* Crescendo, angina pectoris of effort present for more than one month with gradual 
acceleration; sudden, angina pectoris of effort present for at least one month without 
any acceleration prior to the presenting episode of angina at rest. 
the present trial 537 patients were enrolled in whom 
unstable angina was diagnosed at admission to the 
coronary care unit. This diagnosis was based on a 
combination of findings-prolonged chest pain at 
rest, evidence for causal myocardial ischaemia, and 
absence of signs of acute myocardial infarction such 
as chest pain refractory to treatment with nitrates or 
fentanyl or characteristic electrocardiographic signs. 
Unstable angina according to the HINT criteria is a 
subcategory of unstable angina as defined above. 
This diagnosis may also be viewed a subcategory of 
syndromes of prolonged chest pain at rest leading to 
admission to a coronary care unit, the diagnosis of 
suspected acute myocardial infarction being another 
subcategory. Many patients who are admitted to a 
coronary care unit have symptoms and signs in be-
tween those typical for unstable angina (i.e. reversible 
ischaemia) and those typical for acute myocardial 
infarction (i.e. irreversible ischaemia). The HINT 
patients specifically represent one end of the clinical 
spectrum; they have a low probability of evolving 
myocardial infarction at the moment of diagnosis. In 
4% (22 out 537) myocardial infarction had already 
developed to the extent that enzyme activities were 
Table 3.6 Medication being taken at hospital admission 
Pre-randomisation MI Previous beta blockade 
Yes No No Yes 
(N = 22) (N = 515) (N = 338) (N = 177) 
Maintenance treatments 
None 15 (68%) 294 (57%) 241 (71%) 53 (30%) 
Beta blockers 4 (18%) 177(34%) 177 
Nitrates 100 (19%) 26 (8%) 74 (42%) 
Anticoagulants 3 (14%) 76 (15%) 31 (9%) 45 (25%) 
Diuretics 4 (18%) 96 (19%) 42 (12%) 54 (31 %) 
Cardiac glycosides 17 (3%) 9 (3%) 8 (5%) 
Antiarrhythmic drugs 5 (!%) 5 (!%) 
Calcium antagonists* 5 (!%) 4 (!%) I (I%) 
Antiplatelet drugs I (5%) 16 (3%) 13 (4%) 3 (2%) 
Other antihypertensives 3 (14%) 37 (7%) 13 (4%) 24 (14%) 
Treatments for pain relieft 
No pain 2 (9%) 187 (36%) 122 (36%) 65 (37%) 
Spontaneous 2 (9%) 34 (7%) 20 (6%) 14 (8%) 
G I yceril trini tra te sl 17 (77%) 272 (53%) 177 (52%) 95 (54%) 
Glyceril trinitrate or fentanyl iv I (5%) 22 (4%) 19 (6%) 3 (2%) 
Ml, myocardial infarction; sl, sublingual; iv, intravenous. 
* Other than nifedipine, t given after hospital admission. 
Table 3.7 Time delays before randomisation 
Pre-randomisation MI Previous beta blockade 
Yes No No Yes 
(N = 22) (N = 515) (N = 338) (N = 177) 
Pain free interval 
<I hour 4 (18%) 133 (26%) 89 (26%) 44 (25%) 
1-3 hours 12 (55%) 186 (36%) 121 (36%) 65 (37%) 
>3 hours 6 (27%) 196 (38%) 128 (38%) 68 (38%) 
Randomisation delay 
<I hour 3 (14%) 167 (32%) 112 (33%) 55(31%) 
1-3 hours 14 (64%) 234 (45%) 154 (46%) 80 (45%) 
>3 hours 5 (23%) 114 (22%) 72 (21 %) 42 (24%) 
Hospital delay 
< 1 hour 1 ( 5%) 63 (12%) 43 (13%) 20 (II%) 
1-3 hours 9 (41 %) 240 (47%) 162 (48%) 78 (44%) 
>3 hours 12 (54%) 212 (4!%) 133 (39%) 79 (45%) 
MI, myocardial infarction; pain free interval, time between relief of chest pain and 
randomisation; randomisation delay, delay between qualification and randomisation; 
hospital delay, time between hospital admission and randomisation. 
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Table 3.8 Baseline characteristics from electrocardiogram when pain absent 
Pre-randomisation MI Previous beta blockade 
Yes No No Yes 
(N = 22) (N = 515) (N = 338) (N = 177) 
ST-segment depression at baseline 
None 7 (32%) 214 (42%) 155 (46%) 59 (33%) 
0·01-0·04 mV 4 (18%) 69 (13%) 52 (15%) 17 (10%) 
0·05-0·09 m V 4 (18%) 119 (23%) 72 (21 %) 47 (27%) 
0·10-0·19 mV I (5%) 68 (13%) 32 (10%) 36 (20%) 
0·20-0·50 mV 4 (18%) 25 (5%) 13 (4%) 12 (7%) 
ST-segment code missing 2 (9%) 20 (4%) 14 (4%) 6 (3%) 
ST-segment elevation at baseline 
None 4 (18%) 100 (19%) 64 (19%) 36 (20%) 
0·00-0·04 m V 7 (32%) 127 (25%) 89 (26%) 38 (21 %) 
0·05-0·09 m V 4 (18%) 164 (32%) 110 (33%) 54 (31 %) 
0·10-0·19 mV 5 (23%) 91 (18%) 54 (16%) 37 (21 %) 
0·20-0·50 mV 13 (2%) 7 (2%) 6 (3%) 
ST-segment code missing 2 (9%) 20 (4%) 14 (4%) 6 (3%) 
T-wave inversion at baseline 
. Upright 8 (36%) 145 (28%) 109 (32%) 36 (20%) 
0·01-0·09 mV 7 (32%) 149 (29%) 102 (30%) 47 (27%) 
0·10-0·50 mV 7 (32%) 192 (37%) 109 (32%) 83 (47%) 
>0·50 mV 24 (5%) 15 (4%) 9 (5%) 
T-wave code missing 5 (!%) 3 (!%) 2 (1 %) 
ST-T abnormalities at baseline* 
None 13 (59%) 269 (52%) 191 (57%) 78 (44%) 
T-wave inversion only 2 (9%) 121 (23%) 78 (23%) 43 (24%) 
ST non-anterior 18 (4%) 9 (3%) 9 (5%) 
ST anterior 5 (23%) 87 (17%) 46 (14%) 41 (23%) 
ST-segment code missing 2 (9%) 20 (4%) 14 (4%) 6 (3%) 
CIIS-score at baseline 
<9 4 (18%) 161 (31 %) 115 (34%) 46 (26%) 
9-20 5 (23%) 161(31%) 96 (28%) 65 (37%) 
>20 11 (50%) 172(33%) 113 (33%) 59 (33%) 
Missing 2 (9%) 21 (4%) 14 (4%) 7 (4%) 
MI, myocardial infarction: ST-T, ST-segment or T-wave, CIIS, cardiac infarction 
injury score. 
* T-wave inversion, T-wave inversion of at least 0·10 mV; ST nonanterior, ST-
segment depression or elevation of at least 0·10 mV in nonanterior leads only; ST 
anterior, ST-segment depression or elevation of at least 0·10 mV in anterior leads 
(V2-Vs)-
over twice the normal limit. These cases of pre-
randomisation myocardial infarction could have been 
diagnosed immediately had instantaneous laboratory 
measurements been available. They form a special 
group of patients who are, by definition, no longer 
at risk for developing myocardial infarction in the 
follow-up period. 
Of 515 patients without pre-randomisation myo-
cardial infarction 93 (18%) had at least 0·10 mV ST-
segment depression at baseline, and of 303 patients 
with pain while in hospital 118 (39%) had at least 
0·1 m V ST -segment depression during pain. The per-
centages for ST-segment elevation were 20% and 
22%, respectively. These findings confirm the clinical 
impression that patients whose electrocardiographic 
signs impressed as particularly ominous while still 
indicative of reversible ischaemia were generally with-
held from the triaL 
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Table 3.9 Baseline characteristics from electrocardiogram when pain present 
Pre-randomisation MI Previous beta blockade 
Yes 
(N = 22) 
No No Yes 
(N = 515) (N = 338) (N = 177) 
ST-segment depression during pain 
No in-hospital pain 3 (14%) 196 (38%) lf8 (38%) 68 (38%) 
None 5 (23%) 96 (19%) 69 (20%) 27 (15%) 
0·01-0·04 mV I (5%) 33 (6%) 25 (7%) 8 (5%) 
0·05-0·09 m V 3 (14%) 56 (11 %) 37 (II%) 19 (II%) 
0·10-0·19 mV 5 (23%) 60 (12%) 35 (10%) 25 (14%) 
0·20-0·50 mV 4 (18%) 52 (10%) 33 (10%) 19(11%) 
>0·50 6 (I%) 5 (2%) I (I%) 
ST-segment code missing I (5%) 16 (3%) 6 (2%) 10 (6%) 
ST-segment elevation during pain 
No in-hospital pain 3 (14%) 196 (38%) 128 (38%) 68 (38%) 
None 6 (27%) 90 (17%) 69 (20%) 21 (12%) 
0·01-0·04 mV 5 (23%) 66 (13%) 40 (12%) 26 (15%) 
0·05-0·09 m V 3 (14%) 80 (16%) 51 (15%) 29 (16%) 
0·10-0·19 mV 4 (18%) 49 (10%) 35 (10%) 14 (8%) 
0·20-0·50 mV 18 (4%) 9 (3%) 9 (5%) 
>0·50 mV I (0%) I (0%) 
ST -segment code missing (5%) 15 (3%) 5 (!%) 10 (6%) 
Comparison of pain ECG with baseline ECG 
Not possible* 6 (27%) 223 (43%) 141 (42%) 82 (46%) 
Same ST-segment coding 3 (14%) 82 (16%) 56 (17%) 26 (15%) 
More ST-segment depression 10 (45%) 159 (31%) 105(31%) 54 (31 %) 
More ST-segment elevation 6 (27%) 101 (20%) 65 (19%) 36 (20%) 
Both 3 (14%) 50 (10%) 29 (9%) 21 (12%) 
MI, myocardial infarction; ECG, electrocardiogram. 
*No pain observed after hospital admission, no (codable) electrocardiogram during 
pain available, or no (codable) pain free electrocardiogram available for comparison. 
Eligibility in HINT not only depended on symp-
toms and signs at hospital admission but also on 
history and the patient's reaction to initial manage-
ment. Furthermore, clinic personnel on routine duty 
needed to enter patients. Special measures were taken 
to maintain high quality of operations. Nevertheless, 
mistakes are unavoidable in a trial like this, and 
ineligible patients were included. These ineligible 
patients were excluded from the HINT cohort and 
hence from the analysis. HINT was designed to answer 
a therapeutic issue specific to unstable angina as 
defined. These ineligible patients can not be regarded 
as having this form of unstable angina. Their inclusion 
in the analysis would contaminate the findings of 
those patients that specifically represent the syndrome 
of unstable angina as defined. It may be argued that 
patients whose ST-segment or T-wave changes or ab-
normalities could not be confirmed by the Classifica-
tion Committee are also ineligible. These patients 
were nevertheless retained because the treating phy-
sician's assessment of electrocardiography needed to 
prevail. 
When the trial started chewing a capsule of nifedi-
pine to relief chest pain was allowed before random-
isation. Later it was realized that this might com-
promise internal validity and the protocol was 
changed. All enrolments in which nifedipine was used 
to relieve pain were grouped as improper. 
In contrast to ineligible patients, who are known 
not to have unstable angina, patients with unassess-
able records were poorly documented so that unstable 
angina could not be established. They had to be 
excluded for practical reasons. 
It is generally accepted that exclusions based on 
pre-randomisation data do not compromise internal 
validity, provided that the exclusion criteria are 
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Table 3.10 Heart rates and blood pressure at baseline 
Pre-randomisation MI Previous beta blockade 
Yes No No Yes 
(N = 22) (N = 515) (N = 338) (N = 177) 
Heart rate 
< 70 beats min-1 8 (36%) 253 (49%) 136 (40%) 117 (66%) 
70-100 beats min-1 13 (59%) 249 (48%) 190 (56%) 59 (33%) 
> 100 beats min-1 1 (5%) 12 (2%) 11 (3%) 1 (1 %) 
Missing 1 (0%) I (0%) 
Systolic blood pressure 
<126 mmHg 13 (59%) 180 (35%) 113 (33%) 67 (38%) 
126--140 mmHg 7 (32%) 172 (33%) 111 (33%) 61 (34%) 
>140 mmHg 2 (9%) 160 (31 %) 111 (33%) 49 (28%) 
Missing 3 (1 %) 3 (1%) 
Diastolic blood pressure 
<81 mmHg 12 (54%) 230 (45%) 143 (42%) 87 (49%) 
81-90 mmHg 5 (23%) 163 (32%) 105(31%) 58 (33%) 
>90 mmHg 5 (23%) 119 (23%) 
Missing 3 (1 %) 
MI, myocardial infarction. 
absolutely objective and clear[41 • The exclusions 
from HINT were applied centrally by the Classifica-
tion Committee, on the basis of pre-randomisation 
data only, without knowledge of the patient's treat-
ment assignment. 
It appeared impossible to obtain reliable data on 
patients who were diagnosed as unstable angina at 
admission to hospital but who were not entered. This 
was due to the temporary nature of the early diag-
nosis, which generally speaking is not recorded. The 
problem is exemplified in our own records: the clini-
cal case notes usually made no reference whatsoever 
to the preceding episode of unstable angina in HINT 
patients who developed myocardial infarction after 
randomisation. The absence of these data does not 
hamper generalization of the HINT findings. The 
description of the included patients (together with 
the clinical course of the placebo groups) ultimately 
determines the clinical spectrum of unstable angina 
actually studied. Generalization of trial findings is 
dependent on the characteristics of the patients that 
were included; it does not pertain to patients that 
were excluded. By the same token, the total number 
87 (26%) 32 (18%) 
3 (1 %) 
of enrolments as a percentage of the total number of 
admissions to the participating coronary care units 
has nothing to do with the relevance of investigated 
treatment effects for patients who present with this 
form of unstable angina. 
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Design and methods 
TRIAL MEDICATION 
Patients not on previous maintenance treatment with 
a beta blocker (for more than three days) were 
randomly assigned to receive either double placebo, 
nifedipine six 10 mg doses per 24 hours plus meto-
prolol placebo, metoprolol two 100 mg doses per 24 
hours plus nifedipine placebo, or both drugs. No 
loading dosages were given. Both nifedipine and 
metoprolol (or their placebos) were started at the 
same time. Patients on previous maintenance treat-
ment with a beta blocker were randomly assigned to 
receive placebo or nifedipine six 10 mg doses per 24 
hours, while the previous treatment with a beta 
blocker was continued; before 13 November 1982 
with the same compound and dose as given before, 
thereafter with two 100 mg doses of metoprolol per 
24 hours. Both randomisation procedures were per-
formed for each Clinical Centre separately and in 
equal proportions. 
Unless persistent chest pain developed, the trial 
medication was continued for at least 48 hours, 
preferably until angiography was performed or until 
two days before discharge, so that post-discharge 
medication could be started in the hospitaL In some 
Clinical Centres trial medication was discontinued 
after 48 hours in all patients. 
An episode of chest pain with pronounced ST-
segment or T -wave changes, repeated attacks of chest 
pain, uncontrollable chest pain, ominous ST-segment 
or T-wave changes without chest pain, or suspected 
side-effects warranted discontinuation of trial 
medication. The decision to reduce or discontinue 
trial medication was the responsibility of the treating 
physician. A coding envelope was packed with each 
package of trial medication so that the true substance 
of the trial medication could be identified in case of 
emergencies. 
CONCOMITANT TREATMENT 
All patients received routine care for at least 48 
hours, including electrocardiographic monitoring. 
Haemodynamic monitoring was instituted if the 
treating physician thought that it was indicated. 
The use of other drugs that may interfere with the 
0195-668X/87/08H035+ 14$02.00/0 
evaluation of trial medication effects was restricted: 
(1) beta blockers other than the ones described above 
were not allowed; (2) oral long-acting nitrates were 
continued unchanged if they had been given before 
admission to hospital-otherwise they were not 
allowed; (3) neither the prophylactic use of sublingual 
glyceryl trinitrate, nor a glyceryl trinitrate or a nitro-
prusside infusion was allowed (transdermal glyceryl 
trinitrate was not available at that time); (4) calcium 
antagonists other than the trial medication were not 
allowed. Other drugs were used as follows: (1) sed-
atives or anticoagulants according to local practice; 
(2) antiarrhythmic drugs, digitalis, diuretics, and 
antihypertensive agents other than beta blockers on 
indication only. 
Chest pain was initially treated as described. If 
pain persisted further measures were left to the 
discretion of the treating physician. 
DATA COLLECTION AND FOLLOW-UP 
All patients were closely followed over the period 
from hospital admission until 48 hours after ran-
domisation. A detailed scheme of measurements to 
be obtained and events to be registered was provided. 
No specific trial observations or measurements were 
required after 48 hours. Long-term follow-up was 
continued until at least one year after randomisa-
tion. 
Twelve-lead electrocardiograms were recorded, in 
duplicate, every six hours and during and after epi-
sodes of chest pain. Blood samples for assays of 
creatine kinase or its ME-isoenzyme were obtained 
every six hours until 54 hours after randomisation. 
(As there is an intrinsic delay in the release of 
enzymes after the onset of myocardial infarction, 
enzyme rises between 48 and 54 hours after random-
isation were considered consequential to myocardial 
necrosis that had occurred within 48 hours.) Activi-
ties of glutamic oxaloacetic and pyruvic trans-
aminase, lactic acid dehydrogenase, and alpha-
hydroxybuteric acid dehydrogenase were determined 
every 24 hours. Slight deviations of this scheme were 
allowed. All enzyme determinations were performed 
locally and subsequently related to local normal 
values (see chapter 3). Heart rate was recorded every 
hour. Indirect blood pressures were recorded every 
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six hours. Phase V was taken as the diastolic pres-
sure. 
A detailed logbook of episodes of chest pain and 
other medical events was kept. Whenever trial med-
ication was given, this action was recorded on the 
patient case record form. If trial medication was 
discontinued, the time of discontinuation and the 
reason why were recorded, the latter in the follow-
ing categories: (1) for recurrent chest pain, (2) for 
side effects, and (3) for other reasons. Incidental 
departures of the trial medication scheme were noted. 
Other drugs being taken by the patient were regis-
tered as well. 
Information on clinical events after 48 hours was 
collected from clinical records. The time of dis-
continuation of trial medication (if still applicable), 
the occurrence of myocardial infarction (serial 
enzyme values) or death, and medications being 
taken or prescribed when the patient left hospital 
were recorded. 
Cardiac catheterization and coronary angio-
graphy, unless contra-indicated, were performed 
preferably before discharge but not within 48 hours 
after randomisation. Information on all angiograms 
made before January 1985 was collected. 
Definition of clinical events 
BASIC CONSIDERATIONS 
Four (major) clinical events were considered: (1) 
pre-randomisation myocardial infarction; (2) myo-
cardial infarction within 48 hours; (3) recurrent 
ischaemia within 48 hours; (4) myocardial infarction 
within one week. Precise definitions are given below. 
The Classification Committee reviewed the clinical 
course of each patient from a standardized report 
and ascertained which events had occurred. The com-
mittee members were neither privy to the patient's 
trial medication assignment nor to findings at sub-
sequent angiography. 
MYOCARDIAL INFARCTION 
Myocardial infarction within 48 hours was con-
sidered to have occurred if there was a serial enzyme 
pattern characteristic for acute myocardial infarction 
with at least one cardiac enzyme significantly raised 
within 54 hours. Express criteria for 'a typical enzyme 
pattern' were not defined. Patients who died under 
the clinical picture of acute myocardial infarction 
were also classified in this category. The occurrence 
of myocardial infarction within 48 hours was consid-
ered undefined for patients with pre-randomisation 
myocardial infarction. 
For all patients classified as myocardial infarction 
within 48 hours the Classification Committee deter-
mined the most likely time of onset of myocardial 
infarction retrospectively from the complete clinical 
history. The decision was based on the temporal 
relationship between the occurrence of chest pain, 
changes in the electrocardiogram, and enzyme rises. 
Onset of myocardial infarction was related to an epi-
sode of chest pain. The time of onset was not further 
specified if the Classification Committee determined 
that myocardial infarction had started before admis-
sion to hospital. The Classification Committee was 
obliged to choose a time of onset, even if no obvious 
time of onset was available. 
The Classification Committee gave a description 
of electrocardiographic abnormalities and changes 
over the period from hospital admission until 48 
hours after onset of myocardial infarction for all 
patients with myocardial infarction. Q-waves, ST-
segment displacements, and T-wave inversions were 
scored at hospital admission, at randomisation, at 
onset of myocardial infarction. Further, the appear-
ance of new permanent or temporary abnormalities 
within 48 hours after onset of myocardial infarction 
was recorded. A Q-wave was scored when greater 
than 0·03 s. Q-wave equivalents (R-wave greater than 
0·03 s in V 1 and R/S ratio greater than 1 in V 2 were 
scored as inferoposterior Q-waves. ST-segment 
displacements were scored when at least 0·1 m V. 
T -wave inversions were scored when at least 0·1 
mV. All electrocardiographic abnormalities were 
scored for three groups of leads: anteroseptal (leads 
V 1 to V 5 , inferior /posterior (leads II, III, and a VF), 
and lateral (leads I, aVL, and V6 ). To complete the 
electrocardiographic evaluation, the Classification 
Committee determined the location of the infarction: 
anteroseptal, infero-posterior, or lateral. The decision 
depended, in a hierarchy of descending importance, 
on the location (leads as above) of new Q-waves, of 
new permanent T-wave inversions, or of ST-segment 
or T-wave changes at onset. 
Myocardial infarction which had occurred in the 
remainder of the first week after randomisation was 
ascertained with similar criteria. 
RECURRENT ISCHAEMIA WITHIN 48 HOURS 
Recurrent ischaemia was considered to have 
occurred if a chest pain episode with accompanying 
ST-segment or T-wave changes had taken place. The 
Classification Committee's decision was taken inde-
pendently of the treating physician's opinion, which 
was expressly recorded. The treating physician's 
judgement on the anginal nature of the chest pain 
was accepted at face value. Episodes of chest pain 
were taken into account irrespective of previous 
discontinuation of trial medication. Chest pain epi-
sodes of which no electrocardiograms were available 
were ignored. However, if the treating physician had 
decided to discontinue trial medication for recurrent 
chest pain and if no electrocardiograms were avail-
able, the episode was considered the equivalent of a 
chest pain episode with ST-segment or T-wave 
changes. 
OUTCOME EVENTS FOR TRIAL MEDICATION EFFECT 
ASSESSMENT 
For the assessment of trial medication effects 
'recurrent ischaemia or myocardial infarction within 
48 hours' was taken as the main outcome event. 
Further, ·myocardial infarction within 48 hours', 
'myocardial infarction within 48 hours with subse-
quent Q-wave formation', and 'myocardial infarction 
within one week' were taken as secondary outcome 
events. 
Results 
OCCURRENCE OF MYOCARDIAL INFARCTION 
As has been mentioned in chapter 3, 22 of 
537 patients (4%) of the HINT cohort had a pre-
randomisation myocardial infarction. Of the remain-
ing 515 patients 92 (18%) developed (signs of) acute 
myocardial infarction within 48 hours after random-
isation. Three patients died under the clinical pic-
ture of acute myocardial infarction, and significant 
enzyme rises with a pattern characteristic for acute 
myocardial infarction occurred in the other 89 
patients. In another seven patients significantly raised 
post-randomisation enzyme values were found, but 
they were considered to be non-specific: raised activ-
ities of glutamic oxaloacetic transaminase in one 
patient with a known alcohol problem, raised activ-
ities of creatine kinase in two patients with a recent 
intramuscular injection, and four measurement 
errors. Figure 4.1 shows the presumptive time of 
onset of acute myocardial infarction in 92 patients 
with myocardial infarction within 48 hours. In 43 
patients (47%) myocardial infarction was thought to 
have occurred before randomisation despite cardiac 
enzyme concentrations being below twice the upper 
limit for normal at that time, in 38 patients (41 %) 
even before admission to hospital. Table 4.1 shows 
electrocardiographic changes that occurred at the 
(presumptive) onset of myocardial infarction. No 
electrocardiographic changes as defined were ob-
served in 19 patients. Figure 4.1 also shows the time 
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Figure 4.1 Timing of the onset of myocardial infarction 
and the first significant rise in enzyme concentration for 
92 cases of myocardial infarction within 48 hours in 515 
patients without enzymatic evidence of infarction at 
randomisation. The time of the onset of myocardial infarc-
tion was determined retrospectively by the Classification 
Committee from the complete clinical history. The upper 
line represents the cumulative distribution of the time of 
onset of myocardial infarction-that is, it represents for 
each point in time after randomisation the total number of 
patients with an onset before that time. In 43 cases the 
onset was judged to have taken place before randomisation; 
the upper line thus starts at 43. Similarly the lower line 
represents the cumulative distribution of the time of first 
rise in enzyme concentration to over twice the local upper 
limit of normal. No significantly raised enzyme values could 
be observed in two patients who died soon after onset of 
myocardial infarction. 
Table 4.1 Electrocardiographic changes at the (presump-
tive) time of onset of myocardial infarction in 92 patients 
with myocardial infarction within 48 hours 
Patients with MI < 48 h 92 
Onset before hospital admission 
Onset after hospital admission 
New Q-waves 
New ST-segment elevations 
New ST-segment depressions 
NewT-wave inversions 
No changes 








* Numbers in parenthesis indicate percentages of patients 
with myocardial infarction within 48 hours with an onset 
after hospital admission. 
The time of onset of myocardial infarction was determined 
retrospectively by the Classification Committee from the 
complete clinical history. 
All patients with pre-randomisation myocardial infarction 
had an onset before admission to hospital. 
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Table 4.2 Permanent electrocardiographic abnormalities 
which developed after onset of myocardial infarction, as 
registered by the Classification Committee (numbers of 
patients with percentages in brackets) 
New Q-waves 
New T-wave inversions only 
Neither of these 
MI0 









MI0 , prerandomisation myocardial infarction; MI48 , myo-
cardial infarction within 48 hours. 
* Includes two cases of fatal Q-wave infarctions not 
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Figure 4.2 Timing of the appearance of new Q waves and 
of permanent new T-wave inversions for 92 cases of myo-
cardial infarction within 48 hours without enzymatic evi-
dence of infarction at randomisation, as determined by 
the Classification Committee. The upper line represents the 
cumulative distribution of the time of appearance of a Q-
wave and the lower line that of new permanent T-wave 
inversion. 
of first occurrence of a significant rise in activities of 
creatine kinase or its ME-isoenzyme. Table 4.2 shows 
the electrocardiographic changes that occurred after 
onset of myocardial infarction. New Q-waves devel-
oped in 50 of 92 patients (54%) with myocardial 
infarction within 48 hours. Figure 4.2 shows the time 
of first appearance of new Q-waves and of new perm-
anent T-wave inversion. Table 4.3 shows the loca-
tions of the infarctions. Table 4.4 shows maximum 
serum activities of creatine kinase, of its ME-
isoenzyme, and of glutamic oxaloacetic transaminase 
over the period from randomisation until 54 hours 
later. Activities of creatine kinase were recorded in 
72 of 89 patients (81 %) with non-fatal infarction 
within 48 hours. Corresponding figures for the ME-
isoenzyme of creatine kinase and for glutamic oxalo-
acetic transaminase were 59 (66%) and 87 (98%). 
Only a few infarctions were associated with high 
enzyme releases. 
One patient with myocardial infarction within 48 
hours died after 48 hours. Of 423 patients without 
myocardial infarction within 48 hours 20 (5%) 
developed myocardial infarction in the remainder of 
the first week after randomisation; four of them died. 
RECURRENCE OF CHEST PAIN 
Table 4.5 shows recurrence of chest pain within 48 
hours for each category of myocardial infarction 
separately. The episodes of chest pain in patients with 
pre-randomisation myocardial infarction represented 
postinfarction angina. The episodes of chest pain in 
patients with myocardial infarction within 48 hours 
marked the onset of infarction in most patients but 
not in all. In 19 of 92 (21%) patients with myocardial 
infarction within 48 hours no chest pain occurred 
Table 4.3 Location of myocardial infarction, as determined by the Classifica-
tion Committee 
MI 0 MI48 Q-wave non-Q-wave 
(N = 22) (N = 92) (N =50) (N = 42) 
Anteroseptal 8 (36%) 38 (41 %) 15 (31%) 23 (55%) 
Infero-posterior 4 (18%) 36 (39%) 29 (58%) 7(17%) 
Lateral 2 (9%) 15 (16%) 6 (12%) 9 (21 %) 
Not identifiable 8 (36%) 3 (3%) 3 (7%) 
MI 0 • pre-randomisation myocardial infarction; MI48 , myocardial infarction 
within 48 hours. 
Anteroseptal, leads V 1 to V 5 ; Infero-posterior, leads II, III, a VF; Lateral, 
leads I, a VL, V 6 . 
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Table 4.4 Maximum activities of creatine kinase, ME-isoenzyme of 
creatine kinase, and glutamic oxaloacetic transaminase (over the period 
from randomisation until 54 hours later) in 89 patients with a non-
fatal myocardial infarction within 48 hours (numbers of patients with 
percentages in brackets) 
Cardiac enzymes 
CK 




(N = 87) 
MAX 
























CK, creatine kinase; MB-CK, MB-isoenzyme of creatine kinase; GOT, 
glutamic oxaloacetic transaminase; MAX, maximum of the three 
activities. 
* Maximal activities over 54 hours after randomisation are expressed 
as percentages of local upper limit for normaL 
Table 4.5 Recurrence of chest pain within 48 hours of ran-
domisation (numbers of patients with percentages in brackets) 
None 
Without ST-T changes 
Without ECG 
With ST-T changes 
MI0 






(N = 92) 










MI0 , pre-randomisation myocardial infarction; MI48, myo-
cardial infarction within 48 hours; ECG, electrocardiogram. 
Patients to whom more than one category applied were 
placed in the most severe (i.e. the lower) category. 
after randomisation; enzyme rises constitute the only 
evidence for progression to myocardial infarction. In 
97 of 423 patients (23%) without myocardial infarc-
tion within 48 hours one or more episodes of recur-
rent chest pain with accompanying ST -segment or 
T-wave changes occurred. The Classification Com-
mittee decided that recurrent ischaemia had occurred 
in another two patients because the treating physician 
had discontinued trial medication for severe chest 
pain without recording electrocardiograms. Chest 
pain did not recur in 237 of 423 patients (56%) with-
out myocardial infarction within 48 hours. 
BASELINE CHARACTERISTICS IN RELATION TO OUTCOME 
EVENTS 
Table 4.6 shows selected baseline characteristics in 
relation to the defined outcome events. There were 
only small differences between the rates of recurrent 
ischaemia or myocardial infarction within 48 hours 
of randomisation for respective categories of age, sex, 
previous myocardial infarction, history of angina, 
previous beta blockade, and enzyme leveL The rates 
for myocardial infarction within 48 hours varied 
specifically between patients with a sudden onset of 
clinical instability (the categories 'no' and 'sudden') 
on the one hand and those with a more gradual onset 
of clinical instability (the categories '< I month' and 
'crescendo') on the other ljland. The length of the 
pain free interval was stron6-Iy related to the rate of 
recurrent ischaemia or myJcardial infarction within 
48 hours: 62% of patient~ who had a pain free 
interval of less than one hour developed recurrent 
ischaemia or myocardial infarction within 48 as 
opposed to 22% of those in whom the pain free 
interval lasted more than t ree hours. The length of 
the pain free interval was a! o strongly related to the 
other outcome events. i 
Table 4. 7 shows electrocardiographic baseline char-
acteristics derived from the (pain free) electrocardio-
gram in relation to the defined outcome events. The 
rate of recurrent ischaemia or myocardial infarction 
within 48 hours was strongly related to the amount 
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Table 4.6 Selected demographic and clinical baseline characteristics and corresponding outcome event rates 
Outcome events 
Ml0 No Ml 0 RI(Ml48 Ml4s Ml48 +o Ml1w 
Age 
30-54 7 183 69 (38%) 38 (21 %) 22 (12%) 45 (25%) 
55-61 11 171 56 (33%) 22 (13%) 11 (6%) 26 (15%) 
62-70 4 161 66 (41 %) 32 (20%) 17(11%) 41 (25%) 
Sex 
Male 20 387 149 (39%) 82 (21 %) 48 (12%) 96 (25%) 
Female 2 128 42 (33%) 10 (8%) 2 (2%) 16 (13%) 
Previous myocardial 
infarction 
No 14 322 129 (40%) 63 (20%) 38 (12%) 73 (23%) 
History only 3 64 25 (39%) 9 (14%) 4 (6%) 13 (20%) 
Q-waves 5 129 37 (29%) 20 (16%) 8 (6%) 26 (20%) 
History of angina* 
No 8 143 50 (35%) 34 (24%) 18 (13%) 38 (27%) 
< 1 month 5 165 66 (40%) 27 (16%) 16 (10%) 32 (19%) 
> 1 month, crescendo 5 114 37 (32%) 11 (10%) 4 (4%) 19 (17%) 
> 1 month, sudden 4 93 38 (41 %) 20 (22%) 12 (13%) 23 (25%) 
Previous beta blockade 
No 18 338 121 (36%) 63 (19%) 36(11%) 74 (22%) 
Yes 4 177 70 (40%) 29 (16%) 14 (8%) 38 (21 %) 
Pain free interval 
< 1 hour 4 133 82 (62%) 45 (34%) 25 (19%) 53 (40%) 
1-3 hours 12 186 66 (35%) 31 (17%) 17 (9%) 39 (21 %) 
>3 hours 6 196 43 (22%) 16 (8%) 8 (4%) 20 (10%) 
Enzyme values at baselinet 
<100% 457 166 (36%) 79 (17%) 44 (10%) 99 (22%) 
100-200% 58 25 (43%) 13 (22%) 6 (10%) 13 (22%) 
>200% 22 
Ml 0 , pre-randomisation myocardial infarction; RI/Ml48, recurrent ischaemia or myocardial infarction within 48 hours; 
MI48 , myocardial infarction within 48 hours; MI48 +Q' myocardial infarction within 48 hours with subsequent Q-wave 
formation; MI1w, myocardial infarction within one week. 
* Crescendo, angina pectoris of effort present for more than one month with gradual acceleration; sudden, angina pectoris 
of effort present for at least one month without any acceleration before the presenting episode of angina at rest. 
t Maximal values of activities of creatine kinase, ME-isoenzyme of creatine kinase, glutamic oxaloacetic transaminase 
obtained before randomisation are expressed as percentage of local upper limits for normaL 
of ST-segment depression on the (pain free) baseline 
electrocardiogram. Neither ST-segment elevation nor 
T-wave inversion on the baseline electrocardiogram 
related particularly to the defined outcome events. 
The location of the abnormalities (anterior versus 
non-anterior) was not predictive of the outcome 
events. 
Table 4.8 shows electrocardiographic baseline 
characteristics derived from the pain electrocar-
diogram. One hundred and ninety six patients were 
entered on the basis of a chest pain episode at home. 
Among them rates of the defined outcome events 
were substantially lower relative to those among 
patients with pain while in hospitaL Of 16 patients 
who suffered chest pain while in hospital the electro-
cardiogram obtained during pain was either illegible 
or contained Minnesota incompatibilities rendering 
the ST-segment undefined. The rate of recurrent 
ischaemia or myocardial infarction was strongly 
related to the amount of ST -segment depression on 
the pain electrocardiogram. On the other hand, ST-
segment elevation showed no relation to the rates of 
the defined outcome events. The comparison of the 
pain electrocardiogram with the (pain free) baseline 
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Table 4.7 Baseline characteristics from electrocardiogram with pain absent and corresponding outcome event rates 
Outcome events 
MI 0 No MI0 RI/MI48 MI48 MI+S+Q MI1w 
ST-segment depression at baseline 
None 7 214 75 (35%) 32 (15%) 18 (8%) 35 (16%) 
0·01-0·04 mV 4 69 19 (28%) 10 (14%) 5 (7%) II (16%) 
0·05-0·09 m V 4 II9 42 (35%) 18 (15%) 10 (8%) 23 (19%) 
0·10-0·19 mV 1 68 31 (46%) 18 (26%) 12 (18%) 22 (32%) 
0·20-0·50 mV 4 25 16 (64%) 8 (32%) 2 (8%) 15 (60%) 
ST-code missing 2 20 8 (40%) 6 (30%) 3 (15%) 6 (30%) 
ST-segment elevation at baseline 
None 4 100 45 (45%) 22 (22%) 13 (13%) 27 (27%) 
0·01-0·04 mV 7 127 45 (35%) 23 (18%) 14 (II%) 28 (22%) 
0·05-0·09 m V 4 164 66 (40%) 29 (18%) 17 (10%) 34 (21 %) 
0·10-0·19 mV 5 91 24 (26%) II (12%) 3 (3%) 15 (17%) 
0·20-0·50 mV 13 3 (23%) 1 (8%) 2 (15%) 
ST -code missing 2 20 8 (40%) 6 (30%) 3 (15%) 6 (30%) 
T-wave inversion at baseline 
Upright 8 145 50 (35%) 26 (18%) 17 (12%) 29 (20%) 
0·01-0·09 mV 7 149 60 (40%) 29 (19%) 14 (9%) 33 (22%) 
0·10-0·50 mV 7 192 72 (38%) 32 (17%) 17 (9%) 40 (21%) 
>0·50 mV 24 7 (29%) 3 (13%) 1 (4%) 8 (33%) 
T -code missing 5 2 (40%) 2 (40%) 1 (20%) 2 (40%) 
ST-T abnormalities at baseline* 
None 13 269 98 (36%) 49 (18%) 29 (II%) 55 (20%) 
T-wave inversion 2 121 33 (27%) 9 (7%) 4 (3%) II (9%) 
ST non-anterior 18 II (61 %) 7 (39%) 1 (6%) 9 (50%) 
ST anterior 5 87 41 (47%) 21 (24%) 13 (15%) 31 (36%) 
ST -code missing 2 20 8 (40%) 6 (30%) 3 (15%) 6 (30%) 
CIIS-score at baseline 
<9 4 161 58 (36%) 32 (20%) 19 (12%) 34 (21 %) 
9-20 5 161 63 (39%) 24 (15%) 15 (9%) 29 (18%) 
>20 II 172 62 (36%) 30 (17%) 13 (8%) 43 (25%) 
Missing 2 21 8 (38%) 6 (29%) 3 (14%) 6 (29%) 
MI0 , pre-randomisation myocardial infarction; RI/MI48 , recurrent ischaemia or myocardial infarction within 48 hours; 
MI48 , myocardial infarction within 48 hours; MI4840, myocardial infarction within 48 hours with subsequent Q-wave 
formation; MI,w, myocardial infarction within one week; CIIS, cardiac infarction injury score. 
* T-wave inversion, T-wave inversion of at least 0·10 mV; ST non-anterior, ST-segment depression or elevation of at least 
0·10 mV in non-anterior leads only; ST anterior, ST-segment depression or elevation of at least 0·10 mV in anterior leads 
(V2-V 5). 
electrocardiogram was of great importance: event 
rates markedly depended upon the presence of cod-
able ST-segment changes during pain. 
OUTCOME EVENT RATES IN TRIAL MEDICATION GROUPS 
Table 4.9 shows the number of pre-randomisation 
myocardial infarctions per trial medication groups. 
Also shown are the rates for the defined outcome 
events for patients without pre-randomisation myo-
cardial infarction. In patients not on previous main-
tenance treatment with a beta blocker who were 
treated with nifedipine all four event rates were 
higher than the corresponding ones for those on 
placebo. On the other hand, in patients on meto-
prolol or on the combination, event rates were lower 
than the rates for those on placebo. There were no 
appreciable differences between the rates for those 
on metoprolol and those on the combination. In 
patients who were on continued maintenance treat-
ment with a beta blocker, the nifedipine group had 
lower event rates than the placebo group. 
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Table 4.8 Baseline characteristics from electrocardiogram with pain present and corresponding outcome event rates 
Outcome events 
Ml 0 No Ml0 Rl/Ml48 Ml+s Ml+s+o Ml1w 
ST-segment depression during pain 
No pain in hospital 3 196 37 (19%) 17 (9%) 8 (4%) 24 (12%) 
None 5 96 39 (41 %) 13 (14%) 7 (7%) 14 (15%) 
0·01-0·04 mV I 33 13 (39%) 3 (9%) I (3%) 5 (15%) 
0·05-0·09 mV 3 56 25 (45%) 15 (27%) 11 (20%) 17 (30%) 
0·10-0·19 mV 5 60 34 (57%) 18 (30%) 7 (12%) 21 (35%) 
0·20-0·50 mV 4 52 33 (63%) 20 (38%) 13 (25%) 24 (46%) 
>0·50 mV 6 5 (83%) 3 (50%) 1 (17%) 4 (67%) 
ST-code missing 16 5 (31%) 3 (19%) 2 (13%) 3 (19%) 
ST-segment elevation during pain 
No pain in hospital 3 196 37 (19%) 17 (9%) 8 (4%) 24 (12%) 
None 6 90 49 (54%) 26 (29%) 16 (18%) 27 (30%) 
0·01--0·04 mV 5 66 30 (45%) 11 (17%) 7 (11 %) 15 (23%) 
0·05--0·09 m V 3 80 37 (46%) 19 (24%) 9 (11 %) 23 (29%) 
0·10-0·19 mV 4 49 26 (53%) 14 (29%) 8 (16%) 16 (33%) 
0·20-0·50 mV 18 7 (39%) 2 (11 %) 4 (22%) 
>0·50 mV I 
ST-code missing 15 5 (33%) 3 (20%) 2 (13%) 3 (20%) 
Comparison of pain ECG with baseline ECG 
Not possible* 6 223 48 (22%) 24(11%) 12 (5%) 31 (14%) 
Same ST coding 3 82 32 (39%) 11 (13%) 7 (8%) II (13%) 
More ST-segment 
depression 10 !59 87 (55%) 45 (28%) 25 (16%) 55 (35%) 
More ST-segment 
elevation 6 101 60 (59%) 32 (32%) 18 (18%) 40 (40%) 
Both 3 50 36 (72%) 20 (40%) 12 (24%) 25 (50%) 
Ml0 , pre-randomisation myocardial infarction; RI/Ml48 , recurrent ischaemia or myocardial infarction within 48 hours; 
Ml48 , myocardial infarction within 48 hours; Ml4840, myocardial infarction within 48 hours with subsequent Q-wave 
formation; Ml1w, myocardial infarction within one week; ECG, electrocardiogram. 
*No pain observed after hospital admission or no (codable) pain free electrocardiogram available for comparison. 
Table 4.9 Outcome event rates in trial medication groups 
Outcome events 
Ml 0 No Ml 0 RI/M148 Ml+s MI+B+Q Ml1w 
No previous maintenance treatment with a beta blocker 
Placebo 3 84 31 (37%) 13 (15%) 9 (II%) 14 (17%) 
Nifedipine 4 89 42 (47%) 25 (28%) 14 (16%) 28 (31 %) 
Metoprolol 4 79 22 (28%) 13 (16%) 6 (8%) 15 (19%) 
Combination 7 86 26 (30%) 12 (14%) 7 (8%) 17 (20%) 
On continued maintenance treatment with a beta blocker 
Placebo 2 81 41 (51%) 16 (20%) 7 (9%) 19 (23%) 
Nifedipine 2 96 29 (30%) 13 (14%) 7 (7%) 19 (20%) 
Ml0 , pre-randomisation myocardial infarction; RI/Ml48 , recurrent ischaemia or myocardial infarction within 48 hours; 
Ml48 , myocardial infarction within 48 hours; Ml4840, myocardial infarction within 48 hours with subsequent Q-wave 
formation; Ml1w, myocardial infarction within one week. 
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Table 4.10 Use of trial medication at randomisation and during follow-up for each trial 
medication group in 515 patients without pre-randomisation myocardial infarction 
Use in relation to randomisation 
0 6h 24 h 48 h 
No previous maintenance treatment with a beta blocker 
Placebo 84 (100%) 79 (94%) 
Nifedipine 89 (100%) 77 (87%) 
Metoprolol 79 (100%) 78 (99%) 
Combination 86 (100%) 81 (94%) 









Placebo 81 (100%) 72 (89%) 57 (70%) 53 (65%) 
71 (74%) Nifedipine 96 (100%) 88 (92%) 77 (80%) 
In almost all patients with pre-randomisation myocardial infarction trial medication was 
discontinued when the raised enzyme values became known. 
Table 4.11 Reasons for discontinuation of trial medication within 48 hours in 515 patients without 
pre-randomisation myocardial infarction 
No. of 
Reason for discontinuation 
No. of patients 
patients discontinued Chest pain 
No previous maintenance treatment with a beta blocker 
Placebo 84 20 (24%) 10 (50%) 
Nifedipine 89 33 (37%) 23 (70%) 
Metoprolol 79 21 (27%) 9 (43%) 
Combination 86 26 (30%) 14 (54%) 
On continued maintenance treatment with a beta blocker 
Placebo 81 28 (35%) 24 (86%) 
Nifedipine 96 25 (26%) 14 (56%) 
THERAPEUTIC INTERVENTIONS 
Trial medication was discontinued m almost all 
patients with pre-randomisation myocardial infarc-
tion when raised enzyme values became known. 
Table 4.10 shows the use of trial medication at ran-
domisation, and 6, 24, and 48 hours after randomisa-
tion among 515 patients without pre-randomisation 
myocardial infarction. At 48 hours the percentage of 
patients still on trial medication ranged from 63% of 
patients allocated to nifedipine who were not on 
previous maintenance treatment with a beta blocker 
to 76% of patients allocated to placebo who were 
not on previous beta blockade. Trial medication was 
discontinued shortly after 48 hours in another 84 














on trial medication. Table 4.11 shows the reasons for 
discontinuation of trial medication in 515 patients 
without pre-randomisation myocardial infarction. 
The reported side effects for metoprolol or the 
combination were low heart rates. Most of the dis-
continuations under the heading 'other' were because 
of diagnostic findings of myocardial infarction 
(enzyme rises). 
In five patients the randomisation code was broken 
within 48 hours. One patient developed severe symp-
toms of flushing which were considered a side effect 
of nifedipine (the patient was treated with placebo), 
all other cases in order to determine further treatment 
after violent chest pain. In another two patients the 
code was broken after 48 hours because of complica-
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tions. The code was broken for 13 patients at dis-
charge from hospital to determine further therapeutic 
measures. 
Previous maintenance treatment with a beta blocker 
was continued unchanged in 68 of76 (89%) patients 
(without pre-randomisation myocardial infarction) 
admitted to the trial when the protocol required 
unchanged continuation. Of these 76 patients 26 were 
on a subtherapeutic dosage, e.g. one 100 mg dose of 
metoprolol per 24 hours. Previous maintenance 
treatment with a beta blocker was continued with 
two 100 mg doses metoprolol in 81 of 101 patients 
(81%) admitted in the period when the protocol 
required this. Of these patients 25 were on a sub-
therapeutic dosage. In the remaining 21 patients pre-
vious maintenance treatment with a beta blocker was 
either continued unchanged or changed to the beta 
blocker regimen ordinarily used in the pertinent 
clinic. 
Table 4.12 shows the use of drugs other than trial 
medication before admission to hospital, around 
randomisation, after randomisation, and at hospital 
discharge in 515 patients without pre-randomisation 
myocardial infarction. Oral long-acting nitrates had 
been given to 100 patients before admission to hos-
pital and were continued in 76 (76%). In 5 of 415 
patients not on previous treatment with long-acting 
oral nitrates, nitrates were started at randomisation. 
Thus 434 patients did not receive oral long acting 
nitrates at randomisation. These drugs were later 
given, on indication, to 46 (11 %) of these patients. 
Oral long acting nitrates were at least once taken 
after 48 hours by 212 patients. They were prescribed 
at discharge to 190 (37%) of the 515 randomised 
patients. (These tallies are shown in the first line 
of Table 4.12.) Anticoagulants were given to 351 
patients (68%), either at randomisation or on indica-
tion after randomisation. At randomisation or within 
48 hours 14% received diuretics, 3% digitalis and 
3% platelet aggregation inhibiting drugs. A con-
tinuous glyceryl trinitrate infusion was started, 
on indication, after randomisation in 13% of the 
patients. 
Chest pain was relieved spontaneously in 16% of 
259 patients without pre-randomisation myocardial 
infarction who experienced chest pain within 48 
hours. In 54% of these patients sublingual glyceryl 
trinitrate sufficed to eliminate chest pain, and in 17% 
measures like sublingual nifedipine, fentanyl, or an 
injection with glyceryl trinitrate were taken. In the 
remaining 13% of patients opiates were needed to 
control chest pain. 
HEART RATE AND BLOOD PRESSURE 
Table 4.13 shows heart rate, systolic blood pres-
sure, and diastolic blood pressure over time per trial 
Table 4.12 Use of drugs around randomisation, within 48 hours, after 48 hours but before hospital 
discharge, and at discharge in 515 patients without pre-randomisation myocardial infarction 
At randomisation Being taken 
Started 
within After At 
++ +- -+ 48h 48 h discharge 
Nitrates 76 24 5 410 46 212 190 
Anticoagulants 74 2 248 191 29 302 225 
Diuretics 50 46 13 406 12 71 74 
Cardiac glycosides 12 5 I 497 I 15 13 
Antiarrhythmic drugs 2 3 3 507 38 37 29 
Other calcium antagonists 5 510 3 3 
Nifedipine 515 60 261 247 
Glyc trinitrate infusion 515 67 46 15 
Positive inotropic drugs 515 10 6 
Antiplatelet drugs 8 8 499 8 23 23 
Beta blockers 177 338 78 410 378 
+ +, the drug was being taken before admission to hospital and was continued at randomisation; 
+ -, the drug was being taken at admission to hospital but was discontinued at randomisation; 
- +. the drug was not being taken before admission to hospital but was started at randomisation; 
- -, the drug was not being taken before admission to hospital and was not started at randomisation; 
Started within 48 h~an indication to start the drug developed within 48 hours after randomisation; 
Being taken after 48 h~the drug was at least once being taken after 48 hours but before hospital 
discharge; 
Being taken at discharge~this drug was being taken (or was prescribed) when the patient left hospital. 
Table 4.13 Heart rate (beats min-1), systolic blood pressure 
(mmHg), and diastolic blood pressure (mmHg) at randomisa-
tion, and at hours 6, 24, and 48 per trial medication group 
Time in relation to randomisation 
Oh 6h 24 h 48 h 
Heart rate (beats min-1) 
No previous maintenance treatment with a beta blocker 
Placebo 74 73 73 75 
Nifedipine 76 74 75 76 
Metoprolol 73 62 61 62 
Combination 74 63 64 64 
On continued maintenance treatment with a beta blocker 
Placebo 67 63 65 67 
Nifedipine 67 67 65 68 
Systolic blood pressure (mmHg) 
No previous maintenance treatment with a beta blocker 
Placebo 134 131 128 126 
Nifedipine 137 126 124 126 
Metoprolol 135 122 119 115 
Combination 138 119 117 116 
On continued maintenance treatment with a beta blocker 
Placebo 135 129 123 120 
Nifidipine 132 118 118 120 
Diastolic blood pressure (mmHg) 
No previous maintenance treatment with a beta blocker 
Placebo 86 82 81 80 
Nifedipine 84 79 78 79 
Metoprolol 86 79 76 75 
Combination 86 75 75 74 
On continued maintenance treatment with a beta blocker 
Placebo 86 84 79 77 
Nifedipine 82 76 74 75 
Values are means per trial medication group for patients 
still on trial medication. 
medication group. Measurements at baseline, at hour 
6, at hour 24, and at hour 48 are described as means 
per trial medication group. Measurements as closely 
as possible to the intended hours were taken. Meas-
urements at hours 6, 24, and 48 needed to be within 
2, 4, and 6 hours, respectively, of the intended time. 
Only measurements taken while the patient still 
received trial medication are included. Heart rates in 
patients not on previous maintenance treatment with 
a beta blocker were lower among patients treated 
with metoprolol or the combination. There were no 
appreciable differences in blood pressure either over 
time or between trial medication groups. A similar 
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picture emerged if measurements obtained after dis-
continuation of trial medication were included. 
ANGIOGRAPHY 
An emergency angiography was performed within 
48 hours in 29 patients (6%) without pre-randomisa-
tion myocardial infarction. An emergency bypass 
operation was subsequently performed in 2 patients 
{0·4%). Percutaneous transluminal coronary 
angioplasty was performed in 2 patients (0·4%). 
Emergency angiography was performed within 48 
hours in two of 22 patients with prerandomisation 
myocardial infarction; it was followed by a coronary 
bypass operation in one patient. 
Table 4.14 shows the findings of post-randomisa-
tion angiography performed within three months of 
randomisation in relation to the defined outcome 
events. With the exception of normal findings, which 
were related to a decreased risk, no relation was 
found between the extent of coronary atherosclerosis 
and outcome event rates. The overall picture hardly 
changed when all angiograms made after randomisa-
tion but before January 1985 were taken into 
account. 
Table 4.15 shows findings at angiography within 
three months of randomisation by trial medication 
group. Patients on previous maintenance treatment 
with a beta blocker had more severe coronary athero-
sclerosis than patients not on previous maintenance 
treatment with a beta blocker. A detailed report of 
the angiographic findings will be published separ-
ately. 
Discussion 
Within a week of start of trial medication myo-
cardial infarction had occurred in 25% (22 + 92 + 
20 out of 537). Thus there is a considerable risk of 
myocardial infarction during this period. Similar 
percentages have been reported before[21 . But the 
time of onset of infarction (retrospectively oeter-
mined from the complete clinical history) relative to 
the time when the diagnosis of suspected angina was 
made was not given. Figure 4.1 shows that the onset 
of myocardial infarction was judged to have occurred 
before the start of trial medication in 43 cases and 
that there were 34 further cases within six hours of 
the start trial medication. Only few infarctions 
occurred later than six hours after the start of trial 
medication. Thus so far as myocardial infarction 
occurs in patients diagnosed at hospital admission as 
having suspected unstable angina, its onset tends to 
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Table 4.14 Angiographic findings in relation to outcome event rates 
Outcome events 
MI0 No MI 0 RI/MI48 MI4s MI4S+Q MI,w 
Angiography within three months 
Not performed 11 145 62 (43%) 41 (28%) 24 (17%) 48 (33%) 
Normal 58 13 (22%) 1 (2%) 1 (2%) 
1-vessel disease 4 94 39 (41 %) 22 (23%) 10(11%) 26 (28%) 
2-vessel disease 2 96 28 (29%) 11 (11 %) 8 (8%) 17 (18%) 
3-vessel disease 5 108 44 (41 %) 15 (14%) 6 (6%) 17 (16%) 
Left main disease 14 5 (36%) 2 (14%) 2 (14%) 3 (21 %) 
Angiography before 1 Jan 1985 
Not performed 8 105 46 (44%) 32 (30%) 19 (18%) 37 (35%) 
Normal 67 13 (19%) I (I%) I (1%) 
!-vessel disease 4 100 41 (41 %) 23 (23%) 10 (10%) 27 (27%) 
2-vessel disease 3 Ill 36 (32%) 15 (14%) 10 (9%) 23 (21 %) 
3-vessel disease 7 117 50 (43%) 19 (16%) 9 (8%) 21 (18%) 
Left main disease 15 5 (33%) 2 (13%) 2 (13%) 3 (20%) 
Ml 0 • pre-randomisation myocardial infarction; RI/MI48, recurrent ischaemia or myocardial infarction within 48 hours; 
Ml48 , myocardial infarction within 48 hours; MI4±-Q• myocardial infarction within 48 hours with subsequent Q-wave 
formation; Ml 1w, myocardial infarction within one tek; normal, no narrowings of at least 50% observed. 
Table 4.15 Angiographic findings (obtained within three months of randomisation) in trial medication groups 
No. of 
Angiographic findings 
No. of patients 
patients with cag* Normal !-vessel 2-vessel 3-vessel Left main 
No previous treatment with a beta blocker 
Placebo 84 65 11 (17%) 19 (29%) 19 (29%) 15 (23%) 1 (2%) 
Nifedipine 89 67 10 (15%) 22 (33%) 13 (19%) 19 (28%) 3 (4%) 
Metoprolol 79 60 13 (22%) 18 (30%) 19 (32%) 9 (15%) 1 (2%) 
Combination 86 64 17 (27%) 12 (19%) 11 (17%) 20 (31 %) 4 (6%) 
On continued maintenance treatment with a beta blocker 
Placebo 81 55 3 (5%) 14 (25%) 13 (24%) 23 (42%) 2 (4%) 
Nifedipine 96 59 4 (7%) 9 (15%) 21 36%) 22 (37%) 3 (5%) 
*I.e., Coronary angiography within three months of randomisation; normal, no narrowings of at least 50% observed. 
cluster around the time of diagnosis. The clinical 
implications of this finding are considerable and it 
shows that treatment which aims at the prevention 
of progression to myocardial infarction will have 
a limited effect because in most cases it comes too 
late. 
Despite the high frequency of myocardial infarc-
tion this trial supports the notion that the prognosis 
of patients with this type of unstable angina is good. 
Total one week mortality was only 1·7% (9/537). Our 
results indicate that the short term risk of recurrent 
ischaemia or myocardial infarction is primarily re-
lated to the interval since the last attack of chest pain 
on the one hand and to the presence of ST -segment 
depressions (not to ST-segment elevations!) either on 
the baseline electrocardiogram or on the pain electro-
cardiogram and to pain related ST-segment changes 
on the other. A multivariate analysis of the short 
term risk in relation to these baseline characteristics 
is provided in chapter 5. 
The data of Table 4.1 indicate that electrocardio-
grams recorded at onset of infarction were not typical 
for infarction. This is understandable in view of the 
fact that evolving infarction was, by definition, 
missed in these patients. The maximal values for 
activities of the cardiac enzymes indicate that the 
infarctions were relatively small. 
The presence of pre-randomisation myocardial 
infarction is a baseline characteristic, which was not 
known and could not have been known to the 
treating physician when the patient was entered. The 
defined outcome events had already occurred before 
randomisation in these patients, and hence they 
were not at risk any more for the defined outcome 
events. For them, relevant outcomes would have been 
mortality, recurrence of myocardial infarction, 
enzymatic infarct size, or left ventricular function. 
However, there are too few of these patients (22) to 
evaluate efficacy in these terms. Therefore they were 
excluded from treatment effect assessment (e.g. from 
Table 4.9). Why were the 43 patients with an onset 
of infarction before randomisation not excluded as 
well? In contrast to the former 22 patients, whose 
diagnosis was based on pre-randomisation enzyme 
values only, the latter could only be identified on the 
basis of enzyme values obtained after randomisation. 
Using these as a basis for exclusion could com-
promise internal validity, for instance if any of the 
trial medications affects the release of enzymes from 
the necrotic myocardium rather than the amount of 
necrosis. 
The aims of early pharmacologic treatment in 
patients identified at hospital admission as having 
suspected unstable angina is the prevention of 
recurrent ischaemia or progression to myocardial 
infarction. Treatment has failed if either of these 
untoward events occurs. For this reason, recurrent 
ischaemia or myocardial infarction (i.e. failure of 
treatment) was chosen as the main outcome event to 
evaluate treatment effects. The other outcome 
events (myocardial infarction within 48 hours, idem 
with subsequent Q-wave formation, myocardial 
infarction within one week) also represent failure of 
treatment but of a more severe kind. To take recur-
rence of ischaemia alone as outcome event would be 
meaningless because one would implicitly assume 
that patients who progress to myocardial infarction 
without renewed chest pain are successfully treated. 
The independent review by the Classification Com-
mittee was undertaken to strengthen the method-
ology of the trial by applying uniform reproducable 
standards in the ascertainment of the (subjective) 
outcome events. All episodes of chest pain and 
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enzyme values were taken into account, irrespective 
of previous discontinuation of trial medication or any 
departure from the trial protocol. The tallies of out-
come events per trial medication group (Table 4.9) 
were thus drafted in strict accordance with the 
intention-to-treat principler31 . The intention-to-treat 
principle follows naturally from the nature of the 
clinical problem: how useful is initiation of early 
treatment with nifedipine or metoprolol in patients 
presenting with symptoms and signs of suspected 
unstable angina. 
Maintenance of the highest possible degree of 
blindness was seen to be particularly important in the 
context of HINT. Nonspecific measures may have a 
substantial impact on recurrence of chest pain or at 
least on the patient's perception of it. Clinic person-
nel and Coordinating Centre staff were responsible 
for the acquisition and processing of information on 
outcome events (e.g. recording electrocardiograms 
and obtaining blood samples for enzyme measure-
ments). Blinding of the Classification Committee was 
extremely important because their decisions were to 
a certain extent subjective, e.g. with regard to the 
presence of ST-segment or T-wave changes during 
pain. We believe that the procedure as a whole was 
such that outcome events were ascertained without 
knowledge of the patient's treatment assignment. It 
has been argued that the chronotropic effect of beta 
blockers precludes the maintenance of blindness in 
trials of beta blockers versus non-beta blocking 
treatments. We also observed that the mean heart 
rates in the beta blocker and the combination groups 
were lower than in the corresponding placebo and 
nifedipine groups. However, the variability in heart 
rate was, as expected, sufficiently large to cause a 
considerable overlap between the groups. For this 
reason, there is sufficient uncertainty in the predic-
tion of the trial medication assignment in an indi-
vidual patient. 
The angiographic findings as presented in Tables 
4.14 and 4.15 are difficult to interpret. To begin with, 
they reflect the degree of coronary atherosclerosis 
that was present weeks after randomisation in those 
patients in whom angiography was performed (72% ). 
Hence they do not represent a baseline characteristic 
in the strict sense. Further, angiography is generally 
carried out after stabilization of symptoms (i.e. a few 
days after hospital admission at the earliest), unless 
there are compelling reasons for an emergency pro-
cedure, e.g. symptoms that are refractory to maximal 
pharmacologic treatment. Thus in most patients 
angiographic findings are not relevant to the initial 
management. 
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Introduction to data analysis 
The methodology and findings of HINT have 
been described in chapters 3 and 4. Together, these 
chapters document the experience of 668 patients 
admitted to hospital for unstable angina between 
1981 and 1984. This experience, however, does not 
represent the ultimate result of HINT. The objective 
of HINT was to learn about the therapeutic benefit 
of nifedipine, metoprolol, and their combination in 
their capacity to prevent recurrent ischaemia or myo-
cardial infarction in suspected unstable angina. More 
specifically, the objective was to obtain estimates of 
the magnitudes of the treatment effects. The eventual 
result of HINT would then be a view (an opinion) 
about these treatment effects. This view will not be 
based on the HINT findings alone-it will also 
depend on findings of other trials, on pathophysio-
logical and pharmacologic insights, and on other 
clinical observations. The principle is that prior views 
are updated in the light of new findings, in this case 
from HINT. The extent to which the prior views are 
updated may be regarded as the inference drawn from 
the trial. 
Even after results from a particular trial become 
available, the opinions of experts usually remain 
quite diverse and, hence, subjective. The reasons for 
this are two-fold: (1) the views formulated before 
disclosure of the results are subjective; and (2) the 
evidence itself from a clinical trial is subject to inter-
pretative differences, in particular as to which indica-
tion findings may be applied. It is thus evident that 
the purpose of data analysis cannot be taken as that 
of reaching a conclusion about the investigated treat-
ment effects. Its purpose is to summarize the evidence 
in the data with respect to these effects. In the end, 
conclusions will be drawn by the reader of the study 
report. 
The summarization of evidence rests on three 
elements: (1) a description of the study design-to 
allow a judgement of internal validity; (2) a summary 
presentation of the observations themselves; and (3) 
estimates of the treatment effects together with an 
indication of their precision. Each of these elements 
is discussed below. 
The description of the study design allows the reader 
to form an opinion about intemal validity. If method-
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ology is seriously flawed, the evidence is invalid and 
no inference whatsoever can be drawn. The presenta-
tion of methodology is usually not considered a part of 
data analysis per se. HINT methodology was presented 
in chapters 3 and 4. Its actual implementation in the 
Clinical Centres, which also pertains to validity, is 
presented in chapter 6. 
The raw observations (the data) contain the in-
formation on the treatment effects under study. They 
need be summarized in concise form, which usually 
consists of tabulations of the observations according 
to key design factors. This process is generally 
referred to as data reduction. Its purpose is to ensure 
that the reader acquires some familiarity with the 
data. It also includes the baseline profile of the 
patients admitted to the trial, which defines the 
clinical spectrum of the disease entity actually 
studied. Reduced data of HINT were presented in 
chapters 3 and 4. 
The primary objective of data analysis is the genera-
tion of valid estimates of the treatment effect(s) in 
combination with an appropriate indication of its 
precision (a confidence interval). Secondary objectives 
are the identification of baseline characteristics that 
are important determinants of the course of the ill-
ness (prognosis) and the identification of baseline 
characteristics that specifically modify treatment 
effects (effect modification or subgroup analysis). 
The derivation of effect estimates, the assessment of 
prognosis, and the study of effect modification are 
generally referred to as data analysis (in its usual 
sense), which in reference to HINT is the subject of 
this chapter. 
Two approaches to effect estimation are presented. 
The first approach, generally referred to as simple 
analysis, is based on a simple, direct comparison of 
outcomes between treatment groups without taking 
account of baseline characteristics; it leads to crude 
(i.e. unstratified) effect estimates. In the second 
approach, commonly known as stratified analysis, 
the investigator also evaluates the role of base-
line characteristics using appropriate stratification 
(or multivariate methods). The effect estimates that 
result from it have been adjusted for known im-
balances in baseline composition of the treatment 
groups. Although we regard stratified analysis 
primary, a detailed presentation of simple analysis 
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seems warranted. Firstly, an understanding of this 
procedure is necessary before the general principles 
of stratified analysis can be appreciated. Secondly, a 
simple analysis is usually performed even if the role 
of baseline characteristics is further explored. 
The conventional approach to data analysis in 
clinical trials is that of statistical hypothesis testing. 
Application of this method in clinical trial data 
analysis is, in our view, based on an improper percep-
tion of the objectives of a clinical trial. The purpose 
of carrying out a clinical trial is to determine the 
magnitude of the therapeutic benefit of the index 
treatment relative to the reference treatment, and not 
to establish whether any therapeutic benefit exists. 
As a consequence, we have refrained from presenting 
P-values or any other quantity associated with statis-
tical hypothesis testing. 
Simple analysis 
MEASURES OF OUTCOME EVENT FREQUENCY 
Table 5.1 shows the general data lay-out for simple 
analysis. Outcome event occurrence at the group level 
is measured as a rate defined as the proportion of 
patients that develops the outcome event during the 
follow-up period: the index rate r1 equals a/n~> and 
the reference rate r 0 equals b/n0 • A rate of this type 
is a dimensionless quantity; its value must range 
between zero and one. Its interpretation specifically 
relates to the time period to which it applies: it 
measures the (average) risk (or probability) of an 
individual patient developing the outcome event 
within the follow-up period when (initially) exposed 
to either index or reference treatment. 














POINT ESTIMATION OF TREATMENT EFFECTS 
Rate 
r 1 = a/n 1 
r0 = b/n0 
A measure of treatment effect reflects the magni-
tude of the therapeutic benefit of the index treatment 
relative to the reference treatment with regard to the 
outcome of interest. In principle, it involves a direct 
comparison of frequency measures for different 
treatment groups. A ratio comparison of two rates is 
called a rate ratio (RR), which may be computed 
directly from the ratio of two rates as follows: 
where r 1 and r0 are the observed rates for the index 
and reference group respectively. An alternative 
would be a difference comparison of two rates: the 
rate difference (RD), which may be computed from 
the difference of two rates as follows: 
a b RD = r 1 - r 0 = -- -. 
n1 n0 
The rate ratio provides a relative measure of the two 
rates while the rate difference provides an absolute 
comparison. The rate ratio is more commonly used, 
because it gives the most intuitive comparison. In 
what follows the rate ratio is taken as the treatment 
effect measure of interest. It represents a point esti-
mate of the true risk ratio, i.e. the ratio of the risk 
for developing the outcome event under index treat-
ment to that under reference treatment. A rate ratio 
of unity points towards equivalence of risk under 
the two (compared) treatments. A rate ratio greater 
than unity indicates that the risk for the outcome 
event under index treatment may exceed that under 
reference treatment (i.e. a deleterious effect of index 
treatment relative to the reference treatment). A rate 
ratio less than unity indicates that the index treatment 
may reduce the risk for the outcome event relative to 
the reference treatment (i.e. therapeutic benefit of the 
index treatment relative to the reference treatment). 
INTERVAL ESTIMATION OF TREATMENT EFFECTS 
The observed rates r 1 and r0 , and thus the observed 
rate ratio, are subject to random variation: other 
values of the rates and of the rate ratio are expected 
if the trial were replicated. Hence, the observed rate 
ratio randomly deviates from the true risk ratio, i.e. 
from the true treatment effect the investigator intends 
to measure. (The concept of precision as outlined in 
chapter 2 thus concerns random variation in the 
rate ratio.) It is essential that the point estimate is 
supplemented with some measure of the random 
variation. Only then, the reader can fully appreciate 
the information on the magnitude of the treatment 
effect that is provided by the data. 
One approach is to use the confidence interval, 
which consists of a range of values (surrounding the 
point estimate) of the true treatment effect consistent 
with the observed data. Values close to the point 
estimate are most consistent with the data, whereas 
those at the outer sides show only marginal consis-
tency. The confidence interval may be considered as 
an interval estimate of the treatment effect. Its width 
is determined by the size of the treatment groups and 
by a chosen value that specifies the degree of consis-
tency between the limits of the interval and the data. 
This so-called confidence level, arbitrarily but con-
ventionally set at 95%, gives the confidence interval 
sufficient width so that it contains the true treatment 
effect (risk ratio) in 95% of the applications. This fre-
quency behaviour has led to the notion that one may 
be 95% confident that the 95%-confidence interval 
will contain the true risk ratio. This does not imply 
that one may indeed be 95% confident that an actually 
calculated 95%-confidence interval contains the true 
risk ratio (even in the absence of biases). Such con-
fidence seems only warranted when no other inform-
ation on the risk ratio is available. The 95%-con-
fidence interval is nothing more than a statistic to 
quantify the precision of the effect estimate. Its width 
primarily depends on the size of the treatment 
groups: the larger the treatment groups are, the nar-
rower the confidence interval. Small studies have 
wide confidence intervals-they convey little in-
formation; large studies have narrow confidence 
intervals-they convey a large amount of informa-
tion. The confidence interval may be viewed to re-
present the stability of the measurement: a short 
interval (in a large study) indicates that values close 
to the one actually observed are expected if the study 
were replicated; a wide interval (in a small study) 
indicates that repeat studies may produce rate ratios 
that are vastly different. The confidence interval 
accounts the effect of random variation only; it does 
not pertain to any form of systematic error that is 
due a deficiency in design, conduct, or analysis of 
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the study. Methods to calculate confidence intervals 
for rate ratios are provided in appendix II on page 
67. 
CRUDE EFFECT ESTIMATION IN HINT 
Table 5.2 shows crude rate ratios with 95%-con-
fidence intervals for comparisons of trial medications 
relative to placebo with regard to three of the four 
defined outcome events. Because the overall occur-
rence of the outcome event "myocardial infarction 
within 48 hours with subsequent Q-wave formation' 
was rather low, effect estimates are not provided for 
this outcome event. 
Stratified analysis 
Valid measurement of the therapeutic benefit of one 
treatment relative to another is only possible with 
groups that could be expected to produce identical 
outcomes in the absence of a differential therapeutic 
effect. A balanced distribution of the risk (or pro-
pensity) for developing the outcome event is a pre-
requisite for valid comparison. The purpose of ran-
domisation is to achieve identity of distribution in 
baseline risk between the treatment groups. As the 
randomisation procedure itself is subject to chance 
variation, distributions are only identical on the long 
run. Randomisation does not guarantee identity of 
risk distributions in a given trial. A minor and some-
times even a major imbalance in baseline risk may 
arise by chance alone. If this occurs, the crude rate 
ratio gives a distorted impression of the true treat-
ment effect. The validity of the effect estimates ulti-
mately depends on the extent to which the random 
assignment procedure has accomplished identity of 
distribution for baseline risk. 
Table 5.2 Crude rate ratios (with 95%-confidence intervals in brackets) for com-
parisons of index trial medications with placebo 
No previous maintenance treatment with a beta blocker 
Nifedipinejplacebo 1·28 (0·90, 1·84) 1·82 (1·01, 3·31) 
Metoprololjplacebo 0·75 (0·48, 1·18) 1·06 (0·53, 2·13) 
Combination/placebo 0·82 (0·53, 1·25) 0·90 (0·44, 1·84) 
On continued maintenance treatment with a beta blocker 
Nifedipinejplacebo 0·60 (0-41, 0·86) 0·69 (0·35, 1·33) 
1·89 (1·08, 3·34) 
1·14 (0·59, 2·19) 
1·19 (0·63, 2·24) 
0·84 (0·48, 1·48) 
RI/M148 , recurrent ischaemia or myocardial infarction within 48 hours; Ml48 , myo-
cardial infarction within 48 hours; Ml 1 w, myocardial infarction within one week. 
Crude rate ratios may be considered treatment effect estimates without taking 
account of baseline characteristics. 
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The fact that randomisation is unreliable in pro-
ducing treatment groups with comparable baseline 
risk is a major concern in data analysis. As baseline 
risk is an abstract and hence immeasurable notion, 
its evaluation is achieved by a careful analysis of 
(measurable) baseline characteristics that bear on 
prognosis. Stratified analysis and multivariate 
analysis are two data analytic tools that provide a 
means of obtaining undistorted effect estimates when 
the data indicate that influential baseline characteris-
tics are differentially distributed. In stratified analysis 
distortion is avoided by evaluating treatment effects 
within strata defined by one or more baseline charac-
teristics. The results of the stratum specific com-
parisons are combined into one single overall esti-
mate. The resulting effect estimate has been adjusted 
for imbalances of the involved baseline characteris-
tics. Multivariate analysis involves the construction 
of a model to describe simultaneously the functional 
relationship between the outcome on the one hand, 
and treatments and baseline characteristics on the 
other. The model allows to obtain effect estimates 
that have been adjusted for the joint imbalance of all 
baseline characteristics entered into the model. 
STRATIFIED ANALYSIS INVOLVING ONE BASELINE 
CHARACTERISTIC 
The general principles of stratified analysis are now 
illustrated in an example from HINT, in which the 
pain free interval is involved in the comparison of 
nifedipine with placebo among patients without pre-
vious maintenance treatment with a beta blocker. The 
resulting treatment effect estimate is adjusted for 
baseline incomparability of the pain free interval. This 
example is presented to ensure that the reader obtains 
an understanding of adjustment by stratified analysis. 
Note that the ultimate goal is to adjust for incom-
parability of overall baseline risk, and not for incom-
parability of one baseline characteristic. 
The pain free interval is a strong indicator of risk 
(see Table 4.6). Table 5.3 provides the required in-
formation for stratified analysis. To begin with, rates 
and tallies for recurrent ischaemia or myocardial in-
farction within 48 hours are presented, both overall 
and according to categories defined by the pain free 
interval. From the denominators of the stratum-
specific rates we read that of 89 patients allocated to 
nifedipine 29 (33%) had a pain free interval of less 
than one hour, in contrast to only 19 of 84 patients 
(23%) allocated to placebo. As this distribution 
indicates that the nifedipine group has a higher risk 
for developing recurrent ischaemia or myocardial in-
farction within 48 hours, it seems natural to inquire 
Table 5.3 Summary information for stratified analysis in-
volving the pain .fi"ee interval. The information refers to the 
comparison of nifedipine with placebo for recurrent ischaemia 
or myocardial infarction within 48 hours among patients not 
on previous maintenance treatment with a beta blocker 
Placebo 
All patients 37% (31/84) 
Pain free interval 
<I hour 63% (12/19) 
1-3 hours 39% (9/23) 
> 3 hours 24% (10/42) 
Standardized rate 39·7% 
Rate ratio 
adjusted via standardization 






25% (7 /28) 
44·2% 
1·11 
1·11 (0·80. 1·59) 




M-N. Miettinen-Nurminen (see text). 
Percentages are observed rates of recurrent ischaemia myo-
cardial infarction within 48 hours. with tallies in brackets. 
Weights were taken proportional to overall stratum size 
among patients not on previous maintenance treatment with 
a beta blocker. The standardized rate ratio was obtained as 
the ratio of the standardized rates. Intervals in brackets 
indicate 95%-confidence intervals. 
as to how much of the apparent (negative) effect of 
nifedipine might be ascribed to it. 
The basic technique is standardization of rates. For 
each trial medication group an overall standard-
ized rate was obtained as a weighted average of 
stratum-specific rates. To do so, we first assigned 
weights to the strata, in this case proportional to the 
size of the overall stratum (i.e. according to the per-
centages in third column of the upper panel in Table 
3.7). The standardized rates were 39·7% for placebo 
and 44·2% for nifedipine. These rates may be inter-
preted as those that would have been obtained had 
randomisation produced a perfect balance for the 
pain free interval. An adjusted rate ratio is obtained 
as the ratio of the two standardized rates. Note that 
the standardized rate ratio has become independent 
of the actual distribution of the pain free interval. 
The weights as chosen above, while intuitively attrac-
tive, are not optimal on precision grounds. Weights 
proposed by Miettinen and Nurminen are preferable 
because they yield (marginally) shorter confidence 
intervals [ll. (The involved calculations, however, are 
complex.) The resulting point estimates with their 
95%-confidence intervals are also presented in Table 
5.3. Crude rate ratios are provided for comparison. 
Other methods for combining the information over 
the strata are available. A statistical discussion of 
these methods is provided in appendix II on page 67. 
The distortion in the crude effect estimate that may 
be attributed to the unbalanced distribution of the 
pain free interval emanates from the comparison of 
the adjusted rate ratio (1·11) with the crude rate ratio 
(1·28). This comparison reveals the magnitude of the 
distortion, which the investigator then must take into 
account in reporting of the results. In general, the 
magnitude of the distortion depends on the degree of 
imbalance but also on the strength of the relationship 
between the baseline characteristic and the outcome: 
a slightly uneven distribution of a very influential 
baseline characteristic may cause a greater distortion 
than a substantial imbalance of a marginally influen-
tial baseline characteristic. Any assessment of baseline 
comparability that fails to appreciate both aspects is 
inappropriate. 
The above example illustrates a concept which is 
known in nonexperimental epidemiology as con-
founding, which is said to be present if there is an 
appreciable difference between the crude and adjusted 
effect estimate. Confounding in the context of clinical 
trials is a chance phenomenon: it results from a ran-
domly arisen imbalance in baseline composition of 
the treatment groups. Confounding in (or distortion 
of) the crude effect estimate is removed by appro-
priate stratification. 
From the stratum-specific rates in Table 5.3, one 
may obtain stratum-specific rate ratios: 1·14, 1·13, 
and 1·04 for the respective categories of the pain free 
interval. The similarity of these stratum-specific rate 
ratios indicates that treatment effects (expressed as 
rate ratios) are essentially equal within each of the 
three strata. The inspection of stratum-specific rate 
ratios for changes in the magnitude of the treatment 
effect according to categories defined by a baseline 
characteristic is referred to as the study of effect 
modification or as subgroup analysis. The study of 
effect modification and the removal of confounding are 
related but different issues, both requiring the division 
of data into strata. The observation of uniform treat-
ment effect in the strata in the above example reflects 
a natural phenomenon outside the study: the absence 
of a differential treatment effect according to the 
length of the time interval between the last attack of 
chest pain and initiation of treatment. By contrast, 
the presence of confounding is due to the fact that a 
baseline characteristic appeared unevenly distributed 
and is, hence, a randomly arisen nuisance. 
We now continue with the assessment of baseline 
risk. Evaluation and description of effect modification 
is provided thereafter. 
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Overall baseline risk 
In most instances not one but several influential 
baseline characteristics require simultaneous assess-
ment: imbalances in two baseline characteristics may 
either mitigate or amplify one another, or marginal 
imbalances in many characteristics may amount to 
substantial distortion. Failure to consider combined 
effects of all influential baseline characteristics may 
lead to effect estimates that are still distorted. Strati-
fied analysis involving several baseline characteristic 
is a direct approach but can only be applied with a 
few baseline characteristics because the number of 
patients per stratum rapidly decreases with an in-
creasing number of baseline characteristics. 
The goal of randomisation is to achieve identity of 
distribution of overall baseline risk. What is needed 
in the evaluation of baseline comparability, is some 
indication of risk in individual patients, one single 
score that pulls together the influence exercised on 
the outcome by the various baseline characteristics, 
which may act as a proxy for overall baseline risk. 
Stratified analysis involving that score would elimin-
ate all distortion that can knowingly be attributed to 
imbalance of baseline risk. This principle was intro-
duced to nonexperimental epidemiology in 1976 by 
Miettinen, where it is known as confounder sum-
marization rzJ_ It capitalizes on the principle that 
baseline comparability ultimately hinges on a com-
posite but univariate dimension: baseline risk. 
Multivariate logistic regression analysis can be used 
to provide that summary score. Logistic regression 
quantifies the joint functional relationship between 
individual baseline characteristics and (aggregate) 
baseline risk. Logistic in this context means that a 
mathematical function known as the logistic function 
is employed to describe the relationship between base-
line characteristics on the one hand and the prob-
ability of developing the outcome event (i.e. risk) on 
the other. The choice of which baseline characteristics 
to include in the model is in the hands of the in-
vestigator: decisions are usually taken on grounds of 
goodness of fit and medical plausibility. The influence 
exercised by the individual baseline characteristics is 
expressed in weights (regression coefficients), which 
can be estimated from the data. The use of this model 
also implies uncertainties about the appropriateness 
of the logistic function to describe the functional 
relationship between baseline characteristics and risk. 
Once the model has been fitted to the data, the 
estimated baseline risk can be calculated for each 
individual patient from the weights and the respective 
values of the baseline characteristics. The next step 
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involves the forming of strata representing different 
levels of baseline risk, which then may be used in 
stratified analysis. Note that estimation of baseline 
risk includes multivariate analysis of the risk profile, 
which is a companion objective of data analysis. 
Multivariate logistic modelling is necessarily some-
what technical. Basic properties of the logistic model 
and the actual fitting of the logistic model to the 
HINT data are described in appendix I (page 65). 
The risk profile of HINT patients is further explored 
below. Stratified analysis involving the grouping of 
patients in categories of baseline risk is provided there-
after. 
DETERMINANTS OF RISK IN HINT PATIENTS 
The baseline risk for recurrent ischaemia or myo-
cardial infarction within 48 hours is defined as the 
probability that recurrent ischaemia or myocardial 
infarction would occur given the patient's baseline 
characteristics and trial medication assignment to 
placebo. It is noted that the modelling procedure 
permits to estimate risk under placebo irrespective of 
the patient's actual trial medication assignment. The 
objective was to find the combination of variables 
that mose closely predicted recurrence of ischaemia 
or occurrence of myocardial infarction within 48 
hours. Baseline characteristics were selected for in-
clusion in the model on the basis of their overall 
(statistical) contribution to prediction and on 
medical plausibility. 
None of the characteristics related to the patient's 
history or medication before admission to hospital 
was selected. Previous maintenance treatment with a 
beta blocker was kept in the model, although it did 
not meet the statistical criterion. Only the interval 
since the last attack of chest pain and certain electro-
cardiographic characteristics (the presence of at least 
0·1 m V ST-segment depression on the baseline electro-
cardiogram, the absence of a pain electrocardiogram, 
the presence of more ST -segment or more ST-
segment elevation during pain than at baseline) were 
sufficiently predictive for recurrent ischaemia or myo-
cardial infarction with 48 hours to be included in the 
model. 
Based on the logistic function, estimated baseline 
risk was calculated for each of the 515 patients 
without pre-randomisation myocardial infarction. 
Patients were ranked accordingly and subsequently 
divided into three strata of low, medium, and high 
baseline risk. The boundaries were chosen so that 
each stratum contained an equal number of patients 
in whom recurrent ischaemia or myocardial infarction 
had occurred. The estimated baseline risk and the 
corresponding grouping are (newly constructed) base-
line characteristics. Table 5.4 shows the distribution 
of the estimated baseline risk. Of 515 patients 59% 
was grouped as 'low', 24% as 'medium' and 17% as 
'high' risk. Also shown are rates of the defined out-
come events per stratum of baseline risk. The observed 
rates for recurrent ischaemia or myocardial infarction 
with 48 hours were 21%, 53%, and 69%. These rates 
indicate that the strata are, indeed, associated with 
substantially different risk levels. 
Table 5.5 shows estimated baseline risk for a host 
of different profiles in baseline composition. By way 
of illustration, a patient without previous main-
tenance treatment with a beta blocker, randomised 
within one hour after relief of chest pain, with 0·2 
mV ST-segment depression during pain, which was 
attenuated to 0·1 m V after relief of chest pain, had an 
estimated baseline risk of 78% (sixth line, left per-
centage in Table 5.5), whereas a patient without pre-
vious maintenance treatment with a beta blocker, 
randomised within six hours of spontaneous relief of 
chest pain at home with only T-wave inversions on 
the baseline electrocardiogram has a baseline risk of 
only 15% (first line, right percentage in Table 5.5). 
These results indicate that the short-term risk of 
recurrent ischaemia or myocardial infarction is 
primarily related to the interval since the last attack 
of pain on the one hand and to the presence of resting 
ST-segment abnormalities and pain related ST-
segment changes on the other. These associations are 
also medically plausible because by definition the 
condition of patients with a long interval between last 
pain attack and diagnosis has stabilized; the second 
finding accords with current views and previous 
findings on the relevance of electrocardiography in 
such patients[3- 5 1. These associations also emerged 
from univariate analysis (see Tables 4.6, 4.7, and 4.8). 
The multivariate analysis, however, placed the contri-
butions of each of the individual baseline characteris-
tics in proper perspective. A comparison of the upper 
panel of Table 5.5 with the lower panel indicates that 
patients on previous maintenance treatment with a 
beta blocker have a higher (innate) risk for developing 
recurrent ischaemia or myocardial infarction, con-
ditional on the presence of other determinants of risk. 
Stratified analysis in HINT involving baseline risk 
The estimated baseline risk is now considered the 
only factor requiring control in stratified analysis. 
Stratified analysis thus proceeds as before, but now 
with the grouping according to estimated baseline 
risk. Before passing to this. we first provide informa-
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Table 5.4 Grouping according to estimated baseline risk for recurrent ischaemia or myocardial 
infarction within 48 hours and corresponding outcome event rates 
Outcome events 
MI 0 no MI 0 
(N = 22) (N = 515 RI/Ml48 Ml4s MI4s+o Mllw 
Baseline risk 
Low 13 303 65 (21%) 28 (9%) 13 (4%) 35 (12%) 
Medium 5 126 67 (53%) 28 (22%) 17 (13%) 32 (25%) 
High 4 86 59 (69%) 36 (42%) 20 (23%) 45 (52%) 
Ml0 , pre-randomisation myocardial infarction; RI/MI48 , recurrent ischaemia or myocardial 
infarction within 48 hours; Ml48, myocardial infarction within 48 hours; MI48+Q• myocardial 
infarction within 48 hours with subsequent Q-wave formation; MI 1w, myocardial infarction within 
one week. 
The boundaries for the risk strata were 44% and 64%. 
tion on the actual composition of the trial medication 
groups. Table 5.6 shows the distributions between the 
trial medication groups of those baseline characteris-
tics that were retained in the logistic model. Distribu-
tions of other baseline characteristics are irrelevant-
for their control does not alter trial medication effect 
estimates. Table 5.6 also shows the distribution of the 
grouping for baseline risk for recurrent ischaemia or 
myocardial infarction within 48 hours; it was distri-
buted differently over the trial medication groups: 
among patients not on previous maintenance treat-
ment with a beta blocker 18% of those assigned to 
nifedipine were high risk; for the other three trial 
medication groups this percentage ranged from 5% 
to 12%. The higher risk of the nifedipine group was 
primarily due to a relatively large proportion (33%) 
of patients in whom trial medication was started with-
in one hour after the last attack of chest pain (the 
strongest determinant of risk, Table 5.5). In patients 
who were on continued beta blockade the same 
applied to patients assigned to placebo, although to a 
lesser extent. 
Table 5.7 shows estimates of the effects that have 
been adjusted for unbalanced distributions of (esti-
mated) baseline risk together with their 95%-confi-
dence intervals for all choices of index trial medication 
relative to placebo. 
(Table 5.8a and 5.8b provide detailed information 
on how these adjusted estimates were obtained in 
stratified analysis involving estimated baseline risk. 
Shown are rates for the three outcome events at issue, 
both overall and according to stratum of (estimated) 
baseline risk for recurrent ischaemia or myocardial 
infarction. Also shown are standardized overall rates 
for each trial medication group (obtained as weighted 
averages of stratum-specific rates with weights pro-
portional to the size of the overall risk stratum), 
adjusted rate ratios and their 95% confidence inter-
vals. Crude rate ratios together with their 95%-confi-
dence intervals are provided for comparison.) 
As could have been expected, adjustment for esti-
mated baseline risk hardly affected the effect estimates 
for metoprolol or the combination among patients 
not on previous maintenance treatment with a beta 
blocker. By contrast, adjustment attenuated the 
salutary effect of nifedipine among patients on pre-
vious maintenance treatment with a beta blocker 
and the negative effect of nifedipine among patients 
not on previous maintenance treatment with a beta 
blocker as well. The width of the confidence intervals 
for 'myocardial infarction within 48 hours' indicates 
that the amount of information for this outcome 
event is only marginal. The amount of information 
with respect to the other outcome events is respect-
able, although not overwhelming. 
Effect modification 
The study of effect modification is aimed at eluci-
dating differences in therapeutic benefit between 
subgroups of patients defined by different categories 
of one or more baseline characteristics. Three sources 
of difficulty usually hinder the study of effect modi-
fication in clinical trials. Firstly, the study size is 
usually marginal with respect to the main comparison, 
which precludes a sufficiently precise assessment of 
effect modification. Secondly, the investigator may 
elect to examine effect modifying properties of a host 
of baseline characteristics and to report those that are 
evident upon inspection. Thirdly, effect modification 
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Table 5.5 Estimated baseline risk for recurrent ischaemia or myocardial infarction 
within 48 hours (with corresponding risk stratum) for different baseline profiles 
Pain free interval (hours) 
<I 
No previous maintenance treatment with a beta blocker 
No pain in hospital 
No ST depression at baseline 
ST depression at baseline 
Pain ECG present, same ST coding* 
No ST depression at baseline 
ST depression at baseline 
Pain ECG present, more ST depression* 
No ST depression at baseline 
ST depression at baseline 
Pain ECG present, more ST elevation* 
No ST depression at baseline 
ST depression at baseline 
Pain ECG present. both* 
No ST depression at baseline 











On continued maintenance treatment with a beta blocker 
No pain in hospital 
No ST depression at baseline 48% (m) 
ST depression at baseline 65% (h) 
Pain ECG present, same ST coding* 
No ST depression at baseline 59% (m) 
ST depression at baseline 75% (h) 
Pain ECG present. more ST depression* 
No ST depression at baseline 72% (h) 
ST depression at baseline 84% (h) 
Pain ECG present. more ST elevation* 
No ST depression at baseline 75% (h) 
ST depression at baseline 86% (h) 
Pain ECG present, both* 
No ST depression at baseline 84% (h) 
ST depression at baseline 92% (h) 
1-3 >3 
21% (I) 15% (I) 
36% (I) 27% (I) 
30% (!) 22% (I) 
47% (m) 37% (I) 
43% (I) 33% (I) 
61% (m) 50% (m) 
47% (m) 37% (I) 
65% (h) 55% (m) 
61% (m) 51% (m) 
76% (h) 68% (h) 
29% (I) 21% (I) 
45% (m) 36% (I) 
39% (I) 30% (I) 
57% (m) 47% (m) 
53% (m) 43% (I) 
70% (h) 60% (m) 
57% (m) 47% (m) 
73% (h) 64% (h) 
70% (h) 61% (m) 
83% (h) 76% (h) 
ST depression at baseline. ST-segment depression of at least 0·1 mV on the baseline 
electrocardiogram; (h). high risk; (m) medium risk; (1), low risk; ECG, electrocardio-
gram. 
Percentages are estimated baseline risk for recurrent ischaemia or myocardial 
infarction within 48 hours, with corresponding risk stratum in brackets. 
* From the comparison of the pain electrocardiogram with the baseline electro-
cardiogram; both more ST-segment depression in some leads and more ST-segment 
elevation in other leads. 
The boundaries for the risk strata were chosen as 44% and 64%. 
may be dependent upon the choice of the effect 
measure. e.g. what appears to be a nonuniform effect 
on a rate ratio scale may seem more or less uniform 
on a rate difference scale. Consequently, results of 
data analysis undertaken to evaluate effect modifica-
tion should be approached with caution. The investi-
gator's judgment about effect modification, and the 
reader's judgment as well, should not be restricted to 
the appearance of the data at hand; when it is avail-
able, outside knowledge from previous studies or 
more general biologic insight should be integrated in 
the evaluation processr6l. 
Table 5.6 Distribution of influential baseline characteristics between trial medication groups 
Previous maintenance treatment with a beta blocker 
No Yes 
All p N M c All p N 
Number of patients 338 84 89 79 86 177 81 96 
Pain free interval 
<I hour 26% 23% 33% 23% 27% 25% 27% 23% 
1-3 hours 36% 27% 36% 47% 34% 37% 35% 39% 
> 3 hours 38% 50% 31% 30% 40% 38% 38% 39% 
Baseline ECG 
Not codable 4% 6% 3% 3% 5% 3% 2% 4% 
No ST ~;?o 0·1 mV 83% 76% 88% 87% 79% 69% 63% 75% 
ST ~;?o 0·1 mV 13% 18% 9% 10% 16% 27% 35% 21% 
Comparison of pain ECG with baseline ECG 
Not possible* 42% 46% 39% 33% 48% 46% 42% 50% 
Same ST coding 17% 15% 19% 18% 14% 15% 16% 14% 
More ST depression 31% 29% 30% 41% 26% 31% 33% 28% 
More ST elevation 19% 17% 24% 19% 17% 20% 22% 19% 
Botht 9% 7% 12% 10% 5% 12% 14% 10% 
Estimated risk of RI/MI48 
Low 64% 67% 60% 66% 65% 49% 42% 54% 
Medium 25% 26% 22% 29% 23% 23% 22% 24% 
High II% 7% 18% 5% 12% 28% 36% 22% 
P. placebo; N. nifedipine; M. metoprolol; c. combination: RI/MI48 , recurrent ischaemia 
or myocardial infarction within 48 hours. 
*No pain observed after hospital admission or no (codable) baseline electrocardiogram available 
for comparison. 
t More ST-segment depression in some leads and more ST-segment elevation in other leads. 
Table 5.7 Adjusted rate ratios (with 95%-confidence intervals in brackets) for com-
parisons of index trial medications with placebo 
RI/M148 
No previous maintenance treatment with a beta blocker 
Nifedipine/placebo 1·15 (0·83, 1·64) 1·51 (0·87, 2·74) 
Metoprolol/placebo 0·76 (0·49. 1·16) 1·07 (0·54. 2·09) 
Combination/placebo 0·80 (0·53, 1·19) 0·88 (0·44, 1·74) 
On continued maintenance treatment with a beta blocker 
Nifedipine/placebo 0·68 (0·47. 0·97) 0·86 (0-45, 1·61) 
1·55 (0·93, 2·73) 
1·17 (0·62. 2·18) 
1·13 (0·62, 2·10) 
1·06 (0·61. 1·79) 
RI/MI48 , recurrent ischaemia or myocardial infarction within 48 hours; Ml48 , myo-
cardial infarction within 48 hours; MI 1 w, myocardial infarction within one week. 
Adjusted rate ratios are treatment effect estimates that have been adjusted for 
unbalanced distributions of baseline risk for recurrent ischaemia or myocardial 
infarction within 48 hours. 
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EFFECT MODIFICATION IN HINT 
In view of the above considerations, we have 
adopted a conservative approach in the exploration 
of the HINT data for baseline characteristics that 
provide evidence for appreciable effect modification. 
To begin with, we have restricted ourselves to the 
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Table 5.8a Summary information for stratified analysis involving estimated baseline risk for recurrent 
ischaemia or myocardial infarction within 48 hours. The information pertains to comparisons of nifedipine, 
metoprolol. combination with placebo among patients not on previous maintenance treatment with a beta 
blocker 
Placebo Nifedipine Metoprolol Combination Weight 
Recurrent ischaemia or myocardial infarction within 48 hours 
All patients 37% (31/84) 47% (42/89) 28% (22/79) 30% (26/86) 
Estimated baseline risk 
Low 23% (13/56) 28% (15/53) 19% (10/52) 16% (9/56) 0·64 
Medium 59% (13/22) 70% (14/20) 39% (9/23) 60% (12/20) 0·25 
High 83% (5/6) 81% (13/16) 75% (3/4) 50% (5/10) 0·11 
Standardized rate 38·6% 44·4% 30·2% 30·7% 
Rate ratio 
Adjusted via standardization 1·15 0·78 0·80 
Adjusted via M-N method 1·15 (0·83, 1·64) 0·76 (0·49, 1·16) 0·80 (0·53, 1.19) 
Crude 1· 28 (0·90. 1·84) 0·75 (0·48. 1.18) 0·82 (0·53, 1·25) 
Myocardial infarction within 48 hours 
All patients 15% (13/84) 28% (25/89) 16% (13/79) 14% (12/86) 
Estimated baseline risk 
Low 5% (3/56) 15% (8/53) 12% (6/52) 7% (4/56) 0·64 
Medium 36% (8/22) 30% (6/20) 22% (5/23) 25% (5/20) 0·25 
High 33% (2/6) 69% (11/16) 50% (2/4) 30% (3/10) 0·11 
Standardized rate 16·1% 24·6% 18·2% 14·1% 
Rate ratio 
Adjusted via standardization 1·52 1·13 0·87 
Adjusted via M-N method 1·51 (0·87. 2·74) 1·07 (0·54. 2-09) 0·88 (0·44. 1·74) 
Crude 1·82 (1·01. 3·31) 1·06 (0·53. 2·13) 0·90 (0·44. 1·84) 
Myocardial infarction within one week 
All patients 17% (14/84) 31% (28/89) 19% (15/79) 20% (17/86) 
Estimated baseline risk 
Low 5% ( 3/56) 17% (9/53) 13% (7 /52) 13% (7 /56) 0·64 
Medium 36% (8/22) 35% (7/20) 22% (5/23) 30% (6/20) 0·25 
High 50% (3/6) 75% (12/16) 75% (3/4) 40% (4/10) 0·11 
Standardized rate 17·9% 27·7% 22·1% 19·8% 
Rate ratio 
Adjusted via standardization 1·55 1·23 1·11 
Adjusted via M-N method [·55 (0·93. 2·73) [ ·17 (0·62. 2· 18) [ ·13 (0·62, 2· 10) 
Crude 1·89 (! ·08. 3·34) 1·14 (0·59. 2·19) [ ·19 (0·63, 2·24) 
M-N. Miettinen-Nurminen (see text). 
Percentages are observed rates. with tallies in brackets. 
Weights were taken proportional to overall stratum size among patients not on previous maintenance 
treatment with a beta blocker. The standardized rate ratio was obtained as the ratio of the standardized 
rates. Intervals in brackets indicate 95%-confidence intervals. 
outcome event 'recurrent ischaemia or myocardial 
infarction within 48 hours', since the information 
with regard to myocardial infarction is too scanty to 
warrant subgroup analysis. Furthermore, the ex-
amination was limited to a few baseline character-
istics that justified further inquiry into their effect 
modifying properties beforehand: (I) the (summary 
score for) baseline risk-for baseline risk is almost 
by definition a potential modifier; (2) the presence of 
in-hospital episodes of chest pain with established 
ST-segment or T-wave changes-for these patients 
more specifically represent the concept of unstable 
Table 5.8b Summary information for stratified analysis involv-
ing estimated baseline risk for recurrent ischaemia or myocardial 
infarction H'ithin 48 hours. The information pertains to the com-
parison of nifedipine with placebo among patients on continued 
maintenance treatment with a beta blocker 
Placebo Nifedipine Weight 
Recurrent ischaemia or myocardial infarction within 48 hours 
All patients 51% (41/81) 30% (29/96) 
Estimated baseline risk 
Low 24% (8/34) 
Medium 67% (12/18) 
High 72% (21/29) 
Standardized rate 47·3% 
Rate ratio 
Adjusted via standardization 







0·68 (0·47, 0·97) 
0·60 (0·41, 0·86) 
Mvocardial infarction within 48 hours 
Ail patients 20% (16/81) 14% (13/96) 
Estimated baseline risk 
Low 9% (3/34) 
Medium II% (2/18) 
High 38% (11/29) 
Standardized rate 17·6% 
Rate ratio 
Adjusted via standardization 




33% (7 /21) 
15·2% 
0·86 
0·86 (0-45, 1-61) 
0·69 (0· 35, 1-33) 
Myocardial infarction within one week 
All patients 23% (19/81) 20% (19/96) 
Estimated baseline risk 
Low 9% (3/34) 
Medium 22% (4/18) 
High 41% (12/29) 
Standardized rate 21·1% 
Rate ratio 
Adjusted via standardization 







1·06 (0·61, 1·79) 
0·84 (0·48, 1-48) 










Percentages are observed rates, with tallies in brackets. 
Weights were taken proportional to overall stratum size among 
patients on continued maintenance treatment with a beta 
blocker. The standardized rate ratio was obtained as the ratio 
of the standardized rates. Intervals in brackets indicate 95%-
confidence intervals. 
angina and treatment effects may be more outspoken 
among these patients; (3) the presence of at least 0·1 
m V segment depression either on the baseline or the 
pain electrocardiogram-for the same reasons as (2); 
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(4) the presence of similar ST-segment elevation-
for ST-segment elevation is known to be associated 
with coronary spasm, and nifedipine is known to 
have specific spasmolytic properties; (5) heart rate-
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Table 5.9a Summary information to assess effect modifying properties of estimated baseline risk for recurrent ischaemia or 
myocardial infarction within 48 hours. The information pertains to comparisons of nifedipine, metoprolol, combination with 
placebo among patients not on previous maintenance treatment with a beta blocker 
Placebo Nifedipine Metoprolol Combination 
Rate Rate RR Rate RR Rate RR 
All patients 37% (31/84) 47% (42/89) 1·28 * 28% (22/79) 0·75* 30% (26/86) 0·82 * 
Estimated baseline risk 
Low 23% (13/56) 28% (15/53) 1·22 19% (10/52) 0·83 16% (9/56) 0·69 
Medium 59% (13/22) 70% (14/20) 1·18 39% (9/23) 0·66 60% (12/20) 1·02 
High 83% (5/6) 81% (13/16) 0·98 75% (3/4) 0·90 50% (5/10) 0·60 
Adjusted rate ratio 1·15 0·76 0·80 
RR, rate ratio relative to placebo (*crude). 
Percentages are observed rates of recurrent ischaemia or myocardial infarction within 48 hours, with tallies in brackets. 
Adjusted rate ratios were obtained via the Miettinen-Nurminen method (see text). 
Table 5.9b Summary information to assess effect modifying proper-
ties of estimated baseline risk for recurrent ischaemia or myocardial 
infarction within 48 hours. The information pertains to the comparison 
of nifedipine with placebo among patients on continued main-
tenance treatment with a beta blocker 
Placebo Nifedipine 
Rate Rate RR 
All patients 51% (41/81) 30% (29/96) 0·60* 
Estimated baseline risk 
Low 24% (8/34) 19% (10/52) 0·82 
Medium 67% (12/18) 30% (7/23) 0·46 
High 72% (21/29) 57% (12/21) 0·79 
Adjusted rate ratio 0·68 
RR, rate ratio relative to placebo (* crude). 
Percentages are observed rates of recurrent ischaemia or myo-
cardial infarction within 48 hours, with tallies in brackets. 
Adjusted rate ratios were obtained via the Miettinen-Nurminen 
method (see text). 
for the chronotropic effect of beta blockade might be 
more salutary among patients with a high heart rate, 
whereas the tendency of nifedipine to cause a reflex 
tachycardia may offset potential benefits among 
these patients. 
Tables 5.9a and 5.9b provide summary informa-
tion that pertains to the exploration of effect modi-
fying properties of the summary score for baseline 
risk. The stratum-specific rate ratios for recurrent 
ischaemia or myocardial infarction within 48 hours 
are consistent over the risk strata; this points to a 
uniform effect over the risk strata. Tables 5.10a and 
5.10b show summary information with regard to 
(adjusted) rate ratios in the above defined subgroups. 
The stratum-specific rate ratios in patie-nts with chest 
pain accompanied by ST-segment or T-wave changes 
indicate that the effect ofmetoprolol (or of the com-
bination) may be more outspoken. The rate ratios in 
patients not on previous maintenance treatment with 
a beta blocker who present explicit ST-segment de-
pression indicate that beta blockade alone is most 
effective, that nifedipine alone might have a more 
outspoken negative effect, and that combination 
treatment may be ineffective. Among patients with 
ST -segment elevation no specific advantage for 
nifedipine was observed. Patients with a heart rate 
over 70 beats min- 1 did not appear to benefit specifi-
cally from treatment with metoprolol. The salutary 
effect of nifedipine among patients on previous 
maintenance treatment with a beta blocker was 
hardly affected by the subgrouping, except for the 
presence of high heart rate, which appeared to 
attenuate the positive effect of nifedipine. 
Discussion 
This discussion pertains to the methodological 
aspects of the data analytic procedures. A general 
discussion of the trial findings is provided in chapter 
nine. 
Clinical trials are carried out to provide empirical 
information to improve treatment of future patients. 
A physician takes a decision on treatment for an 
individual patient on the basis of a careful judgment 
of the expected therapeutic benefit against possible 
disadvantages and costs. Consequently, the objective 
of a clinical trial is to provide evidence with regard to 
the magnitude of the expected therapeutic benefit. 
The goal of data analysis is to extract the pertinent 
information from the data, in the form of estimates 
of the expected therapeutic benefit together with an 
indication of their precision. It is the task of the in-
vestigator to carry out data analysis and to report 
the resulting effect estimates, but conclusions (or 
better stated, incorporation of the evidence in the 
body of medical knowledge) should be left to the 
medical community. 
The traditional statistical approach to data analysis 
in clinical trials based on statistical hypothesis testing 
is at odds with this principle. Hypothesis testing has 
been borrowed from the application of statistics in in-
dustrial quality control experiments, where one takes 
a random sample from a production batch, 'tests' it 
for some aspect of quality, and either 'reject' or 
·accepts' the batch at issue, repeating the process as 
new (identical) batches come along. Based on this 
concept, ?-values and hypothesis testing have been 
introduced (and have become accepted) as the corner-
stone of inference in clinical research. Inference is 
presented in terms of testing a specified null-hypo-
thesis (for example that the nifedipine and placebo 
rates for recurrent ischaemia are the same) against 
alternatives which are neither specified in direction 
nor in magnitude (the nifedipine rate differs from the 
placebo rate). Note that as far as hypothesis testing is 
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concerned the magnitude of the effect is irrelevant: it 
has only relevance as far as the power of the study 
is concerned and therefore bears on study size but 
not on hypothesis testing after the data have been 
acquired. The argument then continues that, if the 
result is significant at some accepted level of the test 
(i.e., the ?-value obtained is smaller than a pre-
specified value arbitrarily but conventionally set at 
0·05) there is a departure from the null hypothesis. 
On the other hand, if the test is not significant, one 
accepts the null-hypothesis. While this seems to be 
an acceptable procedure for the above mentioned 
industrial quality control experiment, it is inappro-
priate for inference in the research setting. To begin 
with, unlike the situation in process industry, where 
the experimentor takes an actual decision (e.g. non-
acceptance of the batch implies destruction of the 
batch), the clinical research investigator does not 
take a general decision on efficacy. [The absence of 
the need to take decisions in the research setting 
should not be confused with the need (for the treating 
physician) to take treatment decisions in individual 
patients!] Furthermore, whereas in process industry 
each inference independently pertains to the quality 
of its specific batch (produced under identical circum-
stances), inferences in different clinical trials with 
similar treatments in similar disease entities are inter-
related. Hypothesis testing is based on the assumption 
that no other information relevant to inference is 
available, from whatever source. While this assump-
tion probably holds in the industrial quality control 
setting, it does not apply to the research setting. 
Why has such an unattractive methodology become 
so popular? Undoubtedly, its appeal derives from the 
apparent objectivity and definiteness of declaring 
observed differences 'statistically significant' or not. 
Scientific inference is reduced to a mechanical process: 
the presence of a treatment effect is established via a 
simple calculation. The process of statistical inference 
based on significance testing has little to do with the 
intellectual process of scientific inference (see chapter 
2). Furthermore, the popularity of hypothesis testing 
is due to misinterpretations around the ?-value con-
cept. The ?-value indicates the probability, that the 
observed rate ratio will depart from unity to the extent 
that was observed or more, assuming that the under-
lying risks are equal (i.e., assuming that no real 
differential treatment effect exists). The definition of 
the ?-value is often formulated as 'the probability of 
the observed differences being due to chance' or some-
thing alike. This definition unjustly suggests that the 
?-value represents the probability that the compared 
treatments are equi-effective. It also leads to the 
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Table 5.10a Summary information to assess effect modifying properties of selected baseline characteristics. The information 
pertains to comparisons of nifedipine, metoprolol, combination with placebo among patients not on previous maintenance 
treatment with a beta blocker 
Recurrent ischaemia or myocardial infarction within 48 hours 
Placebo Nifedipine Metoprolol Combination 
Rate Rate RR Rate RR Rate RR 
All patients 37% 47% 1·15 28% 0·76 30% 0·80 
(31/84) (42/89) (0·83, 1·64) (22/79) (0·49, 1·16) (26/86) (0·53, 1·19) 
Patients with: 
Pain + ST-T changes* 59% 60% 0·98 38% 0·71 47% 0·78 
(N = 172) (23/39) (29/48) (0· 70, I· 39) (18/47) (0-44, 1·09) (18/38) (0·50, 1·17) 
STt;;. 0·1 mVt 44% 67% 1·38 29% 0·66 52% 1·07 
(N = 97) (12/27) (14/21) (0·85, 2.36) (7/24) (0·31, 1·26) (13/25) (0·64, 1·83) 
STf;;. 0·1 mVt 45% 57% 1·03 32% 0·68 18% 0·39 
(N = 87) (9/20) (13/23) (0·60, 1·99) (7/22) (0·31, 1·95) (4/22) (0.14, 1-04) 
Heart rate ;;. 70 b min-1 35% 47% 1·16 32% 0·85 35% 0·91 
(N = 201) (18/52) (27/57) (0· 77, 1·87) (14/44) (0·50, 1·44) (17/48) (0·56, 1·50) 
Percentages are observed rates of recurrent ischaemia or myocardial infarction within 48 hours, with tallies in brackets 
underneath. 
RR-Rate ratios are relative to placebo and are adjusted for estimated baseline risk (Miettinen-Nurminen method), with 
95%-confidence intervals in brackets underneath. 
*Patients with an in-hospital episode of chest pain with ST-segment or T-wave changes confirmed by the Classification 
Committee. 
t Either in the baseline electrocardiogram or on the pain electrocardiogram. 
incorrect notion that when statistical significance is 
observed (i.e. when P < 0·05), one carries a 5% risk 
of falsely concluding that the treatment effects are 
different or, equivalently, that treatments effects are 
truly different in 95% of the instances when statistical 
significance is observed. Decision making in a statis-
tical test is, to a certain extent, similar to decision 
making in a diagnostic test. Those who interpret statis-
tical significance as proof of effect make the same 
mistake as those who accept an abnormal laboratory 
test as proof of disease. The 5% level of a statistical 
test is its false positive rate. A conventional statistical 
test thus has, by definition, a specificity of 95%. The 
power of a statistical test represents its sensitivity. 
The probability of taking the correct decision after 
the observation of a statistically significant outcome 
(a positive test) or after the observation of a nonsig-
nificant outcome (a negative test) corresponds to 
predictive value in the setting of the diagnostic test. 
It therefore depends on sensitivity, specificity, and 
on prior opinion as well. To pretend that treatment 
effects would be truly different in 95% of instances 
when significance is observed amounts to mi-
sinterpretating the meaning of the 5% level of the 
statistical test. 
In our data analysis we have refrained from statis-
tical hypothesis testing and P-values altogether. In-
stead, we have provided readily interpretable point 
estimates of relative treatment effects with corres-
ponding confidence intervals. These are a much better 
representation of the evidence contained in the data 
and should be used in all reporting of findings of 
clinical trials. Note in passing that P-values provide 
no additional information when presented in addition 
to a point estimate and a confidence interval. 
It has been argued that in properly randomised 
trials imbalances in baseline characteristics found 
between treatment groups are to be viewed simply as 
a component of variability, duly reflected in the con-
fidence interval 181. When this view is adopted, data 
analysis ends with simple crude point and interval 
estimation. The opposite view is that one cannot rely 
blindly on randomisation to produce comparable 
treatment groups and that effect estimation should be 
valid (undistorted) conditional on the actual com-
position of the treatment groups. When this view is 
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Table 5.10b Summary information to assess effect modifying 
properties of selected baseline characteristics. The information per-
tains to the comparison of nifedipine with placebo among patients 
on continued maintenance treatment with a beta blocker 
Placebo Nifedipine 
Rate Rate RR 







Pain + ST-T changes* 70% 49% 0·74 
(N = 82) (30/43) (19/39) (0·50, 1·05) 
SH ~ 0·1 mVt 72% 48% 0·73 
(N = 69) (26/36) (16/33) (0·46, 1·08) 
STi ~ 0·1 mVt 43% 19% 0·66 
(N =53) (9/21) (6/32) (0·30, 1·34) 
Heart rate ~ 70 b min- 1 46% 38% 0·88 
(N = 60) (12/26) (13/34) (0·48, 1·61) 
Percentages are observed rates of recurrent ischaemia or myocardial 
infarction within 48 hours with tallies in brackets underneath. 
RR-Rate ratios are relative to placebo and are adjusted for esti-
mated baseline risk (Miettinen-Nurminen method), with 95%-
confidence intervals in brackets underneath. 
*Patients with an in-hospital episode of chest pain with ST-
segment or T-wave changes confirmed by the Classification 
Committee. 
t Either on the baseline electrocardiogram or on the pain electro-
cardiogram. 
adopted, simple analysis is only a starting point for 
further data analysis, which will involve stratification 
or multivariate analysis in an attempt to eliminate 
distortion that may have resulted from unevenly distri-
buted baseline characteristics, if present. Clinical trial 
methodologists are divided over the need for and the 
interpretation of adjusted analyses. Simple or un-
adjusted analysis has an appealing simplicity and 
directness. Meier has made a strong case for regarding 
simple analysis as primary and 'avoiding the inevit-
able problems of interpretation which arise when the 
investigator is free to choose which baseline charac-
teristics to report and to adjust for, thus introducing 
the possibility of even unintentional personal bias' rsJ. 
On the other hand, one cannot expect the reader to 
give credence to simple effect estimates in instances in 
which randomisation has failed to create comparable 
treatment groups. Effect estimates that have been, to 
the best judgment of the investigator, adjusted for 
unbalanced baseline characteristics are an indispens-
able part in the analysis of clinical trial data, even if 
this approach renders the eventual estimates depen-
dent on good and impartial judgment on the part of 
the investigator. In the end, it is to the reader and not 
to the investigator to cast judgment on the propriety 
of simple or stratified analysis. Of course, the problem 
is obviated when the two analyses yield approximately 
the same estimates. A study report should always 
present both analysis. Subjective judgment is often 
required to decide whether a crude (simple) estimate 
differs enough from an adjusted estimate to warrant 
stratified analysis. Note in passing that stratified 
analysis obviates the concept of 'failure of random-
isation'. An unbalanced distribution of one or more 
influential baseline characteristics, which is some-
times called a 'failure of randomisation', does not 
invalidate treatment comparisons; it only requires 
to obtain adjusted effect estimates via appropriate 
stratification. · 
Assessment of baseline comparability explicitly 
amounts to comparing adjusted with (unadjusted) 
crude effect estimates. The traditional manner 
of assessing baseline comparability (in HINT, the 
application of statistical tests to the data of Table 5.6) 
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is meaningless: one knows beforehand that differences 
in baseline distribution must be attributed to chance. 
Furthermore, such tests disregard the impact of the 
imbalance on the effect estimates. From the methodo-
logical point of view, inclusion of this table is in fact 
superfluous; the table was nevertheless retained to 
link adjustment of effect estimation to the traditional 
way of assessing baseline comparability. 
We have chosen the method of stratified analysis 
involving estimated baseline risk to evaluate and 
remove the distortion that is due to imbalance 
between the treatment groups in baseline risk. This 
method combines multivariate modelling (in the con-
struction of the risk score) with stratified analysis (in 
the derivation of the treatment effect estimates). The 
advantages are the following: (1) the method explicitly 
deals with the intuitive concern for comparability of 
baseline risk; (2) treatment effects are expressed as 
readily interpretable rate ratios; and (3) the need (for 
the reader) to interpret a complex multivariate model 
is obviated. A further advantage is its relative lack of 
dependence on the usual assumptions underlying 
multivariate procedures: the fitted model is only re-
quired to provide a proper ranking by risk rather than 
its absolute assessment. There are also disadvantages: 
(1) the method has an ad hoc character and very 
little theoretical statistical work has been done to 
evaluate its performance; (2) it has been argued that 
the resulting confidence intervals are systematically 
too short r11 l and (3) one carries the risk that not all 
distortion is eliminated. We are of the opinion that 
the advantage of transparency by far outweighs the 
alleged disadvantages. 
An alternative approach would have been to obtain 
treatment effect estimates directly from the multi-
variate model. The weights (regression coefficients) 
for the trial medications in Table 5.11 of appendix I 
can be interpreted as trial medication effect estimates: 
their anti-logarithms represent the odds for de-
veloping the outcome event under index treatment 
divided by that under placebo. In the context of a 
clinical trial, however, the odds ratio is an un-
attractive measure. 
When stratum-specific rate ratios differ widely 
between the strata-that is, when effect modification 
is apparently present-overall treatment effects 
become difficult to interpret. The focus of data 
presentation and analysis should shift from the esti-
mation of overall effects to a description of the effect 
as a function of the baseline characteristic. This par-
ticularly applies to instances of qualitative effect 
modification-that is, when a positive treatment 
effect may be presumed to operate in one subgroup 
and a negative effect in another. There were no indica-
tions in the HINT data that this was the case. 
It is a prevalent belief among statisticians that the 
interpretation of observations pertaining to the effect 
of one index treatment (relative to reference treat-
ment) must be modified in the presence of other treat-
ment arms: the multiple comparison problem. The 
aetiology of the alleged problem lies in the interpreta-
tion of P-values. When P-values are calculated for 
more than one treatment comparison, there is an in-
creased probability that at least one P-value reaches 
statistical significance when in fact no differential 
treatment effects exist. This has led to the notion 
that the level of significance need be lowered accord-
ing to some criterion. Note that his reasoning is based 
upon the understanding that the probability of any 
falsely significant finding must be kept below 0·05, in 
disregard of the implied increase in false negative rate 
(beta). The above notion also derives from considera-
tions in industrial quality control experiments, where 
an instrument consisting of various components must 
be considered defective if one component is defective. 
The implied consequence would be, for instance, to 
broaden the confidence interval for the comparison 
of nifedipine to placebo just because additional data 
on other trial medications were collected in HINT. 
We fail to understand why (and how) the collection 
of additional data (on other treatments) should affect 
the precision of the effect estimate of nifedipine (re-
lative to placebo). The ordinary 95%-confidence 
interval still has the property of containing the true 
treatment effect in 95% of cases. With this in mind, 
we have ignored the multiple comparisons problem 
and have obtained confidence intervals for each 
comparison of index trial medication with placebo as 
if it alone was the sole focus of the study. 
HINT may look like having a so-called factorial 
design. One might entertain the idea that the effect of 
combination treatment (among patients not on pre-
vious maintenance treatment with a beta blocker) 
would be the combiT;ed effect of nifedipine and 
metoprolol. We have refrained from data analysis 
based on this principle. Because of the pharmacologic 
and haemodynamic interactions of nifedipine and 
metoprolol, the combination must be considered a 
separate drug whose effect is unrelated to that of 
nifedipine or metoprolol; hence its efficacy must be 
established independently. By the same argument, 
data on the treatment effect of nifedipine (relative to 
placebo) among patients on previous maintenance 
treatment with a beta blocker provide no information 
on the same comparison among patients without 
previous beta blockade. 
We have not applied adjustments for the fact that 
the Policy Advisory Board has looked at the data as 
they accumulated on several occasions. This aspect is 
further discussed in chapter 7. 
Appendix I: Multivariate modeling 
BASIC PROPERTIES OF THE LINEAR LOGISTIC MODEL 
The linear logistic model relates a probability (P) 
for developing the outcome event to the value of a 
baseline characteristic (X) using the linear logistic 
function: 
+ e-(a+bX)" 
Use of the logistic model assumes that, although every 
patient may have his own values of P and of X in the 
equation, the parameters (a and b) of that equation 
are characteristic for the population that patient 
belongs to. The above equation is referred to as a 
regression equation, which indicates that the variate 
X (the independent variate) is used to predict P (the 
dependent variate). Additional independent variates 
(XI> X 2 , etc. with corresponding coefficients bb b 2 ) 
can be accommodated in the model. 
Alternatively, the logistic equation can be written as 
ln(-p-) =a+ bX. 1- p 
The quantity P/(1 - P) is the odds for developing the 
outcome event; the logarithm of the odds (i.e. the left 
hand side of the above equation) is referred to as a 
'log odds' or as a 'logit'. Thus the use of a logistic 
model implies that the logit for developing the out-
come event depends linearly on X. 
From a set of observations on baseline character-
istics Xb X 2 , ••• , Xn in a group of patients and the 
actual occurrences of the outcome events in those 
patients, the parameters of the model a, bb b2 , •.. , bn, 
which were characteristic for the patient group as a 
whole, can be estimated. For this purpose several tech-
niques are available. Walker and Duncan's method 
of iterative solution of the unconditional maximum 
likelihood equation is generally advocated as the most 
reliable and is widely available in statistical computing 
packages. 
FITTING A LOGISTIC MODEL TO DATA 
In constructing a model, the first step is to translate 
the observed baseline characteristics into a set of 
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statistical variates XI> X 2 , ••• , Xn, which can be used 
in the regression model. As an example, previous myo-
cardial infarction (a baseline characteristic with only 
two categories: present or absent) is represented by 
an indicator variate assuming the value 1 if previous 
myocardial infarction is present and 0 if otherwise. 
This variate actually 'indicates' the presence of pre-
vious myocardial infarction. The pain free interval (a 
baseline characteristic with three categories: less than 
one hour, between one and three hours, and greater 
than three hours) can be represented by two indicator 
variates: one indicating the category 'less than one 
hour' and one indicating the category 'between one 
and three hours'; the category 'greater than three 
hours' is implicitly indicated when both variates 
assume the value 0. It is also possible to involve the 
numeric value of the pain free interval as such in the 
logistic regression. 
Forward selection and backward elimination are 
two commonly used methods for deciding which vari-
ates to include in the model. They are as automatic 
selection procedures widely available in statistical 
computing packages. In forward selection variates are 
sequentially entered into the model until no remaining 
candidate variate meets a specified entry criterion, 
usually a significance level. A backward elimination 
procedure starts with a model containing all possible 
variates, from which terms are sequentially elimin-
ated. Many of the automatic selection procedures 
combine elements of forward selection and backward 
elimination. However, model fitting should never be 
a matter of automatic selection. Considerations of 
medical plausibility and interpretability of the co-
efficients should also play a role in the construction 
of the model. 
MODEL FITTING IN HINT 
The summary score for baseline risk represents the 
risk for developing the outcome event under placebo 
treatment. Yet, all patients may be included in the 
fitting procedure provided that (indicator) variates 
representing the patient's trial medication are kept in 
the model. (The baseline risk can be obtained by 
setting these variates to values representing placebo 
treatment (regardless of the patient's actual trial 
medication.) In this way, data on all patients are 
involved in the construction of the model. 
A patient's trial medication was indicated as 
follows: one variate indicated previous maintenance 
treatment with a beta blocker; three variates indicated 
treatment with nifedipine, metoprolol, and the com-
bination respectively in the absence of previous main-
tenance treatment with a beta blocker; another variate 
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Table 5.11 Indicator variates (with coefficients and standard errors) retained in the logistic model to predict the development 




Indicator Coeff. SE Coeff./SE Coeff. SE Coeff./SE 
Nifedipine treatment 0·339 0·344 0·985 0·706 0·414 1·703 
Metoprolol treatment -0·612 0·369 -1·658 0·036 0·456 0·080 
Combination treatment -0·393 0·355 -1·107 -0·165 0·457 -0·362 
Pre-treatment with a beta blocker 0·402 0·352 1·142 -0·040 0·447 -0·092 
Addition of nifedipine -0·807 0·351 -2·299 -0·236 0·444 -0·532 
Pain free interval less than 1 hour 1·228 0·290 4·237 1·283 0·368 3·484 
Pain free interval between 1-3 hours 0-414 0·254 1·632 0·537 0·348 1·542 
Baseline ECG missing 0·246 0·533 0·460 1·262 0·587 2·151 
ST depression ;;;, 0·1 m V on baseline ECG 0·713 0·271 2·627 0·915 0·308 2·971 
Pain ECG absent -0·460 0·304 -1·514 0·029 0-408 0·072 
More ST t during pain than at baseline 0·558 0·258 2·167 0·669 0·309 2·164 
More ST[ during pain than at baseline 0·731 0·271 2·696 0·774 0·304 2·545 
Constant -1·252 0·354 -3·536 -2·946 0·485 -6·073 
RI/MI48 , recurrent ischaemia or myocardial infarction within 48 hours; MI48 , myocardial infarction within 48 hours; 
coeff., coefficient; SE, standard error. 
indicated treatment with nifedipine in the presence of 
continued maintenance treatment with a beta blocker. 
As a general principle only indicator variates were 
used to represent baseline characteristics. Continuous 
variables were divided into thirds (as for heart rate 
and blood pressure in Table 3.10) and indicator vari-
ates for two categories (as described above) were used. 
One variate was used to indicate that the ST-segment 
code on the baseline electrocardiogram was not avail-
able, in which case all other electrocardiographic 
variates were set to 0. Three variates were defined to 
indicate the presence of ST-segment depression of at 
least 0·1 mV, of similar ST-segment elevation, and of 
T-wave inversion of at least 0·10 mV on the baseline 
electrocardiogram. A separate variate was used to 
indicate that the ST-segment code on the pain electro-
cardiogram was not available, in which case all vari-
ates referring to the pain electrocardiogram were set 
to 0. Two variates to indicate a more severe coding 
forST-segment depression and of ST-segment eleva-
tion on the pain electrocardiogram (relative to the 
baseline electrocardiogram) were defined. Enzyme 
values at baseline were not considered because they 
were not known to the clinician when he admitted the 
patient. 
The model to describe the risk for developing re-
current ischaemia or myocardial infarction within 
48 hours was fitted to the data of 515 patients with-
out pre-randomisation myocardial infarction, using 
the PLR program from the BMDP statistical pack-
age. The standard PLR criteria of P < 0·10 for in-
clusion and P > 0·15 for elimination were applied. 
Model fitting was initially carried out within clusters 
of related baseline characteristics. Thereupon, those 
variates that were retrieved from the various clusters 
were collated into one final model. Selection was not 
followed mechanically. Variates representing trial 
medications (including representation of previous 
maintenance treatment with a beta blocker) were 
kept in the model, as were the two variates indicating 
that either the pain or the baseline electrocardiogram 
was missing. (As a consequence of the latter, regres-
sion information on electrocardiograms was ex-
tracted from those patients in whom the respective 
electrocardiogram was available.) A model to de-
scribe the risk for developing myocardial infarction 
within 48 hours was developed simultaneously. 
Table 5.11 shows the variates that were eventually 
retained in the multivariate logistic model for the 
prediction of recurrent ischaemia or myocardial in-
farction within 48 hours with their coefficients and 
standard errors. The regression coefficients in Table 
5.11 have a direct epidemiological meaning: each 
coefficient represents the log odds of developing re-
current ischaemia or myocardial infarction when all 
other factors are controlled. Its antilogarithm is the 
odds ratio of the event considered. As an example, 
the regression coefficient of 'ST-segment depression 
of at least than 0-1 m V on the baseline electrocardio-
gram' is 0-915; its antilogarithm (e0"915 ) is 2·50. This 
means that the odds for developing ischaemia or myo-
cardial infarction within 48 hours for patients with 
at least this amount of ST-segment depression is 2-5 
times as high as it is for patients without it. Similarly, 
coefficients for trial medications can be interpreted 
as trial medication effect estimates (relative to corre-
sponding placebo) expressed as odds ratios. Table 
5.11 also shows the regression coefficients for the 
function to predict the occurrence of myocardial in-
farction within 48 hours. 
ESTIMATION OF BASELINE RISK 
The summary score to estimate baseline risk for 
recurrent ischaemia or myocardial infarction within 
48 hours was obtained by setting the variates indicat-
ing the patient's actual trial medication to values (0) 
indicating treatment with placebo. Next, for an in-
dividual patient the coefficients from Table 5.9 that 
applied to that patient were added. From this sum, 
denoted as Z, the summary score was obtained as 
{1 + exp(- Z)}- 1 • As an example, for a patient on 
previous maintenance treatment with a beta blocker, 
with a pain free interval of less than one hour, with 
ST -segment depression of at least 0-1 m V at baseline, 
with more ST-segment depression during pain, with-
out ST-segment elevations whatsoever Z was calcu-
lated as: 
z = - 1-252 + 0-402 + 1-228 + 0-713 + 0-558 
= 1-649. 
and the summary score was 0·839 [ = { 1 + 
exp(-1-649)}- 1]. Thus, a patient with this baseline 
profile has an estimated baseline risk of 84% for 
developing recurrent ischaemia or myocardial in-
farction within 48 hours. In other words, it is expected 
that 84% of patients with this profile will develop 
recurrent ischaemia or myocardial infarction within 
48 hours (when initially treated with placebo). 
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Appendix II: Statistical calculations 
In this appendix methods to obtain point estimates 
and confidence limits for the rate ratio are provided. 
A more elaborate description can be found else-
wherer6-7·9·121. The 0-975 percentile of the Gauss dis-
tribution (1-960) is used throughout; the formulas 
thus apply to 95%-confidence limits only. 
CONFIDENCE LIMITS FOR UNSTRATIFIED DATA 
When the (unstratified) data are cast in the array 
shown in Table 5.1, the limits of the 95%-confidence 
interval for the risk ratio can be obtained as: 
where X2 is generally taken as the Mantel-Haenszel 
X2 statistic, which is defined as: 
(rl - rof 
r(l - r)(-n )(__!_ + __!_)' 
n- 1 n 1 n0 
) with n = n1 + n0 and r = (a + b)/n. This method is 
known as 'test-based'[ 101. An alternative method is 
to calculate the limits of the 95%-confidence interval 
as: 
r1 ( Jl -r1 1 - fo) 
ro = exp ±1·960 -a-+ -b-. 
This method, based on a log-transformation and an 
estimate of the standard error, has been recom-
mended by Katzr131_ It was criticized by Miettinen 
because its propensity to yield poor results in extreme 
cases but also on theoretical groundsr 11. Miettinen 
and Nurminen have proposed a theoretically more 
attractive method [IJ_ Computer simulations indicated 
a better performance, but the formulas can only be 
solved iteratively. 
POINT ESTIMATION FOR STRATIFIED DATA 
It is assumed that k strata with group size n 1i and 
noi (j = 1, 2, ... , k) are available from which k 
stratum-specific index and reference rates r 1 i and roi 
with corresponding rate ratios RRi ( = r lifr oi) have 
been obtained. 
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The general principle underlying standardization 
is to combine the stratum-specific index rates into 
one overall index rate rj and, similarly, the reference 
rates into one overall reference rate rt, by taking 
weighted averages. The overall RR is obtained as 
RR = rjjr;j. One may choose weights proportional 
to the overall size of the stratum; this approach is 
satisfactory if the treatment groups within each 
stratum have approximately equal sizes, which is 
usually the case in a randomised trial. However, it 
is more efficient to apply the weights proposed by 
Cochran, which are defined as Wi = (n1J + 
n0j)l for j = I, 2, ... , kl14l. These weights reflect 
the comparative amount of information in rj - rt 
under the assumption that index and reference rates 
are equal and constant over the strata. The rate ratio 
thus obtained is computationally equivalent to the 
so-called Mantel-Haenszel estimate of the risk ratio 
(e.g. formula 17.11 in Kleinbauml9l). 
The Miettinen-Nurminen estimate of the overall 
rate ratio chooses weights proportional to the com-
parative amount of information in rj - (RR x r;j), 
conditional on the value of the rate ratio being estim-
ated. These weights can only be obtained iteratively. 
A different approach is to obtain stratum-specific 
rate ratios first and to obtain the overall rate ratio as 
weighted average of these stratum-specific rate ratios. 
As the distribution of ratio estimates is skew, it is con-
ventional to use the logarithmic scale. The weights 
for pooling of the RRi are usually taken as Wi = 
(aibintinoi)/[ai(noi - bi)n 1i + bj(nu - ai)n 0 j], the 
inverse of the variance of In RRi. The overall rate 
ratio is then obtained as 
CONFIDENCE LIMITS FOR STRATIFIED DATA 
Test based confidence limits for standardized rate 
ratios can be obtained as: 
where X 2 is defined as: 
This statistic was, in a slightly different form, intro-
duced by Cochran in 1954, who used the above men-
tioned (Cochran) weights 1141. With these weights, 
the formula is computationally equivalent to the well-
known Mantel-Haenszel chi-square statisticl15l and 
is widely available in computer programs. 
Standard error based confidence limits for stan-
dardized rate ratios are also available, see for instance 
Table 17.16 in Kleinbauml91 . Confidence limits for 
the Miettinen-Nurminen point estimate have to be 
obtained iterativeJylll. 
When the overall rate ratio is obtained by pooling 
stratum-specific rate ratios, test-based confidence 
limits can be obtained as above; standard error based 
confidence limits are also availabJel9l. 
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Errata Appendix 11 
The first formula (PaQe 67) reads as: GJI ± 1·960/,./X2 
The third formula (page 67) reads as: 
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ro a. b . 
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FOR THE HINT RESEARCH GROUP 
Background and history 
The idea for HINT originated from clinicians 
working at the Thoraxcentre in 1979. A provisional 
protocol was approved by the Scientific Council of 
the Interuniversity Cardiology Institute of the Nether-
lands in 1980. Thereupon, Bayer GmbH, Germany, 
agreed to award a grant of Fl 500,000 to the Institute. 
Hassle AB, Sweden, offered additional funding for 
Fl 100,000. The Institute committed itself to provide 
further funding. 
The university clinics that constituted the Inter-
university Cardiology Institute agreed to participate. 
Three non-university clinics were selected. The Policy 
Advisory Board was formed by the end of 1980. The 
Scientific Council of the Interuniversity Cardiology 
Institute together with the heads of the participating 
non-university Clinical Centres would act as Execu-
tive Committee. The Coordinating Centre was set up 
in the then newly established Clinical Epidemiology 
Unit of the Thoraxcentre. 
Detailed planning and development of a trial pro-
tocol and forms continued until February 1981, when 
the first patient was enrolled. On 30 October 1984 
enrolment was discontinued because an interim 
analysis suggested that the risk of myocardial 
infarction was higher in patients assigned to nifedi-
pine than in patients treated with the other trial 
medications. Both Bayer and Hassle and the Dutch 
health authorities were informed of the decision but 
not of the actual data. A paper in which the main 
trial findings were described appeared in November 
1986[11. 
Trial organization 
The HINT Research Group consisted of the fol-
lowing units: 11 Clinical Centres, the Coordinating 
Centre, the Executive Committee, the Technical 
Group, the Policy Advisory Board, and the Classi-
fication Committee. The Clinical Centres together 
with the Coordinating Centre were responsible for 
recruitment and treatment of patients and for col-
lection and analysis of data. The other units were 
created in order to ensure proper conduct of the trial, 
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quality of operations, and optimal communications 
not only among the centres but also towards the 
sponsors and the scientific community as a whole. 
Eleven Clinical Centres, eight from university 
hospitals and three from non-university hospitals, 
were responsible for the enrolment of suitable 
patients, for the management of the patients, and for 
the collection of data. Two university clinics started 
in 1983, when their universities joined the Inter-
university Institute. 
- The Coordinating Centre was located at the Clin-
ical Epidemiology Unit of the Thoraxcentre in 
Rotterdam. Its staff consisted of a trial coordinator, 
an associate trial coordinator, a database manager, 
and administrative personnel. The head of the Clin-
ical Epidemiology Unit functioned as the director of 
the Coordinating Centre, who together with the trial 
coordinator provided scientific direction for the trial 
at the operational level. The tasks of the Coordinat-
ing Centre were to: (1) prepare, update, and maintain 
the trial protocol and corresponding forms; (2) work 
with the investigators in setting up local procedures 
for patient recruitment and data retrieval; (3) dis-
tribute prepacked trial medication; ( 4) collect and 
review data forms; (5) inform Clinical Centres of 
outstanding data forms or of incomplete or incon-
sistent items on submitted forms; (6) prepare patient 
reports for independent review by the Classification 
Committee; (7) prepared, update, and maintain the 
computer data base; (8) generate periodic reports 
evaluating the performance of the Clinical Centres; 
(9) perform the final data anlysis; (1 0) prepare the 
final trial report for approval by the research group 
as a whole. The staff of the Coordinating Centre was 
kept blinded to treatment assignment; it was neither 
informed of treatment monitoring reports. The 
director was an ex officio non-voting secretary to the 
Policy Advisory Board and was in the position to 
generate periodic (unblinded) treatment monitoring 
reports to the Policy Advisory Board. 
The Executive Committee was composed of all 
members of the Scientific Council of the Inter-
university Cardiology Institute and of the principal 
investigators of the participating non-university Clin-
ical Centres. The Executive Committee was the main 
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leadership committee of the study. It had final re-
sponsibility for its scientific conduct. Its specific 
functions were to (1) establish the organizational 
structure; (2) select the Clinical Centres; (3) select the 
members of the Policy Advisory Board and those of 
the Classification Committee; (4) approve the study 
protocol; (5) approve necessary or desirable changes 
in the study protocol based on considerations of 
feasibility or practicability of design; (6) act upon 
recommendations from the Policy Advisory Board 
concerning major changes in study design; (7) review 
performance reports of the Clinical Centres; (8) act 
upon recommendations from the Policy Advisory 
Board in matters of early termination of one or more 
treatment arms; (9) resolve operational problems 
brought before by the Coordinating Centre; (10) 
approve study reports and papers for publication or 
presentation. The Executive Committee was not 
informed of treatment monitoring reports until the 
Policy Advisory Board recommended early termina-
tion. Meetings of the Executive Committee coincided 
with the monthly meetings of the Scientific Council. 
The Policy Advisory Board was composed of repre-
sentatives of the following disciplines: cardiology, 
epidemiology, pharmacology, ethics. Two members 
were appointed on the recommendation of the 
sponsors; these appointments were on personal title 
and required confidentiality. The Policy Advisory 
Board acted in a senior advisory capacity on policy 
matters to the Executive Committee. Its functions 
were to (1) provide final approval of the study pro-
tocol; (2) recommend changes in the study protocol 
(3) audit data collection and data processing; (4) 
advise on key issues regarding data analysis and 
publication. In addition, the Policy Advisory Board 
periodically reviewed treatment monitoring reports 
for evidence of adverse or beneficial trial medication 
effects. The Board was entitled to recommend early 
termination of one or more treatment arms to the 
Executive Committee. The Board met once a year, 
starting from November 1982. The initial review of 
the study plan was carried out in writing. 
The Classification Committee was composed of 
three experienced cardiologists appointed by the 
Executive Committee. The trial coordinators acted 
as non-voting secretaries to the committee. The 
committee's task was to provide an independent 
medical review of clinical data with a view to ascer-
tain eligibility and outcome events. Its members were 
kept blinded to trial medication assignments and 
were not informed of treatment monitoring reports. 
The Technical Group was an informal body com-
posed of nursing and medical personnel involved in 
the trial. This group met periodically to maintain a 
cohesive investigative group. Study progress and 
clinic performance were evaluated. The meetings 
also included tutoring sessions to outline patient 
selection, treatment, and data collection. No treat-
ment monitoring reports were made available. 
Funding of the trial 
The agreement between the Interuniversity Cardi-
ology Institute and the sponsors was based on the 
understanding that the trial organization would be 
completely independent from the sponsors. The 
Executive Committee had the authority to make 
major policy decisions, to terminate the study, and 
to decide on dissemination of the study findings. 
The sponsoring companies were informed of trial 
progress but not of unblinded treatment monitoring 
reports. When the study was terminated, the sponsors 
were fully informed of the findings and of the pro-
posed plan for data analysis and publication. 
The unrestricted Bayer grant of Fl 500,000 was 
designated to provide the university affiliated Clinical 
Centres with new technical equipment; the Hassle 
grant of Fl 100,000 was used to provide the non-
university clinical centres with technical equipment 
required to carry out the trial procedures. The Clini-
cal Centres did not receive further reimbursements 
of costs. The Interuniversity Cardiology Institute 
paid salaries of the personnel of the coordinating 
centre and further expenses as well. The funds of the 
Interuniversity Cardiology Institute are provided by 
the Dutch Ministry of Education. 
Methods and quality control 
PREPARATORY STEPS 
Procedures describing the clinic operations and 
data intake were developed in advance in close col-
laboration with clinic personnel so as to fit clinic 
routine as closely as possible. The forms were in near 
final form when the study was started. Procedures 
for data processing were developed after the trial had 
been started. 
The drugs and their placebo counterparts were 
supplied by Bayer GmbH of Germany (nifedipine) 
and by AB Hassle of Sweden (metoprolol). Pack-
aging and labelling according to the randomisation 
code were done by the Pharmacy Department of 
Bayer. The stock was shipped to Bayer's subsidiary 
in the Netherlands and thence in limited supplies 
under supervision of Coordinating Centre to the 
Clinical Centres. 
Once a Clinical Centre had agreed to participate, 
the study protocol was submitted to its Institutional 
Review Board. To explain the study procedures, ses-
sions with clinic personnel were organized. Attention 
was also paid to the underlying principles of inter-
vention research in general and to those of this trial 
in particular. One staff member, either a senior cardi-
ologist or a senior fellow, was appointed local trial 
coordinator. He was responsible for the local execu-
tion of the trial. When the Centre was ready to begin, 
supplies of trial medication, manuals of procedures, 
and data forms were left at the coronary care unit. 
PACKAGING AND LABELLING OF TRIAL MEDICATION 
The nifedipine capsules were orange and contained 
10 mg nifedipine; the corresponding placebo capsules 
were identical in appearance and taste. The meto-
prolol tablets and their corresponding placebo tablets 
were white and identical in appearance and taste. The 
tablets were dispensed in bottles so as to provide 
treatment for fourteen days. 
Packages of trial medication were identified 
by their randomisation number. Randomisation 
numbers intended for patients not on previous 
maintenance treatment with a beta blocker consisted 
of a four letter code indicating the Clinical Centre 
followed by a three digit sequence number, e.g. 
AZUA-001; randomisation numbers for patients on 
maintenance treatment with a beta blocker were 
followed by a B, e.g. AZUA-001-B. Packages in-
tended for patients not on maintenance treatment 
with a beta blocker had a white label and contained 
two bottles, one marked 'Nifedipin' the other 'Meto-
prolol'. Those for patients on maintenance treatment 
with a beta blocker had a blue label and contained 
one bottle, marked 'Nifedipin'. The bottles contained, 
in accordance with the randomisation code, either 
true medication or placebo. Each package also con-
tained ten self-adhesive labels to identify study forms. 
Each package was complemented with a sealed 
envelope which contained the randomisation code. 
The randomisation number was printed on the pack-
age, on the bottles, and on the envelope. 
For each Clinical Centre two sequences of treat-
ment allocations were prepared in such a way that 
treatments were balanced for every twelve alloca-
tions. The schemes were generated by Bayer GmbH 
Germany after instructions of the director of the 
Coordinating Centre. Only two copies of the schemes 
were generated, one for the Pharmacy Department 
of Bayer to carry out the packing and one for the 
director of the Coordinating Centre. 
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PATIENT RECRUITMENT AND ENROLMENT 
A specially designed admission form was made 
available (Table 6.1 ). Its purpose was to guide the 
treating physician through the (complex) enrolment 
process. The form consisted of numbered series of 
questions and instructions with categorized answers. 
Answers were given by ticking the appropriate box. 
Each box contained a number to indicate the next 
item or the word 'stop' to indicate 'ineligibility'. The 
instructions were devised in such a way that the 
treating physician was prompted to undertake the 
right actions, to check the inclusion and exclusion 
criteria, and to record the requested data. The form 
was self-explaining and obviated consultations of the 
manual. Eligibility was established in items 8 to 16. 
If unstable angina was conjectured but did not satisfy 
the HINT criteria, the respective patient was labelled 
as potential candidate who might qualify if a new 
episode of chest pain should occur (item 13). After 
consent had been obtained (item 17) and eligibility 
had been verified (item 18), patients were placed into 
the appropriate stratum defined by previous main-
tenance treatment with a beta blocker and assigned 
to a randomisation number (items 19 to 21). After 
baseline measurements had been obtained (item 22), 
the first dose of trial medication was handed out 
(item 23). It was required to register new entries 
immediately by mailing a registration form to the 
Coordinating Centre. 
RECORDING OF FOLLOW-UP DATA 
Execution of trial procedures after randomisation 
hinged on the case record form, which provided 
instructions on patient management, measurements, 
and observations. Key information on episodes of 
chest pain, other clinical events, the administration 
of drugs, electrocardiography, blood sampling, heart 
rate, and blood pressure was recorded on the case 
record form. Electrocardiograms were recorded in 
duplicate. Measurements of activities of cardiac 
enzymes and were recorded separately, as were 
angiographic findings. 
SITE VISITS AND DATA COLLECTION 
Coordinating Centre staff paid regular site visits to 
the Clinical Centres. Central to the site visit was the 
meeting with the local trial coordinator. For each 
randomised patient all data forms and related records 
were scrutinized for completeness and consistency. 
Uncertainties were clarified. The local coordinator 
was asked an opinion as to whether recurrent 
ischaemia or myocardial infarction had occurred 
within 48 hours of randomisation. The occurrence of 
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Table 6.1 The admission form (in English translation). The part of the form in which demographic date were recorded (items 
1-0) and in which the general exclusion criteria were checked (item 7) is not reproduced here 
8. Tick the appropriate and continue from there. 
Unstable angina was diagnosed 
o Upon admission to hospital. 
Did the patient have chest pain at that time? 
o After an attack of chest pain in the hospital. 
Describe clinical course from hospital admission until now: ______ _ 
o After normal enzyme values (in patients originally diagnosed as suspected 
infarction). 
Was chest pain observed in the hospital 
9. Is there a recent history of typical angina at rest or during light activity, lasting 
> 15 min? 
10. Did the last episode of chest pain occur within the last 12 hours? 
11. Does the electrocardiogram obtained at hospital admission show ST-T 
abnormalities typical for reversible myocardial ischaemia? 
12. Is there any other evidence for atherosclerotic coronary 
disease? 
If yes, tick the appropriate. 
o Previous myocardial infarction (documented). 
o Previous episode(s) of unstable angina (documented). 
o At least 50% narrowing of a major coronary artery observed at earlier 
angiography. 
13. WAIT until chest pain with ST-T changes occurs. 
Did this occur? 
If yes, ou _______ _ 
If no, the patient was discharged at: _______ _ 
14. Chest pain was treated as follows: (denote time) 
c Obtain an electrocardiogram 
c Give sublingual glyceryl trinitrate (0.5 mg) 
o Give sublingual glyceryl trinitrate (0.5 mg) 
o Give an intravenous injection of glyceryl trinitrate (max 1 mg in 10 ml 5% 
glucose) 
c Give an intravenous injection of fentanyl (0.05 mg) 
Obtain electrocardiograms after each step. 
Chest pain could be relieved. 
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15. The electrocardiograms show a pattern of ST-T changes suggesting reversible 
ischaemia. 
16. Are you of the opinion that the patient sustains acute myocardial infarction at 
present? 
17. Inform the patient about the nature of the trial and ask consent. 
Informed consent was granted 
18. The patient can be admitted to the trial. 
Was the patient in fact admitted? 
ASSIGNMENT OF TRIAL MEDICATION 
19. Was the patient on maintenance treatment with a beta blocker for more than 
three days? 
20. OPEN the next BLUE MEDICATION BOX, with the label: 
'On maintenance treatment with a beta blocker.' 
The number of the box is: -B. 
The patient will also be treated with two 100 mg doses of metoprolol per 24 hours. 
GO TO 22 
21. OPEN the next WHITE MEDICATION BOX, with the label: 
'Not on maintenance treatment with a beta blocker.' 
The number of the box is: ______ _ 
22. Perform baseline measurements. 
23. START TRIAL MEDICATION. 
(If applicable: start both drugs simultaneously) 
Trial medication was started on _______ at _______ hours. 
24. Fill out the registration form and mail it to the Coordinating Centre as soon as 
possible. 
















I 21 I 
acute myocardial infarction or death after 48 hours 
was ascertained from the clinical case notes. A copy 
of the patient's letter of discharge from the hospital 
was obtained. Stocks of trial medication and study 
forms were checked and replenished. Certain pro-
cedures were reviewed to prevent protocol violations 
recurring. Private discussions with clinic personnel 
were held to assess their practices and philosophy 
with regard to the study. 
Patient forms and other study records were 
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transferred to the Coordinating Centre, where they 
were checked once more. Queries for additional 
information were sent to the local trial coordinator 
as needed. 
ACTUAL CLINIC PERFORMANCE 
The admission forms were sometimes filled out in 
retrospect after the patient had been entered. The 
registration form was mostly not immediately, sent to 
the Coordinating Centre. Therefore, site visits were 
pivotal in the administration of the study. It occurred 
that trial medication \vas issued but that the patient 
concerned could not be identified; this constituted 
an unassessable enrolment (see chapter 3). None of 
the involved randomisation codes was broken. Case 
record forms were, generally speaking, filled out at 
the bed side, but in some Clinical Centres they were 
retrospectively filled out from routine records. 
Coronary angiography was scheduled at the earliest 
convenience but could mostly not be performed 
within one week, which was required by the study 
protocol. 
THE CLASSIFICATION PROCEDURE 
Each case was reviewed on the basis of a patient 
report prepared by the study coordinators. A nar-
rative section summarized key information on the 
patient's history, the events that led to admission to 
hospital and those that occurred during 48 hour 
follow-up. Copies of all electrocardiograms and a 
survey of available enzyme values (until 54 hours) 
were added to the report. No information on events 
after 48 hours was provided. No reference whatso-
ever was made to the patients's treatment assignment. 
The Classification Committee first decided 
whether electrocardiograms during chest pain were 
available. Next, judgment was cast on the presence 
of qualifying ST-segment or T-wave changes or 
abnormalities, and unequivocal violations of the 
admission protocol were noted. Thereafter, outcome 
events were ascertained. The review was first carried 
out in writing. Cases that elicited difference of opin-
ion were discussed in plenary meetings. This was 
necessary for 60% of cases. Decisions by majority 
vote were necessary twice. All cases of myocardial 
infarction were re-examined after termination of the 
trial, so as to determine the onset of infarction and 
to describe electrocardiographic abnormalities which 
had developed after randomisation. 
DATABASE MANAGEMENT 
The study database consisted of all data contained 
on official data forms and supportive records that 
were collected for study purposes, such as electro-
cardiograms, queries, letters of discharge, angio-
graphy reports, annotations, classification reports. 
There was one folder for each patient that contained 
all paper records. The files were stored in locked 
cabinets at the offices occupied by the Coordinating 
Centre. 
The computer database consisted of all codified 
information in the study database. A menu-oriented 
database management system was developed and 
maintained. Database management has been de-
scribed in greater detail elsewherer21 . The database 
consisted of a series of subfiles containing related 
information. The file containing patient identifying 
information was separated from the other files and 
was only accessible to authorized personnel. Patient 
identifying information was not used on data listings. 
A segregated file containing the randomisation codes 
was only accessible to the programmer who designed 
and maintained the general structure of the database 
but who was not involved in actual data manage-
ment. 
As a general principle, codification of (clinical) 
patient data was carried out by staff of the Co-
ordinating Centre, using the narrative section of the 
classification report as the central source of informa-
tion. This provided an extra opportunity for quality 
control. Provisos for automated data processing were 
intentionally left out from clinic forms. The codified 
information was recorded on mark sense cards. The 
system provided error reports on missing data, out-
of-range data, and internal inconsistencies within a 
patient's data. Quantitative information, e.g. heart 
rates and blood pressures, was keyed into the com-
puter via a menu oriented program. Codified informa-
tion of selected electrocardiogram(s) was also 
recorded on marked sense cardsr2l. 
For statistical analysis a separate analysis database 
was created on the central computing facilities of the 
Erasmus university of Rotterdam using SPSS-X and 
BMDP software. The analysis database was also 
extensively checked for internal consistency. The 
randomisation codes were added to the analysis data-
base (but not to any paper records) after termination 
of the study. Corrections to the database were ap-
plied without knowledge of the randomisation code. 
The SPSS-X version of the analysis database was 
used for most statistical analyses. Logistic regressions 
was carried out using the BMDP version. 
Discussion 
Internal validity of a clinical trial first of all rests 
on a sound study design. But an improper procedural 
implementation of an otherwise valid design may 
compromise (internal) validity. It may lead to effect 
estimates that systematically misrepresent the true 
treatment effects. Validity of a procedure can only 
be ascertainedjudgmentally by critical scrutiny of the 
procedures at issue and not from the data. We have 
elaborated on the procedural implementation of 
HINT to provide the reader a basis for judging the 
quality of the evidence. 
Random allocation of treatments is the most crucial 
procedural feature of a clinical trial. Validity of the 
randomisation procedure is largely unrelated to the 
issue of baseline comparability because it is impos-
sible to distinguish between inappropriate randomisa-
tion and chance as the cause of an imbalance between 
treatment groups. Random allocation of treatment 
in HINT was carried out via pre-packed trial medica-
tion, the usual procedure in double-blind evaluation 
of drugs. No mismatches between the randomisation 
code and the actual content of the packages were 
found. The pills (true or placebo) were indistinguish-
able in appearance and taste. One problem, however, 
was detected shortly after the trial was started: the 
randomisation code could be obtained by holding the 
accompanying envelope (for emergencies) against 
bright light. This was immediately corrected. Other-
wise, there were no possibilities to obtain the 
randomisation code in advance (or after randomisa-
tion) without being detected. 
Today, it is widely recommended that eligible 
patients be irrevocably registered before randomisa-
tion r3 J. This is of vital interest in an open com-
parison of, say, surgical treatment with continued 
pharmacologic treatment. The register is supposed to 
record the exact moment of randomisation and hence 
the beginning of the follow-up period for all ran-
domised patients. In the context of a double blind 
comparison of drugs, the procedure seems less urgent-
ly needed. Selective withdrawal would not occur 
unless randomisation codes were broken. In HINT 
we have opted for registration by mail immediately 
after randomisation. This procedure did not function 
well. It has led to unassessable enrolments. This flaw 
does not compromise internal validity because no 
randomisation codes were broken. It seems reason-
able to assume that these mistakes were not guided 
by specific knowledge of the treatment given. 
The difficulties and hazards of carrying out a 
complex trial protocol in patients with an acute ill-
ness have been recognized from the very beginning. 
We have taken explicit measures to enhance protocol 
adherence and to avoid unnecessary violations of the 
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study protocol. The trial forms were designed to be 
self-explanatory. Furthermore, Coordinating Centre 
staff made site visits to the Clinical Centres to discuss 
each enrolment and to evaluate trial proceedings and 
data recording. Errors were noticed immediately, and 
corrective measures could be taken as needed. 
Measures were taken to secure high level perform-
ance of the Classification Committee. Guidelines for 
the review were drafted in advance. All electro-
cardiograms were meticulously studied. No informa-
tion whatsoever on trial medication actually used was 
available to the Classification Committee. The Policy 
Advisory Board functioned as an independent audit 
committee to monitor quality of operations within 
the Coordinating Centre. All codified information in 
the computer database was independently verified 
from the original records. The analysis database was 
extensively checked for missing data, correct ranges, 
and internal consistency. 
A close link between the sponsoring pharma-
ceutical industry and the trial institutions may 
compromise validity. The agreement between the 
sponsoring companies and the Interuniversity Cardi-
ology Institute virtually denied any influence of the 
sponsors on the conduct of the study. This also 
applied to the phase of data analysis and reporting 
of the findings. The Policy Advisory Board was a 
completely independent body-the membership of 
two appointees on behalf of the sponsors was on 
personal title and was subject to confidentiality. All 
staff members of the Coordinating Centre were 
employed by the Interuniversity Cardiology Institute 
of the Netherlands. 
In summary, we are convinced that we have con-
ducted this trial, which is concerned with an acute 
clinical condition, in a manner that complied with 
the highest possible standards of procedural imple-
mentation. 
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Predetermined study size 
The Executive Committee decided in advance that 150 
patients per trial medication group among patients 
not on previous maintenance treatment with a beta 
blocker ought to be enrolled. No specific study size 
was determined for patients on previous maintenance 
treatment with a beta blocker. The decision was 
taken on the presumption that 600 patients not on 
previous maintenance treatment with a beta blocker 
could be accrued over a period of two years. The 
decision was taken after a series of so-called power 
calculations had been made. The power calculations 
are reproduced in appendix III (page 86). 
Progress monitoring 
Progress of the study was reported to the Executive 
Committee once a month. Corrective actions were 
initiated when necessary; these measures included the 
addition of new Clinical Centres to boost patient 
accrual, protocol amendments to eliminate incon-
sistent or unclear issues, and the exertion of peer 
pressure to encourage Clinical Centres with poor 
performance records to improve. 
The Policy Advisory Board served as an external 
advisory-review group. This task was combined with 
that of monitoring treatment effects. The board 
reviewed study progress in an annual site visit to the 
Coordinating Centre. The study plan and associated 
procedures, patient accrual, protocol adherence, data 
collection and processing were scrutinized. The 
(unblinded) treatment monitoring report was re-
viewed in a private meeting with the director of the 
Coordinating Centre. No pre-specified stopping rule 
was adopted. The review sessions were followed by a 
joint meeting with the Executive Committee, in which 
the Policy Advisory Board reported its findings and 
made recommendations on continuation of the study 
and other important policy issues. Table 7.1 shows 
the data of the various treatment monitoring reports. 
The first meeting of the Policy Advisory Board 
took place on 13 November 1982, when 227 patients 
had been enrolled. The study plan was re-examined. 
The board rejected the policy of the unchanged 
continuation of previous maintenance treatment 
with a beta blocker; instead, continuation with two 
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doses of 100 mg metoprolol was proposed. The 
board recommended to continue the study for at 
least another year. The Executive Committee agreed 
to to these recommendations. The second meeting of 
the Policy Advisory Board was held on 3 December 
1983, when 517 patients had been enrolled. The 
board expressed its worry about the many protocol 
violations and about the slackening accrual rate; at 
least two additional Clinical Centres ought to be 
involved in the study. The board recommended to 
continue the study as scheduled. However, the board 
also requested that a treatment monitoring report be 
prepared and mailed to them after six months. The 
third interim report was mailed to the members of 
the Policy Advisory Board on 30 July 1984. In the 
mean time, the Scientific Council of the Inter-
university Institute had decided to allow continuation 
of the study until the first of May 1985 at the utmost. 
After telephonic consultations with the director of 
the Coordinating Centre, the board recommended 
continuation of the study until that date. An extra 
meeting was scheduled in conjuction with a confer-
ence in Rome on 27 October 1984. The main purpose 
of that meeting was to discuss dissemination of the 
findings after termination of the study. Based on the 
data of the interim report on that occasion (fourth 
panel in Table 7.1) the Policy Advisory Board 
reached the conclusion that patient accrual ought 
to be terminated immediately. The full text of the 
recommendation to the Executive Committee is 
reproduced in appendix I (page 82). The Executive 
Committee agreed, and measures to discontinue 
patient inclusion were put into effect immediately. 
The Executive Committee issued a public announce-
ment (see appendix II, page 83). It was forwarded to 
the Dutch Health authorities and to the Dutch 
branches of Bayer and Hassle. 
Conclusion of the Study 
When HINT was terminated, reports and data on 
75 patients were in preparation. The reports were 
finalized and reviewed most expeditiously. Codifica-
tion of electrocardiograms, which was in its early 
phase only, was accelerated. The Classification re-
examined the data on all patients with myocardial 
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Table 7.1 Outcome event rates in trial medication groups at four interim analyses 
Outcome events 
MI0 No MI0 RI/MI48 MI4s MI1w 
No previous treatment with a beta blocker 
First interim analysis: 
Placebo 4 28 12 (43%) 3 (II%) 
Nifedipine 6 25 8 (32%) 4 (16%) 
Metoprolol 9 23 8 (39%) 2 (9%) 
Combination 3 29 9 (26%) 4(12%) 
Second interim analysis: 
Placebo 5 55 17 (31%) 7 (13%) 
Nifedipine 6 57 27 (47%) 16 (28%) 
Metoprolol 5 53 17 (32%) II (21%) 
Combination 4 59 20 (34%) II (19%) 
Third interim analysis: 
Placebo 7 74 25 (34%) 10 (14%) II (15%) 
Nifedipine 6 73 31 (42%) 17 (23%) 21 (29%) 
Metoprolol 6 70 21 (30%) 13 (19%) 14 (20%) 
Combination 5 72 24 (33%) 12 (17%) 14 (19%) 
Fourth interim analysis: 
Placebo 7 86 30 (35%) 12 (14%) 13 (15%) 
Nifedipine 7 95 41 (43%) 26 (27%) 30 (32%) 
Metoprolol 6 89 28 (31%) 17 (19%) 18 (20%) 
Combination 7 88 30 (34%) 16 (18%) 18 (20%) 
Final overall data: 
Placebo 6 99 37 (37%) 17 (17%) 18 (18%) 
Nifedipine 6 107 50 (47%) 29 (27%) 33 (31%) 
Metoprolol 8 103 33 (32%) 20 (19%) 22 (21%) 
Combination 9 102 32 (31%) 16 (16%) 21 (21%) 
On continued maintenance treatment with a beta blocker 
First interim analysis: 
Placebo I 37 22 (59%) 5 (14%) 
Nifedipine 4 37 12 (32%) 3 ( 8%) 
Second interim analysis: 
Placebo 5 62 26 (42%) 8 (13%) 
Nifedipine 71 23 (32%) 7 (10%) 
Third interim analysis: 
Placebo 5 80 36 (45%) 14 (18%) 16 (20%) 
Nifedipine I 83 28 (34%) 10 (12%) 15 (18%) 
Fourth interim analysis: 
Placebo 5 96 44 (46%) 18 (19%) 21 (22%) 
Nifedipine 3 104 35 (34%) 15 (14%) 22 (21%) 
Final overall data: 
Placebo 7 104 50 (48%) 19 (18%) 22 (21%) 
Nifedipine 2 115 36 (31%) 16 (14%) 23 (20%) 
MI 0 , pre-randomisation myocardial infarction; RI/MI48 , recurrent ischaemia or myocardial infaction within 
48 hours; MI48 , myocardial infarction within 48 hours; Ml1w, myocardial infarction within one week. 
First interim analysis: on 13 November 1982; 227 patients. 
Second interim analysis: on 3 December 1983; 383 patients. 
Third interim analysis: on 30 July 1984; 428 patients; by maiL 
Fourth interim analysis: on 27 October 1984; 593 patients. 
Final overall data: data on 668 patients, including those in whom an unequivocal protocol violation had 
occurred before randomisation. 
A few second admissions were erroneously tallied in the fourth interim report. 
Outcome event rates were based upon formal outcome assessments by the Classification Committee except 
for the first interim analysis, which was based upon an informal assessment by the local study coordinator. 
infarction. The plan for data analysis was presented 
to the principal investigators on 31 January 1985 and 
subsequently to the involved pharmaceutical com-
panies. 
The Policy Advisory Board convened on 21 May 
1985 to review the proposed plan for data analysis. 
The board stressed that patients in whom an un-
equivocal violation of the admission protocol had 
occurred did not have unstable angina as defined; 
they ought to be excluded because inclusion would 
hamper generalization. Furthermore, considering 
that the pain free interval (a very influential baseline 
characteristic) appeared unevenly distributed, the 
board recommended to continue the search for in-
fluential baseline characteristics and to apply 
appropriate stratification in the estimation of treat-
ment effects. (The data of the codified electro-
cardiograms were not yet available at that time.) 
Both recommendations were supported by the 
Executive Committee. 
The main findings of the study were disclosed in a 
meeting of the Dutch Cardiac Society in December 
1985. The main study report was drafted in 
collaboration with the local investigators; the final 
version was approved by the principal investigators 
and the members of the Policy Advisory Board. It 
was confidentially made available to the involved 
pharmaceutical industries. It appeared in the 
November 1986 issue of the British Heart Journal. 
The present publication is a final and more elaborate 
account of HINT operations and findings. Further 
publications on electrocardiographic and angio-
graphic findings are in preparation. Furthermore, 
findings on long-term follow-up will be reported. 
Discussion 
Enrolment in HINT was terminated on 30 October 
1984 because an interim analysis suggested that the 
risk of myocardial infarction was higher in patients 
assigned to nifedipine than in patients treated with 
the other trial medications (among patients not on 
previous maintenance treatment with a beta blocker). 
The other treatment arms were also discontinued 
because effects in the other groups were smaller than 
expected. 
Has HINT been terminated too early? We are of 
the opinion that it is unethical to continue a trial to 
produce unequivocal evidence of harm of a certain 
treatment. It suffices to exclude a minimal but rel-
evant therapeutic benefit. Therefore, early termina-
tion of the nifedipine treatment arm among patients 
not on previous maintenance treatment with a beta 
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blocker was by all means justifiable. On the other 
hand, continuation of the other trial medication 
groups would have provided valuable additional in-
formation. But the beneficial effects of the involved 
index trial medications as they eventually appeared 
were not so prominent at the time when patient 
enrolment was discontinued. 
No additional data analytic support was requested 
(or provided) when it was decided to terminate the 
study. At that time the analysis database was not 
organized to the degree that adjusted effect estimates 
could have been provided. The study organization 
may be criticized for this. An important decision such 
as early termination of a large clinical trial should 
only be taken after thorough analysis of all available 
data. 
Inspection of the interim reports together with the 
final data leaves the impression that the treatment 
effects as they appeared have been reasonably stable 
from the second analysis onward. The data suggest 
that the trial was terminated at the time when the 
negative effect for nifedipine (among patients not on 
previous maintenance treatment with a beta blocker) 
was most outspoken. The negative effect as observed 
at the fourth interim analysis, which led to early 
termination of the trial, was attenuated when the 
remaining cases were added to the tallies. This is 
probably due a "regression to the mean' phenom-
enon. So far as effect estimates obtained from trials 
that were terminated ahead of time are biased, a 
natural correction occurred in this case. 
As regards the interpretation of findings from a 
prematurely terminated trial, one should keep in 
mind that early termination, generally speaking, only 
occurs if the accumulating data suggest a treatment 
effect that deviates from what was expected, either in 
a positive or negative sense. The final view on the 
magnitude of the treatment effect, an update of prior 
views in the light of the data at hand, will hence lie 
between what was previously known and what is 
suggested by the data. Thus, prior views tend to 
attenuate treatment effects suggested by trials that 
were terminated ahead of time. 
The Policy Advisory Board did not define a statist-
ical stopping rule in advance. Statistical stopping 
rules are almost exclusively formulated in terms of 
hypothesis testing. Even if one were to accept the 
underlying principles, the problems for trials with 
more than two treatments have not satisfactorily 
been solved [lJ_ The stringency of the stopping criter-
ion would be dependent on the number of compared 
treatments, which is unacceptable from the ethical 
point of view. A statistical stopping rule requires that 
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all contingencies are specified in advance, which is 
unrealistic. Decisions on early termination involve 
many nonstatistical issues. Statistical stopping rules 
do not reflect the complexity of stopping a clinical 
trial in practice. Given these unsolved-and in our 
view insoluble-problems, no attempt was under-
taken to define or to use a formal stopping rule. 
Instead, the Executive Committee relied on the 
board's judgment as to whether it would be useful 
and ethical to continue the study. 
What are the implications of treatment monitoring 
procedures for data analysis and inference? The trad-
itional statistical approach is based upon the con-
tention that the complete stopping rule is known, 
which then can be used to calculate so-called sequen-
tially adjusted P-values. For example, the Beta 
Blocker Heart Attack Trial (BRAT) was pre-
maturely terminated when the statistical stopping 
criterion was metP1 The P-value obtained from the 
data was 0.001. However, when the stopping rule was 
taken into account, the results were only statistically 
significant at the 5% level. Had the same data been 
obtained in a trial with the actual size and follow-up 
planned in advance, the P-value would have been 
0·001. In this reasoning, the interpretation of the 
data not only depends on what was actually observed 
but also on tentative actions that would have been 
undertaken by the investigator had other outcomes 
occurred. It is our impression that the evidence 
provided by the BHA T study is nevertheless taken at 
face value from the data only. This attitude is 
exemplified in the practice of meta-analyses: in a 
review of trials of beta blockers in myocardial in-
farction[31, Yusuf and Peto did not take account of 
the stopping rules of the trials concerned (e.g. of 
BHA T). It is apparently common sense that the 
interpretation of the data is not dependent on bow 
the investigator monitored the data while the data 
were accumulated. A dependence of interpretation 
on stopping rules seems a violation of common 
sense. 
This common sense feeling has a formal basis in 
statistical theory: the so-called likelihood principle 
implies that the interpretation of observations should 
only be based on what was observed; the sequential 
stopping rule that may or may not have been 
followed is irrelevant as far as the interpretation of 
the data is concerned [4-61. It has been argued that 
data analysis that takes account of the stopping rule 
is a 'hoax' [61. If one accepts the P-value as an ap-
propriate basis for inference, then clearly data analy-
sis would be dependent on the stopping rule. Thus, 
the traditional inference based on P-values is funda-
mentally at odds with the likelihood principle and 
with common sense as well. This is another reason to 
reject P-values and statistical hypothesis testing. 
We have based our data analysis on point estim-
ates and confidence intervals. As the formal (statis-
tical) definition of the confidence interval is tied to 
statistical hypothesis testing, the confidence interval 
may also be dependent on the stopping rule. Conse-
quently, data analysis based on confidence intervals 
would not accord with the likelihood principle and 
hence not with common sense. Perhaps, it is possible 
to put the definition of the confidence interval on a 
new (theoretical) footing in such a way that it accords 
with the likelihood principle, e.g. as a Bayesian pos-
terior distribution. This would obviate the depend-
ence of the confidence interval on the stopping rule. 
Unfortunately, no workable solutions have yet been 
provided by formal statistical theory. Our pragmatic 
solution has been to present point and interval estim-
ates without accounting for the interim monitoring. 
As regards predetermined study size, it is imposs-
ible to determine the optimal size of the treatment 
groups in a clinical trial statistically. The size of the 
groups in the present study was essentially deter-
mined judgmentally on intuitive grounds. The power 
calculations only provided additional support in 
establishing the size of the trial medication groups. 
The power calculations presented in Table 7.1 
exemplify the instability of these calculations. The 
four specified alternative hypotheses are not that 
much different-but they are associated with sub-
stantially different power. Any group size between 
75 and 300 patients can be obtained as a result of 
statistical size calculations by slightly altering the 
specified rates. Note in passing, that the power cal-
culations are not needed to appreciate the amount of 
information in the data: the width of the confidence 
intervals already specified the precision of the effect 
estimates. 
Appendix 1: Report of the Policy Advisory Board to 
the Executive Committee on early termination of 
HINT 
I. PREAMBLE 
Upon reviewing the updated data on the Holland 
Interuniversity Nifedipine/metoprolol Trial in its 
meeting on 27 October 1984, the Policy Advisory 
Board reached, for the first time, the following 
conclusions: 
(1) that in patients admitted to hospital for unstable 
angina pectoris in the absence of treatment with beta 
blocking agents at the time, treatment with nifedipine 
without metoprolol is conducive to increased risk of 
non-fatal myocardial infarction; 
(2) that treatment with metoprolol alone as well as 
the combination treatment, while not apparently 
counterproductive, seem unlikely to be efficacious in 
the prevention of myocardial infarction in these 
patients; 
(3) that in unstable angina patients admitted to ho~­
pital while on beta blocking treatment, addition of 
nifedipine appears to be neither counterproductive 
nor efficacious in the prevention of myocardial 
infarction. 
II. RECOMMENDATIONS 
Given these conclusions by the Policy Advisory 
Board, it is imperative that the Executive Committee 
determine without any undue delay (and possibly 
with recourse to whatever data and consultations it 
deems relevant) to what extent it agrees with the 
Policy Advisory Board's conclusions. 
Assuming that the Executive Committee comes to 
essential agreement with the Policy Advisory Board, 
the following recommendations for action are offered: 
(I) that patient enrolment in the study be terminated 
at this time; 
(2) that the manufacturer of nifedipine and the 
Dutch drug regulatory agency be informed, without 
any delay, about the Policy Advisory Board's con-
clusions (see preamble above) and of any possible 
dissent by the Executive Committee; 
(3) that the content of those communications as well 
as of any responses to all inquiries (by colleagues, 
the media, the manufacturer, etc.) be confined to (a) 
citation of the conclusions statement of the Policy 
Advisory Board given in the preamble of this report, 
and (b) reference to the upcoming full report in a 
scientific journal: 
(4) that the scientific report regarding the main 
objectives of the study be prepared and published 
most expeditiously with a view to making the results 
public at the earliest possible time consistent with 
the use of an appropriate forum; this report is to 
reflect input from all principal investigators, and the 
penultimate manuscript should be distributed to 
them, and to the Policy Advisory Board, no later 
than January 31, 1985; 
(5) that no data bearing on relative merits of the 
treatments compared in the study be made public 
prior to the main report; 
(6) that the manuscript of the main report, prepared 
in consultation with the Policy Advisory Board, be 
submitted to the manufacturers and to the Dutch 
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drug regulatory agency immediately upon its accept-
ance for public presentation; 
(7) that the Coordinating Centre submit within the 
next two weeks to both the Policy Advisory Board 
and the Executive Committee an outline of the result 
displays that it plans to produce (in order that 
members of these committees may provide their 
suggestions). 
Appendix II: Public announcement issued by tbe 
Executive Committee after early termination of HINT 
ANNOUNCEMENT 1 NOVEMBER 1984 
The Holland Interuniversity Nifedipinejmeto-
prolol Trial (HINT) has been carried out under the 
auspices of the Interuniversity Cardiology Institute 
of the Netherlands since 1981. The coronary care 
units of all university hospitals together with those 
of three non-university clinical centres participate in 
this study. The objective of this randomised, double 
blind, placebo controlled trial is to determine whether 
nifedipine (a calcium antagonist) or metoprolol (a 
beta blocker) prevent recurrence of ischaemia or 
progression to myocardial infarction when given to 
patients diagnosed as having unstable angina at 
admission to the care unit. Unstable angina is defined 
as the occurrence of chest pain which lasts for at 
least 15 minutes in combination with objective signs 
and symptoms of ischaemia of the myocardium, 
provided that outward signs of acute myocardial 
infarction are absent. 
When the study was started a Policy Advisory 
Board, composed of international experts who were 
in no other way involved with the study, was insti-
tuted in order to counsel the Executive Committee 
with regard to the progress of the study. Its members 
are the cardiologists M. E. Bertrand, C. R. Conti, D. 
G. Julian, A. Vedin, the pharmacologist E. L. Noach, 
and the epidemiologist 0. S. Miettinen. 
On 11 October 1984, 675 patients had been en-
rolled in the study. Based on an interim analysis of 
data on 593 patients, the Policy Advisory Board, 
in its meeting of 27 October 1984, had reached the 
following conclusions. 
I. that in patients admitted to hospital for unstable 
angina, in the absence of treatment with beta 
blocking agents at the time (of entry in the study) 
treatment with nifedipine without metoprolol is 
conducive to increased risk of non-fatal myocar-
dial infarction; 
2. that treatment with metoprolol alone as well 
as with the combination, while not apparently 
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counter-productive, seems unlikely to be effica-
cious in the prevention of myocardial infarction 
in these patients; 
3. that in patients admitted to hospital while on beta 
blocker treatment addition of nifedipine appears 
to be neither counterproductive nor efficacious in 
the prevention of myocardial infarction. 
Because of these conclusions of the Policy Advisory 
Board, the Scientific Council of the Interuniversity 
Cardiology Institute of the Netherlands has, in its 
meeting of 30 October 1984, decided to discontinue 
patient enrolment as of today. This decision has been 
taken after consultations with the participating non-
university Clinical Centres. 
The trial data are now being further analyzed. 
Until the analysis is completed (this is expected . 
before 31 January 1985) and a report that presents 
the findings and describes the conclusions is accepted 
for publication, no further announcements will be 
made. 
Appendix III: Statistical power calculations 
The power calculations were carried out on the 
basis of expected rates for recurrent ischaemia or 
myocardial infarction within 48 hours among patients 
not on previous maintenance treatment with a beta 
blocker. The (statistical) null-hypothesis is that the 
expected rate in all four trial medication groups is 
the same. This hypothesis could be tested using the 
standard chi-square test for a two by four contin-
gency table. Four so-called alternative hypotheses 
were considered: (A) the placebo rate is 40%, either 
of the two trial medications brings this rate down to 
20%, the combination to 10%; (B) the placebo rate 
is 22·5%, either of the two trial medications brings 
this rate down to 15%, the combination to 10%; 
(C) the placebo rate is 30%, one of the two trial 
medications brings this down to 10%, the other trial 
medication is ineffective, either alone or in com-
bination; (D) the placebo rate is 30%, none of the 
trial medications alone is effective but the combina-
tion brings the rate down to 10%. Under any of these 
hypotheses, the chi-square statistic follows a non-
central chi-square distribution. The noncentrality 
parameter can be calculated from the specified alter-
native hypothesis [7l. Table 7.2 shows the calculated 
statistical power for each specified alternative hy-
pothesis when 30, 50, 70, 100, and 150 patients would 
be assigned to each trial medication group. The upper 
panel shows the power calculations for testing at the 
conventional 5% significance level; the lower for 
testing at the 1% level. The choice of the rates under 
the four alternative hypotheses was based on a hunch 
Table 7.2 Statistical power (%) of the chi-square test (for significance levels of 5% and I%) for four alternative hypotheses 
(A-D) with various trial medication group sizes (N) 
Expected rates for RI/MI48 Statistical power 
Hypothesis* Pia Nif Met Com N= 30 N =50 N= 70 N = 100 N= 150 
5% level of significance 
A 40% 20% 20% 10% 66% 89% 97% 97% >99% 
B 23% 15% 15% 10% 15% 28% 34% 50% 69% 
c 30% 10% 30% 10% 62% 86% 95% 99% 99% 
D 30% 30% 30% 10% 42% 65% 81% 93% 99% 
I% level of significance 
A 40% 20% 20% 10% 43% 73% 90% 98% >99% 
B 23% 15% 15% 10% 5% 12% 15% 27% 46% 
c 30% 10% 30% 10% 38% 68% 86% 97% >99% 
D 30% 30% 30% 10% 21% 42% 61% 82% 96% 
*Hypotheses A-D as defined in appendix III. 
RI/MI48 , Recurrent ischaemia or myocardial infraction within 48 hours; Pia, placebo; Nif, nifedipine; Met, metoprolo1; 
Com. combination of nifedipine and metoprolol. 
By way of illustration. the third line of the first panel reads as follows: If nifedipine would reduce a placebo rate of 30% 
to 10% and if metoprolol would be ineffective, one would have a 62% chance of obtaining a statistically significant 
(P < 0·05) result in a trial with 30 patients per trial medication group; this probability becomes 99% in a trial with at least 
100 patients per trial medication group. 
of the involved clinicians; no specific data were avail-
able. 
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Introduction 
The primary task of a physician is to cure illness and 
to relieve suffering. Clinical research is motivated by 
the wish to improve and facilitate treatment of future 
patients. Much of the argument around clinical trial 
design, analysis, and interpretation focuses on ques-
tions of internal validity and statistics. It should not 
be forgotten, however, that valid and precise estima-
tion of the treatment effect within the context of the 
clinical trial is meaningless by itself and is never, as 
such, the ultimate research objective. Rather, it is a 
means of achieving an objective, the objective being 
to provide empirical evidence of the usefulness of a 
particular treatment used for a particular indication. 
Thus clinical trials should not only be judged on their 
validity and precision. To be relevant, meaningful 
generalization should be possible-that is, the find-
ings should support conclusions about the thera-
peutic benefit to be expected in a defined clinical 
indication which can be recognized in the reality of 
every day medical practice. This clinical indication 
derives from the disease entity actually studied in 
the clinical trial. It is stressed that 'disease entity' 
and 'clinical indication' in this context refer not only 
to a generic type of disease or illness but also to a 
particular stage in its development. 
Generalization hinges on three issues: (1) the 
patients actually studied have to be representative for 
the indication at issue; (2) the study treatments must 
be representative for its eventual use in clinical 
practice; (3) the disease outcome(s) under study must 
represent clinically relevant objectives for therapeutic 
intervention. 
Regrettably, little attention is generally given to 
the first of the above issues. The disease entity 
actually studied in a given clinical trial is determined 
by who was 'caught' by the patient enrolment pro-
cedure. The usual inclusion and exclusion criteria 
(even if they are well defined and described, which is 
not always the case) are aspects of this procedure 
but rarely define the indication studied completely. 
The medical environment where the trial is done also 
plays a role. Thus the descriptive profile of actually 
enrolled patients is of critical importance in assessing 
which indication they represent. Confusion about 
generalization will result if there is the slightest room 
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for uncertainty about this profile and the way it came 
about. 
Appropriate generalization further depends on the 
conceptual homogeneity of the disease entity. As an 
example, generalization is extremely difficult, if not 
impossible, from an unstable angina trial which 
included patients with recently developed symptoms, 
patients with refractory symptoms, and patients with 
stabilized symptoms as well-for these patients rep-
resent three physiologically and clinically distinct 
categories of unstable angina with different thera-
peutic objectives. The overall findings may certainly 
not indiscriminately be generalized to each of the 
three indications. 
Confusion about the nature of the disease entity 
studied, and consequently about the indication to 
which the findings may be generalized, seems to be 
particularly a feature of clinical trials in acute cardiac 
patients. This is hardly surprising. 
Some, but not all, patients with prolonged anginal 
pain at rest will develop objective evidence for myo-
cardial infarction (necrosis) within a few hours. Other 
will sustain an attack of reversible ischaemia without 
subsequent myocardial necrosis. With current diag-
nostic methods it is impossible to reliably differen-
tiate between the two at hospital admission. No 
matter how 'typical' the clinical picture at hospital 
admission may be for either condition, diagnostic 
certainty about its exact nature can only come from 
subsequent serial electrocardiograms and cardiac 
enzyme assessments. The latter in particular take 
several hours to become abnormal in patients with 
evolving myocardial infarction. 
Given the rapidly changing nature of the relevant 
diagnostic and other clinical information, it is particu-
larly difficult to specify the defining characteristics 
of a treatment indication arising during the first 
hours or days after the onset of symptoms of pro-
longed anginal pain at rest. As a result, clinical in-
vestigators in this field have apparently found it dif-
ficult to design enrolment procedures which define 
recognizable clinical indications. The major com-
plicating factor is that the initiation of treatment 
often cannot and should not be delayed until the 
exact nature of the underlying condition has been 
clarified. As an example, it makes little sense to delay 
infarct size limiting treatment until all diagnostic 
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criteria for acute myocardial infarction are met, or 
to attempt to prevent progression to myocardial 
infarction in a patient with suspected unstable angina 
if already evolving myocardial infarction must be 
excluded first by enzyme tests (which require six 
hours to become positive in infarction and in many 
instances much longer owing to laboratory delay). 
In order to discuss the significance of recent trials 
in patients with prolonged anginal pain at rest, it 
is helpful to group them according to the clinical 
indications under study in relation to their defining 
characteristics and the relevant disease outcomes. We 
propose, and will use below, the classification drawn 
up in Table 8.1 for trials starting after hospital 
admission. (Prehospital trials are a category by 
themselves and are outside this scope.) This tabula-
tion was devised so as to reflect the reality of clinical 
diagnosis and treatment decisions at the coronary 
care unit. It is our opinion that trials in this field 
should be designed so as to fit specifically in one of 
these general categories-for inclusion of an 
unspecified (or even a specified) 'mix' of patients 
from different categories will pose insurmountable 
problems in generalization. It must furthermore be 
stressed that trials within each general category are, 
of necessity, restricted to only one part of its clinical 
spectrum. Inclusion may be deliberately restricted to 
a specific subtype only. Even if this is not the case, 
restriction occurs because patients are excluded when 
either an accepted indication or a contra-indication 
for the investigational treatment exist, or when other 
concomitant disease is present, etc. 
Apart from these specific restrictions, which will 
vary from trial to trial and will impose constraints 
on generalization, there are general constraints for 
each of the above categories that must be borne in 
mind. 
In a trial in suspected unstable angina the in-
Table 8.1 Categorization of clinical trials in patients admitted to hospital for prolonged anginal pain at rest 
Disease entity (indication) 
For trials started immediately at 
hospital admission 
Suspected unstable angina 
Suspected acute myocardial infarction 
For trials started later during hospital stay 
Defining characteristics 
Chest pain at rest and 
electrocardiograms suggestive of 
reversible ischaemia 
No enzyme assessments required 
Chest pain and electrocardiograms 
suggestive of acute myocardial 
infarction; 
No enzyme assessments required 
Confirmed unstable angina after Recent chest pain at rest with ECG 
stabilization of symptoms suggestive of reversible ischaemia 
Confirmed unstable angina; unstable 
clinical condition (refractory 
angina) 
Confirmed acute myocardial 
infarction; stable clinical condition 
Complications of acute myocardial 
infarction 
> 24 hours relief of chest pain 
No significant enzyme rises 
No new Q-wave formation 
Recurrent episodes of chest pain 
No signs of evolving myocardial 
infarction 
Electrocardiograms and enzymes 
typical for myocardial infarction 






Short-term recurrence of chest pain 
Progression to myocardial infarction 
and its sequelae 
Enzymatic infarct size 





Recurrence of angina 
Occurrence of myocardial infarction 
Mortality 
Progression of coronary 
atherosclerosis 
Short-term recurrence of chest pain 
Progression to myocardial infarction 
Recurrence of myocardial infarction 
Mortality 
Progression of coronary 
atherosclerosis 
Subsequent clinical course 
vestigators intend to study the effect of a particular 
treatment in patients who are suffering from attacks 
of reversible angina; patients who already experience 
evolving myocardial infarction are excluded as much 
as possible. In contrast, in a trial in suspected acute 
myocardial infarction the investigators intend to 
include only patients with evolving myocardial 
infarction. The distinction (in an individual patient) 
between reversible ischaemia and necrosis can only 
be made subsequently on the basis of serial enzyme 
assessments (hours after relief of chest pain) and 
electrocardiograms (days after the attacks). Thus, it 
is inevitable that patients with evolving myocardial 
infarction will be included in a trial in suspected 
unstable angina and vice versa. It follows that the 
eventual diagnosis of infarction, as such, is a relevant 
outcome in assessing treatment effects in both types 
of trials. However, later subgrouping based on the 
final diagnosis is inadmissable as far as internal 
validity is concerned-for the phenomena that make 
up the final diagnosis (serial electrocardiograms 
and enzyme assessments) occur after randomisation 
and may have been influenced by the study treat-
ment. Such subgrouping would also be irrelevant as 
far as generalization is concerned: treatment recom-
mendations can be based only on past and present 
symptoms and signs, not on those of the future. 
Trials in patients with confirmed unstable angina 
after stabilization of symptoms are restricted to 
patients in whom myocardial ischaemia was con-
sidered to have been the cause of the presenting 
symptoms but in whom necrosis subsequent to the 
last anginal attack was excluded on the basis of 
repeat normal enzyme levels. The diagnosis at hos-
pital admission is irrelevant: patients admitted under 
the diagnosis of suspected acute myocardial infarc-
tion may end up in this type of trial when enzymes 
turn out to be normal. Furthermore, it is important 
to know which treatments were prescribed at entry 
because the indication signifies in this instance suc-
cess of treatment that was started to alleviate the 
presenting symptoms. Many trials of this type have 
a follow-up extending beyond hospital stay and 
therefore resemble to a certain extent the secondary 
prevention trials in post-infarction patients. 
Confirmed unstable angina in continued unstable 
condition (i.e. recurring attacks of anginal pain) 
forms a well recognized indication for further phar-
macologic or invasive treatment. Refractory angina 
belongs to this category. Trials would be specifically 
restricted to patients in whom myocardial ischaemia 
is considered to be the cause of the continuing 
symptoms and in whom enzymatic or electrocardio-
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graphic evidence has remained negative for evolving 
infarction. The diagnosis at hospital admission is to 
a large extent irrelevant: a patient admitted under 
the diagnosis 'suspected acute myocardial infarction' 
may end up in a study like this when enzyme values 
turn out to remain normal. In design, trials in these 
disease entities resemble those in suspected unstable 
angina at hospital admission with one important 
proviso: the continued instability represents an 
inherent failure of the treatment which was given up 
to the moment of randomisation. Thus, the nature 
of the treatment already given at entry may interact 
with the effect of the investigational treatment in a 
variety of ways, and generalization is conditional not 
only on the nature of the clinical condition in the 
patients who were actually enrolled but also on the 
treatment(s) given before entry. It is noted that this 
principle also applies to trials starting at hospital 
admission in reference to treatment that may have 
been used before, for instance when unstable angina 
develops in patients already being treated for stable 
angina. 
With regard to trials in patients with confirmed 
recent myocardial infarction, there is generally little 
debate about what constitutes clinical proof of 
infarction, although one may argue about the specific 
electrocardiographic and enzymatic criteria. Thus 
any patient who develops such proof becomes a 
candidate for this type of trial. Again, the initial 
diagnosis at hospital admission is irrelevant as far as 
eligibility is concerned. These trials take the form of 
the well-known postinfarction or secondary preven-
tion trial, in which patients are usually treated and 
followed for prolonged periods of time. 
Another category of trials in confirmed recent myo-
cardial infarction is designed to evaluate therapeutic 
measures for complications of acute myocardial 
infarction (e.g. postinfarction angina, arrhythmias, 
heart failure, or cardiogenic shock). 
Methods 
In this review we limit ourselves to randomised 
trials whose findings may be directly related to the 
findings of HINT. These include trials of nifedipine 
or beta blockade in suspected unstable angina or in 
suspected acute myocardial infarction and further 
trials in confirmed unstable angina after stabilization 
of symptoms. 
The main features and findings of recent trials are 
summarized in tabular form. They are grouped in 
accordance with the scheme presented in Table 8.1. 
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Table 8.2 Summary findings of the Muller trial ofnifedipine 
versus conventional treatment in suspected unstable angina l31 
All patients 
Failure of treatment* 
Rate ratio 
95%-confidence interval 





27% (17 /63) 30% (l9/63) 
1·12 
(0·64, 1·94) 
14% (9/63) 14% (9/63) 
1·00 
(0-43, 2·31) 
Patients not on previous maintenance treatment with a beta 
blocker 
48 h recurrence of chest pain 34% (11/32) 70% (19/27) 
Rate ratio 2·05 
95%-confidence interval (1·22, 3·61) 
Patients with previous maintenance 
blocker 
treatment with a beta 
48 h recurrence of chest pain 
Rate ratio 
81% (25/31) 50% (18/36) 
0·62 
95%-confidence interval (0-41, 0·89) 
Percentages are observed rates, with tallies in brackets. 
* A 'failure of treatment' occurred if chest pain continued 
to occur within 48 hours of the last increase in the original 
assigned treatment, or if the treatment was discontinued for 
side-effects. 
t Within 14 days, as evidenced by raised enzyme values. 
Unstable angina: an episode of chest pain within the last 24 
hours, not exceeding 45 min in duration, and considered 
characteristic of unstable angina, provided that either 
electrocardiographic evidence of reversible ischaemia or 
other evidence of coronary artery disease was present and 
that no electrocardiographic or enzymatic evidence of acute 
myocardial infarction was present. 
Treatment: Nifedipine treatment consisted initially of four 
20 mg doses per 24 hour; conventional treatment of a 
combination of propranolol four 20 mg doses per 24 hours 
and isosorbide dinitrate four 10 mg doses per 24 hours. If 
propranolol was not acceptable, conventional treatment 
consisted of isosorbide dinitrate only. A double-dummy 
technique was used. Previous maintenance treatment with a 
beta blocker was continued, irrespective of trial medication 
assignment. If chest pain recurred, the dosage was (in two 
steps) increased to maximally four 30 mg doses nifedipine 
or to four 60 mg doses propranolol and four 20 mg doses 
isosorbide dinitrate per 24 hours, provided that no adverse 
effects occurred. If the maximal dosages did not eliminate 
chest pain, the other treatment was added. 
There is a separate section about trials which could 
not be grouped according to this scheme. 
As a summary of the evidence, the rates of the 
main disease outcomes are given for the index and 
reference groups, together with the rate ratio and its 
95%-confidence interval, the latter calculated 
according to the method provided by Miettinen and 
Nurminen flJ. All rates are on intention-to-treat 
basis, for eligible patients. Mortality rates are for 'all-
cause' mortality. 
It has become fashionable of late to talk about 
'meta-analyses' in this context and define this as a 
new type of research r21 . But there is nothing really 
new: clinicians confronted with trial results have 
always been required implicitly to weigh the new 
evidence in the context of prior opinions about the 
credibility of the mechanism of action involved and 
already existing empirical evidence, including that 
from other trials. 
To resolve the confusion created by apparently 
conflicting results from different trials, meta-analysis 
relies on the pooling of results from different trials 
by statistical methods. At first sight this may look 
attractive: it seems advantageous to have one 
'bottom-line' confidence interval (or P-value) to 
supplement the confusing array of different values 
from the individual trials. While meta-analyses start 
correctly from the premise that all available evidence 
must be taken into account, there is justifiable con-
cern about the premises of statistical pooling. Further-
more, one is confronted here with a problem that is 
not only statistical in nature. Generalization of 
findings from clinical trials is a process which goes 
beyond statistical inference (see chapter 2). as is 
application of findings to medical practice. Therefore 
we shall do without formal statistical pooling. 
Findings from trials in suspected unstable angina 
In 1984 Muller and co-workers published findings 
of a randomised placebo-controlled trial designed to 
assess the effect of initial treatment with nifedipine 
(relative to conventional treatment) in eliminating 
recurrent chest pain and in preventing myocardial 
infarction in patients admitted to hospital with sus-
pected unstable angina (Table 8.2) r31 . Unstable 
angina was defined as chest pain at rest (details are 
in Table 8.2). Patients were randomised to receive 
treatment with nifedipine or conventional treatment 
consisting of isosorbide dinitrate and propranolol 
(details in Table 8.2). If chest pain recurred, dosages 
were (in two steps) increased; if the maximal dosages 
did not eliminate chest pain, the other treatment 
was added. The report does not explicitly mention 
whether randomisation was delayed until at least one 
series of enzyme values was available. Of 133 random-
ised patients four were identified by the creatine 
kinase core laboratory as having experienced myo-
cardial infarction immediately before randomisation 
and another four patients were found not to have 
met the electrocardiographic inclusion criteria, 
leaving a total of 126 patients available for effect 
assessment. 'Failure of treatment' was defined as 
chest pain at the maximal original treatment level or 
severe adverse effects and occurred to the same extent 
in the two treatment groups. This was also the case 
for progression to myocardial infarction within 14 
days. The authors also reported that 'in the subgroup 
of patients who were on maintenance treatment with 
propranolol treatment with nifedipine controlled 
pain more rapidly than did nitrates and (if not contra-
indicated) propranolol'; on the other hand, 'in the 
subgroup of patients who were not on maintenance 
treatment with a beta blocker nitrates and (if not 
contra-indicated) propranolol controlled pain more 
rapidly than did nifedipine'. These statements are 
based on comparisons of curves that indicate the 
cumulative incidence of being pain free for at least 
48 hours. Rates for 'failure of treatment' were not 
given for each mode of previous maintenance treat-
ment with a beta blocker separately. However, rates 
for 'recurrence of chest pain within 48 hours' could 
be derived from these curves. They are summarized 
in the lower part of Table 8.2. 
Findings from trials in suspected acute myocardial 
infarction 
NIFEDIPINE 
Table 8.3 shows design features and major findings 
from four randomised placebo-controlled trials de-
signed to evaluate the effect ofnifedipine in suspected 
acute myocardial infarction. All trials have included 
patients presenting with symptoms and signs typical 
for acute myocardial infarction. In most trials pre-
defined electrocardiographic abnormalities were 
required for patient eligibility. Progression to myo-
cardial infarction, infarct size as determined by 
enzyme kinetics, and mortality were the main out-
comes. All trials excluded patients on maintenance 
nifedipine treatment. 
Muller and co-workers randomised 171 patients 
who were retrospectively categorized: patients with 
pre-randomisation enzyme rises or new Q-wave 
formation were grouped as 'acute myocardial 
infarction'; the remaining patients were grouped as 
'threatened myocardial infarction'f4 l. No differences 
in rates of progression to myocardial infarction or 
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infarct size indices emerged from the comparison. 
The higher two-week mortality for nifedipine patients 
vanishes when six-month mortality rates are taken 
into account. Rates of myocardial infarction were 
also equal among patients with threatened myocard-
ial infarction only: 75% in both treatment groups. 
Simes and co-workers reported the results of the 
Norwegian Nifedipine Multicenter Trial, which in-
cluded 222 patientsf5l. In this trial nifedipine 
appeared not to influence progression to myocardial 
infarction, enzymatic infarct size, or mortality. 
Branagan and co-workers reported findings from a 
small trial with 98 patientsf6l. Wilcox and co-
workers reported on the TRENT study (trial of 
nifedipine in acute myocardial infarction), in which 
4491 patients were included[7l. No data on infarct 
size were collected. Twenty-eight days mortality rates 
were virtually identical for the two treatment groups. 
The effect of nifedipine was not related to previous 
beta blockade. 
BETA BLOCKERS 
A great number of trials with different beta block-
ers (given either orally or intravenously or both ways) 
in suspected acute myocardial infarction have been 
performed. Most of them were quite small and not 
especially designed at comparing mortality rates. 
Yusuf et al and Hjalmarson have provided useful 
reviewsf8 -9 l. We limit ourselves to two major large-
scale trials with short-term mortality as primary 
outcome, whose findings dominate. 
Table 8.4 summarizes the main design features and 
results of the Metoprolol in Acute Myocardial 
Infarction (MIAMI) trial and the more recently 
published, but otherwise concurrent, First Inter-
national Study of Infarct Survival (ISIS-1) 
trial [l 0 •11l. Patients not on previous beta blockade 
were admitted within 24 and 12 hours respectively of 
an episode of chest pain thought to be characteristic 
for acute myocardial infarction. Study treatment was 
started intravenously and was continued orally there-
after. MIAMI was a double-blind study. ISIS-I 
provided an open comparison against a policy to 
refrain from beta blockers as much as possible. The 
observed treatment effects were almost identical: rate 
ratios of 0·87 and 0·86, respectively. When the data 
of all other available trials of early beta blockade 
(starting with an intravenous dose) were pooled 
(together approximately 6000 patients), the same 
trend was observed flll. The percentage of patients 
in whom eventually evidence for myocardial necrosis 
was established was not affected by either treatment. 
It must be noted, however, that a small difference 
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Table 8.3 Summary of four placebo-controlled trials of nifedipine in suspected acute myocardial infarction 
Trial 
Mullerr41 Sirnesr51 Branagan r61 TRENTr71 
Design features 
Year of publication 1984 1984 1986 1986 
Dosage nifedipine (mg per 24 h) 120 50 40 40 
Start of treatment <6h <12 h <24 
Start of treatment 78% > 3 h 5 h (mean) 3 h (mean) 7 h (mean) 
Follow-up 14 days 6 weeks 4 days 28 days 
Total number of patients 171 222 98 4491 
Outcomes 
Myocardial infarction* 
Nifedipine 84% (75/89) 67% (74/110) 61% (28/46) 64% (1429/2240) 
Placebo 85% (70/82) 74% (83/112) 44% (23/52) 64% (1442/2251) 
Rate ratio 0·99 0·91 1·38 1·00 
95%-confidence interval (0·86, 1·13) (0·76, 1·08) (0·94, 2·04) (0·95, 1·04) 
Infarct size index t 
Nifedipine 14·1 25 710 
Placebo 14·3 23 655 
Ratio 0·99 1·09 1·08 
Mortalityt 
Nifedipine 10·1% (9/89) 9·1% (10/110) 10·9% (5/46) 6·7% (150/2240) 
Placebo 8·5% (7/82) 8·9% (10/112) 9·6% (5/52) 6·3% (141/2251) 
Rate ratio 1·18 1·02 1·13 1·07 
95%-confidence interval (0-48, 2·96) (0·45, 2·30) (0·37, 3-47) (0·86, 1· 33) 
Percentages are observed rates, with tallies in brackets. 
* The development of enzymatic or electrocardiographic signs of acute myocardial infarction within 48 hours of random-
isation; Muller also provided percentages for patients without raised enzyme values at randomisation: 75% in both treat-
ment groups. 
t Peak ME-creatine kinase release; the means of the Muller study pertain to all patients (0 was substituted for patients 
without raised enzyme values); those of the other studies pertain to patients with raised enzyme values only. 
t Mortality figures relate to six months (Muller), six weeks (Simes), and one month (TRENT and Branagan) periods. 
Muller also provided mortality figures for 14 days; these were 0% for placebo and 8% for nifedipine. 
was observed in MIAMI patients who were random-
ised within seven hours of onset of chest pain. 
Of the smaller trials two deserve special mention-
for they included patients with 'threatened infarc-
tion'. In 1978 Norris and co-workers reported on a 
trial on the 'protective effect of propranolol in 
threatened myocardial infarction' r121. Threatened 
infarction was defined as chest pain typical for myo-
cardial infarction in the absence ofST-segment eleva-
tions greater than 0·2 mV in the precordial leads or 
0·1 m V in the inferior leads. Patients with established 
unstable angina were excluded. Patient were assigned 
at random 'by the envelope method' to receive 
propranolol or no beta blockade. The main outcome 
event was the development of raised creatine kinase 
levels. The rates were 55% (11/20) for propranolol 
and 97% (22/23) for reference patients. The rate ratio 
was 0·58; 95%-confidence interval: (0·35, 0·81). 
In 1983 Yusuf reported findings in patients with 
threatened infarction (defined as above) which were 
randomised to receive atenolol (76 patients) or no 
beta blockade (94 patients) P 31 . Patients with electro-
cardiographic signs of evolving myocardial infarction 
were also randomised: 168 patients to atenolol and 
139 to placebo. Irregularities during randomisation 
with 'the envelope method' were reported. The rates 
for infarction within ten days among patients with 
threatened infarction were 49% (37 /76) for atenolol 
and 66% (62/94) for placebo. The rate ratio was 0·74; 
95%-confidence interval: (0·55, 0·96). 
Findings from trials in confirmed unstable angina after 
stabilization of symptoms 
Table 8·5 summarizes design features of two trials 
designed to evaluate protective effects of acetyl 
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Table 8.4 Summary of two selected controlled trials of beta blockade in suspected 
acute myocardial infarction 
Trial 
Design features 
Year of publication 
Index treatment 
Dosage (mg per 24 hours) 
Reference treatment 
Start of treatment 
Start of treatment 
Duration of treatment 











































3·9% (317 /8037) 
4·6% (367 /7990) 
0·86 
(0·74, 0·99) 
*Myocardial infarction enzymatically or electrocardiographically (MIAMI only) 
confirmed. 
tAll-cause mortality over treatment period (14 days for MIAMI, 7 days for 
ISIS-I) on intention-to-treat basis. 
salicylic acid in patients with confirmed unstable 
angina after stabilization of symptoms. Lewis and co-
workers entered 1266 men with either new onset 
angina of effort, worsening angina of effort, or 
angina at rest who had experienced an episode of 
unstable angina in the week preceding hospital 
admission, provided that some evidence of coronary 
atherosclerosis was presentl141 . Patients were 
screened within 48 hours after hospital admission and 
were randomised when a second electrocardiogram 
obtained after three hours confirmed the diagnosis 
of unstable angina. No further information on the 
delay between relief of symptoms and start of trial 
medication was provided. The trial regimen consisted 
of 325 mg of buffered acetyl salicylic acid daily or 
placebo. The most important finding was a decrease 
to one half of the incidence of acute myocardial 
infarction or death at twelve weeks. There was a 
(retrospectively) segregated group of patients (36 
patients in each trial medication group) who had 
acute myocardial infarction at entry as evidenced 
from raised values for ME-creatine kinase within 12 
hours of randomisation. These patients are not in-
cluded in the tallies. 
Cairns et a!. entered 555 patients (75% men 
and 25% women) who appeared clinically to have 
unstable anginal 151. An unstable pain pattern 
(crescendo pain or pain at rest) and evidence for 
myocardial ischaemia (either from a Rose question-
naire for exertional angina, transient ST -segment or 
T-wave abnormalities during chest pain, or relief by 
glyceryl trinitrate in less than ten minutes on three or 
more occasions in the hospital) were required for 
eligibility, as was the absence of evidence for acute 
myocardial infarction in the preceding twelve weeks. 
The presence of evolving myocardial infarction was 
ruled out. The deadline for entry was eight days after 
admission to the coronary care unit. The drug regi-
mens were double placebo, acetyl salicylic acid (1300 
mg per 24 h) and sulfinpyrazone placebo, sulfin-
pyrazone (800 mg per 24 h) and acetyl salicylic acid 
placebo, or the combination of both drugs. No 
benefit for sulfinpyrazone was observed. As there is 
little evidence that sulfinpyrazone has a cardio-
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Table 8.5 Summary of two placebo-controlled trials of acetyl salicylic acid in 




Year of publication 1984 1985 
Index treatment ASA ASA* 
Dosage (mg per 24 hours) 324 1300 
Reference treatment Placebo Placebo 
Start of treatment t < 7 days < 8 days 
mean unknown unknown 
Follow-up 12 weeks 18 months 
Totahmmber of patients 1266 555 
Outcomes 
Failure of treatment t 
ASA 5% (31/625) 12% (33/276) 
Placebo 10% (65/641) 15% ( 42/279) 
Rate ratio 0-49 0-79 
95%-confidence interval (0· 32, 0-74) (0·52, 1·21) 
Mortality 
ASA 1·6% (10/625) 5·8% (16/276) 
Placebo 3·3% (21/641) 10·0% (28/279) 
Rate ratio 0·49 0·58 
95%-confidence interval (0·23, 1·01) (0· 32, 1·03) 
ASA, acetyl salicylic acid. 
Percentages are observed rates, with tallies in brackets. 
*The Cairns trial also included treatment with sulfinpyrazone; these tallies only 
take account of the aspirin treatment. 
"j" In reference to the last episode of chest pain. 
t Death from whatever cause or the development of acute myocardial infarction. 
§All-cause mortality on intention-to-treat basis. 
Unstable angina: Angina of new onset, worsening angina, or angina at rest in 
combination with other evidence of atherosclerotic coronary disease, in the 
absence of baseline evidence of acute myocardial infarction (see also text). 
vascular effect, we have pooled the results of the sul-
finpyrazone and the placebo arms. Rates for myo-
cardial infarction or death (intention-to-treat) over 
an average follow-up period of 18 months were 12% 
under acetyl salicylic acid in comparison to 15% 
under placebo, a rate ratio of0-77. The rate ratio for 
all cause mortality was 0·58. There were no differ-
ences in recurrence of unstable angina necessitating 
hospital admission or in indications for bypass sur-
gery. 
Findings from further trials in unstable angina 
In 1982 Gerstenblith and co-workers reported a 
placebo-controlled randomised trial designed to 
assess the effect of nifedipine (40 to 80 mg per 24 h) 
when added in a randomised double-blind fashion to 
a standard regimen of propranolol (160 mg per 24 h) 
and nitrates ( 40 mg per 24 h) in patients with unstable 
angina at rest [161 . A later trial from the same institu-
tion did exactly the opposite. Gottlieb and co-
workers randomised patients who all had been 
treated with nifedipine (80 mg per 24 h) and nitrates 
(40 mg per 24 h) to either additional propranolol (at 
least 160 mg per 24 h) or placebo [1 71_ In both trials 
patients admitted to hospital with a diagnosis of 
unstable angina, characterized by chest pain at rest 
with transient changes on the electrocardiogram were 
randomised after enzyme concentrations had 
remained below twice the normal level within 24 
hours beforehand. It was not required for patients to 
remain pain free over these 24 hours. 'Failure of 
treatment' was defined as sudden death, myocardial 
infarction, or persistent angina requiring surgery or 
angioplasty during the four (Gerstenblith) or one 
(Gottlieb) month follow-up period. Rates of treat-
ment failure in the Gerstenblith trial were 44% (30/ 
68) under nifedipine and 61% (43/70) under placebo, 
a rate ratio of 0·72; 95%-confidence interval: (0·51, 
0·99). The difference was mainly due to persistent 
chest pain requiring surgery (18/68 under nifedipine 
versus 29/70 under placebo). Rates of treatment 
failure in the Gottlieb trial were 38% (16/42) for 
propranolol and 46% (18/39) for placebo, a rate ratio 
of 0·83; 95%-confidence interval: (0·49, 1·38). Most 
(74%) of these failures consisted of an indication for 
surgery or angioplasty. 
In 1981 Telford and Wilson reported findings of a 
randomised, double-blind, placebo controlled trial of 
heparin, atenolol, and their combination in the pre-
vention of myocardial infarction in patients with the 
'intermediate coronary syndrome'r181 . Four hundred 
patients with either accelerating angina of effort, 
angina at rest, or 'subendocardial' infarction were 
enrolled. No indication was given when treatment 
was started in reference to onset of the presenting 
symptoms. Of the randomised patients 186 were 
withdrawn from the analysis: 51 did not satisfy the 
entry criteria; 84 were incorrectly diagnosed as 
cardiac pain; 43 had unrecognized acute 'transmural' 
myocardial infarction which had already occurred 
before admission; and 8 were psychologically unsuit-
able. The main outcome event was the occurrence of 
'transmural' infarction within the treatment period of 
seven days. The rates were 17% (9/54) for placebo, 
13% (8/60) for atenolol; 2% (1/51) for heparin; 4% 
(2/49) for the combination. The rate ratio for heparin 
(disregarding atenolol) was 0· 20; 9 5 %-confidence 
interval: (0·06, 0·62). 
Discussion 
The fate of a patient with prolonged anginal pain 
at rest may be cast away during the first few hours. 
Treatment may affect early fatal complications and 
progression to myocardial infarction in those who 
survive initially. Trials in acute patients are therefore 
extremely important. Given the rapidly changing 
symptoms and signs in the early hours they are 
difficult to design so as to allow clear-cut general-
ization of results to indications which can be recog-
nized in clinical practice. Most of the unstable angina 
trials, unfortunately, mix aspects of early treatment 
(cooling off) with secondary preventive measures. 
Generalization of many of these trials is therefore 
problematic. 
As regards the indication studied in the Muller 
unstable angina trial, the report does not explicitly 
mention whether known normal enzyme values were 
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required for eligibility or not. In addition there was 
no placebo reference group and interpretation 
depends on the way one rates conventional treat-
ment. These features hamper generalization. The 
data of this trial indicate that in patients not on 
previous maintenance treatment with a beta blocker 
treatment with nitrates and propranolol may elim-
inate episodes of recurrent chest more rapidly and 
more thoroughly than nifedipine may do. The data 
also indicate that in patients on maintenance treat-
ment with a beta blocker the addition of nifedipine 
may control chest pain more rapidly than treatment 
with nitrates and additional beta blockers may do. 
This dependency of nifedipine's efficacy in achieving 
control of chest pain on the presence of previous 
treatment with a beta blocker was similar to that 
observed in HINT. 
The findings of TRENT provide substantial evid-
ence that nifedipine is of no benefit in the prevention 
of early death in suspected acute myocardial infarc-
tion. The other three nifedipine trials in suspected 
acute myocardial infarction support this finding. In 
addition, they provide some indication that nifedi-
pine neither influences eventual myocardial infarc-
tion nor limits infarct size. The width of confidence 
limits of the Branagan study clearly indicates that 
such a small study is actually noninformative. 
The role of other calcium-antagonists in suspected 
acute myocardial is not yet defined. Calcium antagon-
ists are far from homogeneous and what applies to 
nifedipine may not apply to verapamil or diltiazem. 
In this context, however, the findings of the Danish 
verapamil study must be mentioned [l 9 l. In this 
randomised placebo-controlled trial treatment with 
verapamil or placebo was started at hospital admis-
sion in all patients suspected of possibly having acute 
myocardial infarction, provided that they were not 
on a beta blocker or a calcium antagonist already. 
However, treatment was continued for six months 
only if infarction was confirmed; if this was not the 
case (in 60% of patients), study treatment was dis-
continued as soon as the diagnosis became clear. 
Thus the design mixes aspects from acute interven-
tion and secondary prevention trials in such a way 
that it cannot be considered as internally valid for 
either indication. Generalization of the, otherwise 
unpromising, results is virtually impossible. 
The diltiazem trial reported by Gibson entered in 
patients with non-Q-wave infarction [lOJ_ Entry must 
therefore have taken place at least 24 hours after 
onset of infarction. Notwithstanding its relatively 
short follow-up (14 days), this trial thus belongs to 
the category of secondary prevention trials after 
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confirmed myocardial infarction and was hence not 
discussed herein. 
The role of beta blockers in suspected acute myo-
cardial infarction has been delineated by the MIAMI 
and ISIS-I trials. The observed treatment effects in 
these trials, together with their 95%-confidence 
intervals, provide strong evidence that these beta 
blockers have a positive, albeit modest, effect on 
early mortality in the low risk subgroup of patients 
with suspected acute myocardial infarction in a suit-
able haemodynamic condition. Lowering mortality 
should not be the only reason for beta blockade as 
supportive treatment in this condition. Other modest 
beneficial effects were observed in MIAMI, such as a 
reduced need for opiates, anti-arrhythmic drugs, and 
cardiac glycosidesr101. Safety of beta blockers in this 
indication appears not to be an issue, as long as one 
takes account of contra-indications. It has been 
argued that it must be regretted that clinical use-
fulness of the drugs was in neither study evaluated 
by comparing the percentages of patients without any 
complications during hospital stayr21 1_ 
The two trials provide evidence for metoprolol and 
atenolol in the first place. Whether this effect on early 
mortality may also be expected with other beta 
blocking agents is a matter of judgment, based on 
pharmacologic insight, maybe in combination with 
results of other trials in (late) myocardial infarction. 
Importantly, patients already on beta blockade 
were excluded. As a result, a withdrawal effect cannot 
be the explanation. Otherwise, it is obvious that the 
treatment effects observed in both studies were 
modest and that very large numbers were required 
to estimate the effect sufficiently precisely. This was 
to be expected: by excluding patients with signs of 
cardiac failure the high risk patients are eliminated 
and one is left with a group of patients with a low 
mortality within the safe confinement of a coronary 
care untit, where complications such as ventricular 
fibrillation need not be fataL 
An effect of beta blockade on early mortality would 
gain credibility if there was a clear explanation for 
mechanism. Trials are not done to elucidate mechan-
isms of action but the data may provide some clues. 
Prevention of ventricular fibrillation cannot be the 
only explanation because the effects on its incidence 
were very modest in both MIAMI and ISIS-I. Infarct 
size limitation may show up in trials like these as a 
difference between the percentages of eventually 
confirmed myocardial infarction. In MIAMI such 
differences were observed only for patients treated 
early (within 7 hours from onset). Evidence from 
earlier studies on beta blockade and infarct size 
have been conflicting. Examination of the data of 
(small) trials in which infarct size was measured 
indicate that a moderate effect on enzyme levels may 
be expected from early intravenous beta blockader81_ 
These studies however showed conflicting results, 
most likely at least in part due to the fact the patients 
were entered with different delays after onset of 
symptoms. Also, theoretical doubts in regard infarct 
size limitation by beta blockers have been raised rzz1_ 
Threatened infarction was defined as the occur-
rence of characteristic chest pain suggestive of acute 
myocardial infarction but (as yet) without diagnostic 
electrocardiographic changes. It is thus a subcategory 
of 'suspected acute myocardial infarction' and is 
distinct from suspected unstable angina. The trials 
by Norris and Yusuf are infarction trials in the first 
place. Both present specific problems of interpreta-
tion. In the Norris trial, the placebo rate for eventual 
infarction, and consequently the rate ratio, is rather 
extreme and does not accord with other trials. We 
hypothesize, in retrospect, that chance may have 
inflated the observed treatment effect in a small trial 
like this, which may have led to 'P-value biased' 
publication. The Yusuf trial raises doubts about its 
internal validity. The unequal distribution of threat-
ened infarction over the overall treatment groups 
together with the reported irregularities in the 
randomisation procedure with the (in itself unreli-
able) envelope method suggests that physicians have 
been able to manipulate treatment assignment. 
The evidence provided by the two acetyl salicylic 
acid trials in unstable angina is very convincing 
within the context of the two trials themselves. The 
Cairns trial may, in all probability, be taken as 
having included patients with confirmed unstable 
angina after stabilization of symptoms. Therefore its 
findings can be generalized to a recognizable clinical 
indication: secondary preventive measures in un-
stable angina after stabilization of symptoms. The 
Lewis trial, by contrast, has included a mixture of 
patients with stabilized symptoms and those in the 
midst of clinical instability: patients were entered 
within 51 hours of admission to hospital until seven 
days after an episode of unstable angina; but also 
patients who had, in retrospect, acute myocardial 
infarction at entry were entered. The fact that a mix-
ture of different categories of patients was included 
does not imply that the findings may therefore be 
generalized to both indications. No information was 
provided as to how many patients were in stable 
condition and how many were still unstable. So it 
remains speculative as to whether the indication per-
tains to 'cooling of' unstable angina or to secondary 
prevention in patients with a recent history of un-
stable angina. We have speculated that most patients 
were already in stable clinical condition upon entry 
and have therefore grouped the Lewis trial under this 
heading. (With this in mind, we also considered it to 
be justifiable to omit the segregated group of patients 
with infarction around entry from the intention-to-
treat analysis.) 
Generalization from the Gerstenblith and the 
Gottlieb study is difficult. It is not entirely clear 
which indication was studied. In both studies the 
absence of myocardial infarction was confirmed on 
the basis of enzyme assays. But were the patients in 
both studies still experiencing episodes of chest pain 
at the moment of randomisation. Or had symptoms 
been stabilized? If they were still experiencing anginal 
attacks while on the standard treatment regimen, 
they must be considered refractory to the respective 
standard treatment regimens, in which case they were 
therapeutic failures (of propranolol and nitrates in 
the first study and of nifedipine and nitrates in the 
second study) and qualitative interactions must be 
expected. Indeed, both studies observed a favorable 
effect of the addition of nifedipine in the first study 
and of propranolol in the second. Although the 
indication for additional treatment would be clear as 
such in both instances, the effects would not be 
generalizable outside the specific context in which 
they were observed. If patients were, on the other 
hand, in a stable condition at randomisation, the 
indication would amount to secondary prevention in 
patients with a recent history of unstable angina. 
Again would the indication be clear as such, although 
different in nature. A different generalization would 
consequently result but again would have to remain 
strictly within the context of the specific context 
studied. If the admitted patients would constitute a 
mix of both types of patients, generalization becomes 
virtually impossible. Combination studies as the 
latter two can, generally speaking, not be generalized 
to effects of mono-treatment as first choice treat-
ment. However, they may provide important guide-
lines for what to do in clinical practice if (established) 
standard treatment fails and other measures must be 
considered. 
The trial by Telford and Wilson included patients 
in different phases of unstable angina and evolving 
myocardial infarction, which was not further speci-
fied. Furthermore, almost 50% of randomised pati-
ents were excluded from the analysis, and not only 
for unequivocal violations of the admission protocol. 
Therefore, generalization of this small, internally 
invalid study is doubtful. As a matter of fact, the 
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results by themselves also raise questions-for 
heparin virtually eliminated myocardial infarction. 
The rate ratio for heparin in this small study was 
0·2·, which seems too much of the good. 
Although we did not explicitly review trials of 
coronary bypass surgery in unstable angina, it is 
important to mention how they fit into the scheme 
of Table 8.1. The National Cooperative Unstable 
Angina Pectoris Trial was designed to compare 
pharmacologic treatment with coronary bypass sur-
gery in unstable angina patients after an observation 
period of 24 hours after relief of pain, without 
enzyme risesE231 . Surgery was performed after 8 days 
on the average. Other trials, also performed in the 
seventies, had similar selection procedures E241. 
These trials thus pertain to the indication 'confirmed 
unstable angina after stabilization of symptoms'. It 
was widely accepted that the data of these trials 
indicated that urgent surgical treatment after an 
interval of 24 hours had no advantage over urgent 
pharmacologic treatment in terms of early mortal-
ity; E25l. As regards angioplasty, no randomised 
studies have yet been performed. 
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9 General discussion 
J. G. P. TIJSSEN, M. L. SIMOONS, P. J. DE FEIJTER, AND J. LUBSEN FOR THE HINT RESEARCH GROUP 
Introduction 
In chapter 5 we have put forward that the primary 
task of investigators is to summarize the evidence 
obtained from a clinical trial and that conclusions 
(i.e. incorporation of the findings into the existing 
body of scientific knowledge) should be left to the 
medical community at large. It is customary that 
investigators also present their personal conclusions 
and we will do so likewise. 
This discussion consists of some general remarks 
on methodological aspects of the design of HINT 
and its execution, to be followed by an estimation of 
the frequency by which unstable angina is seen at 
admission to the coronary care unit and we will pro-
vide a description of its short-term clinical course. 
Furthermore, trial medication effects as observed in 
HINT are related to findings of other trials, and a 
management strategy for unstable angina is 
proposed. Finally, some of the new developments in 
the treatment of unstable angina and possibilities for 
further clinical research are outlined. 
Methodological aspects 
A violation of the admission protocol occurred in 
I 31 patients. Because these patients did not have un-
stable angina as defined by the HINT protocol, we 
excluded them from the analysis (see discussion 
chapter 3). Another 22 patients with pre-randomisa-
tion myocardial infarction were no longer at risk of 
the defined outcome events, and these patients were 
also excluded from trial medication effect assessment 
(see discussion chapter 4). We believe this to be the 
correct procedure. To allow for effect analyses based 
on other principles, tallies in which these patients 
were included have also been provided (Tables 4.9 
and 7.1). 
We have chosen to quantify treatment effects as 
rate ratios and to express the inherent uncertainty in 
these effect estimates by the corresponding 95%-
confidence intervals. This provides a better indication 
of the magnitude of the expected therapeutic benefit 
and of the statistical strength of the evidence rather 
than the customary significance levels (P values) do. 
We feel that they should be used in all reporting of 
clinical trials. 
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Although the total number of patients entered in 
HINT is large, the treatment groups by themselves 
are rather small. In a randomised trial with small 
groups differences between the groups in baseline 
risk may occur due to random variation. Table 5.6 
indicates that this indeed was the case. This observa-
tion does not imply that our procedure of treatment 
allocation was faulty; it can be calculated that an 
imbalance of at least this size may occur in about 
16% of similar, truly random allocations. We used 
risk stratification based on a composite logistic func-
tion of influential baseline characteristics and have 
expressed trial medication effects as ratios of 
weighted averages of stratum specific rates, an ap-
proach which ensures that the estimation of trial 
medication effect becomes independent of the actual 
distribution of baseline risk in the groups that are 
compared. It must be noted, however, that the com-
position of the function to estimate baseline risk 
requires judgment on the part of the investigator; 
the procedure thus contains an element of sub-
jectivity. Those readers who reject the underlying 
principles should base their inference on unadjusted 
effect estimates, which have also been provided 
(Table 5.1 ). 
An important feature of HINT was its early termin-
ation upon a recommendation by the Policy Advisory 
Board. The decision as such is beyond dispute in this 
context. Even in retrospect, we regard it very unlikely 
that other decisions with regard to nifedipine mono-
therapy would have been taken, had the final effect 
estimates been available at that time. From the 
efficacy assessment point of view, the distinction 
between 'no effect' and a 'detrimental effect' is moot. 
From the ethical point of view, it is unjustifiable to 
continue a trial in spite of a negative trend until the 
distinction between 'no effect' and 'detrimental effect' 
can be established beyond reasonable doubt. As far 
as the other treatments are concerned, other deci-
sions, however, might have been taken in the pre-
sence of a more detailed analysis. It goes without 
saying that data management must be organized in 
such a way that a full analysis can be carried out at 
short notice and that decisions on data analytic pro-
cedures should be taken before the issue of possible 
termination arises. 
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Occurrence and clinical course of unstable angina 
HINT aimed to select a group of patients 
with episodes of prolonged anginal pain at rest, 
either observed or by history. This diagnosis of 
unstable angina at rest (a subcategory of unstable 
angina) was based upon a combination of find-
ings~prolonged chest pain at rest, evidence for 
myocardial ischaemia, and absence of signs of acute 
myocardial infarction (chapter 3). Eligibility for 
HINT represents a distinct clinical entity (and hence 
a potential indication for treatment) clearly 
recognised at admission to hospital: symptoms 
and signs indicating acute but still reversible 
myocardial ischaemia. 
Because of the provisional and changing nature of 
the admission diagnosis (see chapter 1) it is difficult 
to collect data which depict the frequency by which 
the syndrome of unstable angina as defined in HINT 
is encountered among patients currently admitted to 
the coronary care unit. This frequency probably 
depends on the extent to which a particular clinic acts 
as a secondary referral centre, on the threshold for 
patients coming to the emergency room, on the delay 
times involved, etc. Figures on discharge diagnoses of 
all admissions to the coronary care unit are available 
for one participating department. In 1986, 1150 
patients were admitted to the coronary care unit of 
the Thoraxcentre, the referral centre in the Rotterdam 
area. The 56 cases with angina at rest among 250 
secondary referrals (i.e. patients referred from other 
hospitals) represented in virtually all instances failure 
of previous intensive pharmacologic treatment. 
Hence the HINT findings do not bear on them. Of 
the remaining 900 patients (primary admissions) 101 
had a discharge diagnosis of 'angina at rest'. Patients 
who developed myocardial infarction but who in-
itially presented with symptoms and signs of unstable 
angina are not counted in this category. Based on 
our prospective HINT data, this applies to 20--25% 
of patients with 'angina at rest' at hospital admission. 
This would lead to an estimated 135 patients with 
the admission diagnosis 'angina at rest'. Allowing for 
the fact that an admission diagnosis of 'angina at 
rest' may eventually be revised into 'atypical chest 
pain' or 'crescendo angina', we estimate that each 
year approximately 150 patients are admitted with 
angina at rest to the Thoraxcentre. Of these patients, 
approximately 50% appears to be on maintenance 
treatment with a calcium antagonist, which leaves 75 
patients to whom the research issue investigated in 
HINT is relevant. Thus in this hospital, the syndrome 
represented by the HINT patients pertains to appro xi-
100% patients with suspected unstable angina at 
hospital admission. 
4% cardiac enzymes already raised, indicating that 
acute myocardial infarction that was not 
recognised at hospital admission. 
8% in the process of developing enzymatic signs of 
acute myocardial infarction. 
9% experience myocardial infarction within 48 
hours. 
19% experience new episodes of chest pain without 
infarction within 48 hours. 
60% patients with an uncomplicated clinical course 
over 48 hours. 
Figure 9.1 Short-term clinical course of patients admitted 
to the coronary care unit with symptoms and signs indicating 
unstable angina. 
mately 8% of all current primary admissions to the 
coronary care unit. 
It is generally recognised that the differentiation 
between unstable angina and acute myocardial in-
farction at hospital admission is difficult. The short-
term clinical course of these patients, based on the 
HINT data, is summarized in Fig. 9.1. 
The risk profile of these patients (Table 5.5) in-
dicates that there is considerable variation in risk. 
Broadly speaking, two categories of patients can be 
discerned: (1) those with chest pain persisting until 
after hospital admission, accompanied by ST -segment 
changes in the electrocardiogram (high risk patients); 
and (2) those whose chest pain had subsided spon-
taneously before admission to hospital and who 
have an almost normal electrocardiogram (low risk 
patients). On the basis of a few baseline characteristics 
substantial differences in clinical course can be pre-
dicted, e.g. a 75% risk for recurrent ischaemia or 
myocardial infarction within 48 hours in typical 
high risk patients versus 25% in typical low risk 
patients. 
This finding may have important clinical implica-
tions. In high risk patients stabilization of symptoms 
with pharmacologic treatment seems unlikely. This 
may constitute a point to schedule angiography early, 
without waiting for symptoms to recur. Further 
treatment would then be guided by the physician's 
knowledge of the coronary anatomy. On the other 
hand, low risk patients can be admitted to a 'medium 
care unit', and a wait-and-see policy as far as an-












Figure 9.2 Rate ratios of recurrent ischaemia or myocardial 
infarction within 48 hours (with 95%-confidence intervals) 
for all comparisons of active trial medication with corres-
ponding placebo. For instance, the rate ratio for metoprolol 
is the rate of recurrent ischaemia or myocardial infarction 
within 48 hours in the metoprolol group divided by that in 
the placebo group (among patients not on previous main-
tenance treatment with a beta blocker). Thus a ra!e ratio of 
1 indicates that metoprolol has no effect. A rate ratio of 
< 1 points to a preventive effect and a rate ratio of > 1 to a 
negative effect. These rate ratios have been adjusted for 
incomparability of baseline risk (chapter 5) (N-nifedipine, 
M-metoprolol, C---combination). 
Commentary on observed trial medication effects 
Estimated trial medication effects (the rate ratios 
from Table 5.7) are depicted in Fig. 9.2. Of the trial 
medications studied, the addition of nifedipine to 
previous maintenance treatment with a beta blocker 
was clearly beneficial. None of the other treatment 
effects came out unequivocally effective, but the data 
indicated that treatment with metoprolol may exert a 
beneficial short-term effect in patients not on previous 
maintenance treatment with a beta blocker. Further-
more, the fixed combination of metoprolol with 
nifedipine would not provide any further gain. (The 
rate ratio of the combination relative to metoprolol 
alone was 1·06, 95%-confidence interval: (0·67, 
1·70).) On the other hand, the data also indicated 
that one may not expect therapeutic benefit from 
nifedipine monotherapy when given to patients that 
were not on previous maintenance treatment with a 
beta blocker. In particular, there was a worrisome 
trend towards an increased risk for myocardial in-
farction for nifedipine alone: a rate ratio of 1·51, 
95%-confidence interval: (0·87, 2·74). 
These findings fit a pattern of results observed in 
other trials, which have been described in chapter 
eight. Only one of these (by Muller and co-workers) 
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explicitly addressed the indication 'unstable angina' 
as admission diagnosis fll. The effect of nifedipine 
was compared to that of conventional treatment with 
beta blockers and nitrates, and it was also observed 
that nifedipine's efficacy in achieving control of chest 
pain largely depended on the presence of previous 
maintenance treatment with a beta blocker: if present, 
nifedipine was efficacious; if not, nifedipine seemed 
to promote recurrence of chest pain. Thus, two in-
dependent clinical trials have provided evidence for 
the existence of a qualitative interaction of nifedipine 
and previous beta blockade as far as efficacy in pre-
venting recurrent chest pain or progression to myo-
cardial infarction is concerned. 
What could be the explanation for this finding? It 
could be that in patients whose condition has become 
unstable in spite of maintenance treatment with a 
beta blocker, increased vasomotor tone or coronary 
spasm plays a larger role than it does in patients not 
on previous beta blockade. This would explain the 
efficacy of additional treatment with a coronary 
spasmolytic agent as nifedipine. Another possibility 
would be that a potential harmful reflex tachycardia, 
which may be induced by nifedipine, is offset by pre-
vious or concomitant use of a beta blocker. 
The comparison of nifedipine monotherapy with 
placebo (among patients not on previous beta block-
ade) virtually excludes a major preventive effect of 
nifedipine used in this way for this indication. This 
accords with findings from four recent trials, which 
all indicated that no therapeutic benefit may be 
expected of nifedipine when given to patients with 
suspected acute myocardial infarction (see chapter 
8). It must be emphasised that animal experiments 
already indicated that no protective effect may be 
expected from nifedipine when given after onset of 
ischaemia rzJ. 
Nifedipine was originally recommended to be of 
particular value of patients with ST-segment eleva-
tion in the electrocardiogram, which may reflect 
transmural myocardial ischaemia due to coronary 
spasm f3l. These patients, however, did not seem to 
benefit particularly from nifedipine treatment (Tables 
5.10a and 5.10b). It is noted, however, that these 
effect estimates lack precision. 
It has been suggested that a beta blocker might 
be contra-indicated in patients with unstable angina 
because it might induce coronary spasm in some 
patientsf4 l. The findings of HINT indicate that this 
alleged effect is not an important therapeutic con-
sideration. By itself the evidence from HINT for a 
salutary effect of treatment with metoprolol (among 
patients not on previous maintenance treatment with 
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a beta blocker) was not conclusive; the 95%-confi-
dence interval was rather wide. The rationale for a 
beta blocker such as metoprolol as 'first choice' in 
this indication must therefore be based in part on 
their established efficacy in suspected acute myocar-
dial infarction (see chapter 8). Taken together, these 
findings point towards a wide range of indications, 
varying from symptoms and signs typical for unstable 
angina (reversible ischaemia) to those typical for 
uncomplicated acute myocardial infarction (limited 
necrosis), in which beta blockers such as metoprolol 
or atenolol can be expected to provide a modest thera-
peutic benefit. 
Some authors have recommended that patients 
with unstable angina at rest be immediately treated 
with a combination of a nitrate, a beta blocker, and 
a calcium antagonistr5 l. The data of HINT do not 
support this recommendation as far as the combina-
tion of metoprolol and nifedipine is concerned: this 
combination appeared not to provide greater thera-
peutic benefit than that provided by metoprolol 
alone. 
In summary, a beta blocker such as metoprolol 
must be considered an important therapeutic option 
in the initial pharmacotherapeutic approach to un-
stable angina. On the other hand, a calcium antagonist 
such as nifedipine, either as monotherapy or in com-
bination with a beta-blocker, does not appear to be a 
first therapeutic option. Nifedipine, however, seems 
to be a useful addition to the therapeutic regimen 
when initial treatment with a beta blocker has failed. 
Proposed management strategy 
Today, the initial therapeutic approach in the 
management of unstable angina is pharmacologic, as 
it was in 1980 when HINT was designed. The thera-
peutic objective is to stabilize the symptoms and to 
prevent progression to myocardial infarction. As a 
consequence, the treatment effects observed in HINT 
are relevant for the initial management of patients 
with unstable angina admitted to the coronary care 
unit in 1987. 
What follows is a proposed management strategy. 
It may be viewed as an update of the scheme provided 
in Table 1.2, in which our conclusions from HINT 
have been incorporated. It is noted that this scheme 
contains many elements which are, of necessity, based 
on theoretical arguments supported by clinical ex-
perience rather than on results of HINT or other 
randomised clinical trials. 
The first consideration in the management of 
patients coming to the hospital with symptoms and 
signs indicating unstable angina would be to distin-
guish between high and low risk patients. The typical 
high risk patient has chest pain when arriving at the 
hospital and has at least 0·1 m V ST -segment dis-
placement (and even more during chest pain) in the 
electrocardiogram. Admission to the coronary care 
unit seems warranted. Angiography may be scheduled 
at an early convenience. Intensive pharmacologic 
treatment starts with a combination of beta blockers, 
intravenous glyceryl trinitrate, and heparin. A cal-
cium antagonist is included in the above regimen only 
if a beta blocker was already being taken when un-
stable angina developed. If a beta blocker is contra-
indicated, one may consider to substitute a calcium 
antagonist in the above regimen, the choice of which 
is, at present, primarily guided by pharmacologic 
properties. If pharmacologic treatment of this sort 
fails, immediate angiography is performed and, 
depending on the findings, angioplasty or bypass 
surgery can be carried outr6l. If pharmacologic 
treatment is successful, (semi)elective angiography is 
indicated, and angioplasty or bypass surgery may be 
carried out, depending on the angiographic findings. 
Long-term preventive treatment may include platelet 
aggregation inhibiting drugs or a beta blocker. 
The typical low risk patient arrives at the hospital 
after spontaneous relief of chest pain at home and 
appears to have an almost normal electrocardiogram, 
or at least no substantial ST-segment displacements. 
This patient need not necessarily be admitted to the 
coronary care unit. Initial treatment with a beta 
blocker, or with an additional calcium antagonist 
when beta blockers were already being taken, suffices. 
If chest pain recurs (with accompanying ST-segment 
displacements on the electrocardiogram), the patient 
becomes a 'high risk' patient and subsequent manage-
ment develops as described above. If chest pain does 
not recur, or if no ST-segment changes are observed 
during chest pain, exercise testing and/or 24 hours 
ambulatory electrocardiography is performed to 
identify which patients should be further evaluated 
by angiography. 
It is noted that not all patients present with a 
clinical picture as clear-cut as above as far as risk 
stratification is concerned. The treating physician's 
subjective assessment of risk may be then the deciding 
factor in the treatment choice. 
New developments 
As stated in the discussion of chapter 4, the timing 
of the onset of infarction in HINT patients indicated 
that treatment which aims at the prevention of pro-
gression to myocardial infarction will have a limited 
effect because in most cases it will come too late. 
Therefore, thrombolytic treatment, either with intra-
coronary or intravenous streptokinase or with intra-
venous recombinant tissue-type plasminogen activa-
tor, must be considered a therapeutic option worthy 
of further investigation, in particular in high risk 
unstable angina patients whose symptoms have 
occurred within the last few hours. Of the HINT 
patients, 21% (22 + 92 out of 537 patients) developed 
signs of acute myocardial infarction within 48 hours. 
Of these infarctions, infarct size might have been 
limited in those with an onset before randomisation, 
whereas some infarctions with an onset after random-
isation may even have been prevented altogether 
by thrombolytic treatment. Furthermore, thrombo-
lytic treatment may also prevent recurrence of symp-
toms[7l_ On the other hand, the risks of thrombolytic 
treatment (in particular for a rare cerebro-vascular 
accident) must have greater weight in unstable angina 
than in acute myocardial infarction. In this context it 
is important to note that most of the HINT infarcts 
were enzymatically rather small (Table 4.4). Of 
course, the balance of expected therapeutic benefit 
against risks will change considerably if one were to 
consider high risk patients only. 
The assessment of the efficacy of intravenous 
thrombolytic treatment will be an important target 
for future clinical research in unstable angina. One 
may consider clinical trials in which the efficacy of 
intravenous thrombolytic treatment is compared with 
that of conventional treatment. 
New developments which arise from the above 
arguments (as collected from a recent review of cur-
rent concepts and managementf8l) need be evaluated 
in clinical trials with a design similar to that of 
HINT. The problems of carrying out a randomised 
trial in this indication in such a way that its findings 
have real clinical significance are compounded by the 
fact that clinical management of this syndrome 
involves a chain of decisions to be taken at various 
stages of the disease, which sometimes follow one 
and another within hours. HINT was a trial in which 
only one step in this process (the decision on the 
initial use of a beta blocker, a calcium antagonist, or 
their combination) was assessed. Hence it provided 
only information on the initial choice between these 
agents. An alternative approach would be to compare 
overall management strategies by clinical trial, e.g. a 
conservative approach (for instance beta blockade 
only and late angiography) versus an aggressive 
approach (full medication and early angiography/ 
angioplasty/surgery). Efficacy in such a comparison 
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can be measured by the total number of infarcts 
eventually diagnosed in, for instance, the first two 
weeks. Consequently, such a trial would be much 
easier to carry out-for the complication of 
determining (in an unbiased way) whether recurrent 
ischaemia has occurred is avoided. On the other 
hand, more patients have to be enrolled. Further-
more, one might consider to perform such a trial in 
high risk patients only. The entry criteria would be 
more simple (e.g. in-hospital chest pain with at least 
0·1 m V ST -segment displacement on the elec-
trocardiogram, in the absence of symptoms and signs 
of acute myocardial infarction). An other 'advantage' 
would be a higher infarct rate so that treatment 
effects on this outcome can be measured with greater 
precision. This statement does not imply that mana-
gement of the low risk patient is unimportant per se; 
the research questions involved are, however, at pre-
sent less well suited for clinical research. 
Further unresolved questions regarding the treat-
ment of unstable angina pectoris include the relative 
efficacy of angioplasty and bypass surgery in the 
treatment of refractory angina. Also, elimination of 
silent ischaemia has been suggested as an important 
approach in the long-term management of unstable 
anginaf9 l. Further work is needed to define com-
parative efficacy of various drugs in reducing asymp-
tomatic and symptomatic episodes of myocardial 
ischaemia and its relation to an improvement in 
mortality and morbidity in patients with unstable 
angina r 1 OJ_ 
Whatever treatment or management strategy is 
under study, the distinction between early manage-
ment and late long-term preventive treatment should 
be appreciated in the design of future trials. A further 
important aspect is to distinguish between efficacy of 
a certain drug in hitherto untreated patients and 
efficacy of the same drug in patients who already 
have failed one or more previous (standard) treat-
ments. The HINT findings exemplify the by itself 
plausible notion that a positive effect of additional 
treatment with a certain drug (after failure of standard 
treatment) cannot necessarily be generalized to a 
positive effect of the same drug when given alone, as 
'first choice' treatment. It follows from this that the 
interpretation of trials which have included an un-
specified mixture of both types of patients will remain 
unclear. 
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SUMMARY A multicentre, double blind, placebo controlled, randomised trial of nifedipine, 
metoprolol, and nifedipine and metoprolol combined was conducted in a group of 338 patients 
with unstable angina not pretreated with a f3 blocker and of nifedipine in 177 patients pretreated 
with a f3 blocker. The main outcome event was recurrent ischaemia or myocardial infarction 
within 48 hours. Trial medication effects were expressed as ratios of event rates relative to placebo. 
In patients not pretreated with a f3 blocker the event rate ratios with associated 95% confidence 
intervals were 1·15 (0·83, 1·64) for nifedipine, 0·76 (0·49, 1·16) for metoprolol, and 0·80 (0·53, 
1·19) for nifedipine and metoprolol combined. In patients already on a f3 blocker the addition of 
nifedipine was beneficial (rate ratio 0·68 (0·47, 0·97)). Equal numbers of patients developed 
myocardial infarction and reversible ischaemia. Most infarctions occurred early, within six hours 
of randomisation. In patients not already on a f3 blocker the nifedipine rate ratio for infarction only 
was 1·51 (0·87, 2·74). 
These results suggest that in patients not on previous f3 blockade metoprolol has a beneficial 
short term effect on unstable angina, that fixed combination with nifedipine provides no further 
gain, and that nifedipine may be detrimental. On the other hand, the addition of nifedipine to 
existing f3 blockade when the patient's condition becomes unstable seems beneficial. 
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Patients admitted to a coronary care unit with acute 
chest pain present a spectrum of signs and symptoms 
ranging from those that are characteristic of acute 
myocardial infarction to chest pain without myo-
cardial ischaemia. Within these two extremes a 
subgroup of patients can be identified who have 
signs and symptoms that are atypical of myocardial 
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infarction but characteristic of myocardial isch-
aemia-anginal pain at rest not severe enough to 
suggest myocardial infarction, combined with 
changing electrocardiographic findings compatible 
with ischaemia but not directly diagnostic of 
infarction. This syndrome is usually called unstable 
angina. Patients with this diagnosis at admission to 
the coronary care unit may be in the process of 
sustaining a myocardial infarction. Alternatively, 
the infarction may not yet have occurred, and the 
patient should be considered at risk for recurrent and 
possibly irreversible ischaemia. 1 - 3 
After initial pain relief the aims of early treatment 
are the prevention of recurrent ischaemia or myo-
cardial infarction and the restoration of a stable con-
dition. Calcium antagonists and f3 blockers are 
among the agents that have been advocated as being 
useful in this respect. 4- 8 Calci urn antagonists are 
thought to increase oxygen supply by coronary vaso-
dilation and f3 blockers are assumed to reduce oxygen 
demand by decreasing heart rate and myocardial 
contractility. 9 10 However, f3 blockers have also been 
implicated as a potential cause of increased coronary 
vasomotor tone11 12 and calcium antagonists in the 
coronary steal phenomenon. 9 13 Furthermore, 
several cases of severe congestive heart failure have 
been reported in patients treated with both 
drugs.14 15 
In 1980 the Holland Interuniversity Nifedipine/ 
metoprolol Trial (HINT) research group initiated a 
randomised, double blind, placebo controlled, mul-
ticentre trial to assess the role of calcium antagonists 
and f3 blockers in the treatment of unstable angina. 
At that time this role had not been defined. 16 The 
objective of the trial was to determine whether 
nifedipine (a calcium antagonist) and metoprolol (a f3 
blocker) could prevent recurrence of ischaemia or 
progression to myocardial infarction when given 
either alone or in combination to patients diagnosed 
as having unstable angina at admission to the coro-
nary care unit. The trial was confined primarily to an 
observation period of 48 hours, although long term 
follow up continues. The protocol was designed to 
follow established cardiological practice as closely as 
possible. In particular, patients were admitted to the 
trial as soon as unstable angina was suspected before 
myoca;:-dial infarction could be excluded by enzyme 
measurements. 
The trial was carried out under the auspices of the 
Interuniversity Cardiology Institute, in which all 
academic cardiology departments in the Netherlands 
participate. The trial was funded by the Dutch Min-
istry of Education. In addition, it was supported by 
grants from Bayer GmbH, Wuppertal, Germany, 
and Hassle AB, Molndal, Sweden. 
The first patient was enrolled on 1 February 1981. 
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On 30 October 1984 enrolment was discontinued 
because an interim analysis suggested that the risk of 
myocardial infarction was higher in patients assigned 
to nifedipine than in patients treated with the other 
trial medications. The data on which this decision 
was based are reproduced in appendix I. Both Bayer 
and Hassle and the Dutch health authorities were 
informed of the decision but not of the actual data. 
This report deals with the main findings on the 
efficacy of nifedipine and metoprolol in preventing 
recurrent ischaemia and myocardial infarction in 
the 515 patients who were eventually available for 
analysis. 
Patients and methods 
ORGANISATION 
Eight university and three non-university cardiology 
departments participated. Before the start of the trial 
the protocol was approved by the Scientific Council 
of the Interuniversity Cardiology Institute and by 
the principal investigators of participating non-
university hospitals (together they formed the Exec-
utive Committee) and by the ethics committees at 
each participating centre. A Policy Advisory Board 
of acknowledged experts in related fields, not other-
wise associated with the trial, also approved the pro-
tocol and adopted the task of progress monitoring. 
Until the decision was taken to discontinue the trial 
only this board was informed of the interim results. 
Data were processed by the Clinical Epidemiology 
Unit of the Thoraxcentre in Rotterdam, which also 
provided overall coordination. Its staff was kept 
unaware of the patient medication assigned and 
interim results until the trial was discontinued. 
The clinical course, electrocardiograms, and labo-
ratory data of each patient up to 48 hours after start 
of trial medication were reviewed by a committee of 
three experienced cardiologists. This Classification 
Committee, which was unaware of the trial medica-
tion assignment and findings at subsequent angio-
graphy, determined which clinical events had taken 
place up to 48 hours after randomisation, according 
to predefined guidelines. 
PATIENT RECRUITMENT AND INCLUSION 
CRITERIA 
At admission to hospital patients were screened for 
immediate inclusion before the results of the enzyme 
measurements were known. Chest pain (if present) 
was treated with sublingual glyceryl trinitrate (max-
imum two 0·5 mg doses) and if it persisted an intra-
venous injection of glyceryl trinitrate (maximum 1 
mg in 10 ml 5% glucose) or fentanyl (0·05 mg) was 
given. 
To qualify for admission to the trial the presence 
of either of the following was required: a chest pain 
402 
episode in the hospital accompanied by a varying 
pattern of ST-T changes suggesting reversible myo-
cardial ischaemia; a history of typical angina at rest 
or during light activity occurring within 12 hours of 
admission and lasting > 15 min combined with 
either ST-T abnormalities, a documented history of 
myocardial infarction or unstable angina, or at least 
50% narrowing of a major coronary artery observed 
at earlier angiography. Patients who did not qualify 
at hospital admission were included on the basis of 
the above criteria when chest pain subsequently 
developed, provided that available enzyme values 
were below twice the local upper limit for normal. 
If pain could not be relieved as described above, 
the patient was not admitted to the trial. In addition, 
the following exclusions were applied: age > 70, new 
Q wave formation on the electrocardiogram, acute 
myocardial infarction within one week, maintenance 
treatment with nifedipine, heart rate below 50 or 
above 120 beats/minute, systolic blood pressure < 
100 mm Hg, systolic blood pressure > 170 mm Hg 
and diastolic pressure > 110 mmHg, conduction 
abnormalities other than bundle branch block, ana-
emia (haemoglobin < 6·5 mmol/1, if known), clin-
ically overt heart failure, congenital or valvar heart 
disease, cardiomyopathy, serious pulmonary or 
other non-cardiac disease, and previous par-
ticipation in this trial. After eligibility had been 
established, oral informed consent was asked for and 
if it was obtained the trial medication was started 
without further delay. 
TREATMENT 
All patients received routine care for at least 48 
hours. Sedatives and anticoagulants were given 
according to local practice. Oral long acting nitrates 
were continued if they had been given before admis-
sion to hospital; otherwise these drugs were not part 
of the standard regimen. Antiarrhythrnics, digitalis, 
diuretics, and antihypertensive agents other than f3 
blockers were given on indication only. Previous 
maintenance treatment with a f3 blocker was con-
tinued; before 13 November 1982 with the same 
compound and dose as given before, thereafter with 
two 100 mg doses ofmetoprolol per 24 hours. Chest 
pain was initially treated as described above. If pain 
persisted the decision to use further measures was 
left to the discretion of the attending physician. 
Trial medication was added to the standard regi-
men as follows. Patients not on previous mainte-
nance treatment with a f3 blocker for > 3 days were 
randomly assigned to receive either double placebo, 
nifedipine six 10 mg doses per 24 hours plus meto-
prolol placebo, metoprolol two 100 mg doses per 24 
hours plus nifedipine placebo, or both drugs. 
Patients on previous maintenance treatment with a 
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f3 blocker were randomly assigned to receive placebo 
or nifedipine six doses of 10 mg per 24 hours. No 
loading dosages were given. Both nifedipine and 
metoprolol (or their placebos) were started at the 
same time. Both randomisation procedures were 
performed for each clinic separately and in equal 
proportions. 
Unless persistent chest pain developed, the trial 
medication was continued for at least 48 hours, pref-
erably until catheterisation or discharge. In the event 
of suspected side effects trial medication was reduced 
or discontinued. The treatment code could be bro-
ken but only if it was considered mandatory by the 
attending physician. For this purpose a coding 
envelope was packed with each package of the trial 
medication. 
DATA COLLECTION AND FOLLOW UP 
Twelve lead electrocardiograms were recorded every 
six hours as well as during and after episodes of chest 
pain over the period from hospital admission until48 
hours after start of trial medication. The extent of 
ST depression and elevation was coded as described 
in appendix II in two electrocardiograms recorded 
before start of trial medication-that is, the last 
electrocardiogram obtained in the absence of pain 
(the baseline electrocardiogram) and for patients 
with pain while in hospital an electrocardiogram 
made during pain (the pain electrocardiogram). 
Blood samples for measurement of activities of 
creatine kinase or its isoenzymes or both were 
obtained at least once before start of trial medication 
and every six hours until 54 hours thereafter. The 
activities of glutamic oxaloacetic and pyruvic trans-
aminases, lactic acid dehydrogenase, and rx hydroxy-
butyric acid dehydrogenase were determined every 
24 hours. After 54 hours enzyme measurements were 
left to local routine but were recorded when avail-
able. All enzyme determinations were performed 
locally and were subsequently related to local normal 
values. Heart rate was recorded every hour and 
blood pressure every six hours. 
Cardiac catheterisation and coronary angio-
graphy, unless contraindicated, were performed 
preferably before discharge but not within 54 hours 
after start of trial medication. 
DEFINITION OF OUTCOME EVENTS AND DATA 
ANALYSIS 
A patient was classified as having "pre-random-
isation myocardial infarction" when concentrations 
of one or more cardiac enzymes measured before the 
start of trial medication were significantly raised-
that is, to more than twice the local upper limit for 
normal. In this case no outcome classification was 
defined. For all other patients the following two out-
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come events were defined: recurrent ischaemia or 
myocardial infarction within 48 hours-that is, chest 
pain with ST-T changes and/or enzymatic evidence 
of infarction as defined below; myocardial infarction 
within 48 hours-that is, cardiac death or character-
istic serial enzyme pattern with at least one cardiac 
enzyme significantly raised within 54 hours (as there 
is an intrinsic delay in the release of enzymes after 
the onset of myocardial infarction enzyme values 
until 54 hours after randomisation were taken into 
account). Myocardial infarction which occurred 
within the remainder of the first seven days was 
recorded according to clinical diagnosis. For all cases 
classified as myocardial infarction within 48 hours 
the most likely time of onset was determined retro-
spectively from the complete clinical history. In 
addition, the time of appearance of a Q wave lasting 
> 0·03 seconds or of a Q wave equivalent (R > 0·03 
seconds in Vl and R/S > 1 in V2) was noted. 
Those patients for whom an unequivocal protocol 
violation occurred before the start of trial medication 
were excluded from analysis. These exclusions were 
applied retrospectively by the Classification Com-
mittee. Patients were retained, however, if the com-
mittee disagreed with the attending physician's 
assessment of qualifying ST-T abnormalities or 
changes. Treatment effects were assessed in terms of 
the occurrence of the two outcome events defined 
above. In accordance with the protocol, patients 
classified as having pre-randomisation myocardial 
infarction were excluded from this assessment. 
Treatment effects were expressed as the ratio of the 
rate of the respective outcome event observed in 
patients allocated to a specific index trial medication 
to that observed in patients allocated to a specific 
reference trial medication. For instance, the effect of 
nifedipine relative to placebo is the rate of the out-
come event in the nifedipine group divided by that 
in the placebo group. Thus a rate ratio of one indi-
cates that nifedipine has no effect relative to placebo. 
A rate ratio of < 1 points to a preventive effect and 
a rate ratio > 1 to a detrimental effect. The 95% 
confidence intervals of the rate ratio estimates are 
also given. 
We used a composite logistic prediction function 
to determine which baseline characteristics were 
independently related to the risk of recurrent 
ischaemia or myocardial infarction within 48 hours. 
The baseline risk of recurrent ischaemia or myo-
cardial infarction within 48 hours (that is, the proba-
bility that such an event would occur) was·estimated 
for each patient separately given individual baseline 
characteristics and the prediction function. Patients 
were subsequently divided into three subgroups of 
low, medium, and high risk. 
In the analysis we found that despite random 
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allocation, trial medication groups differed in terms 
of the distribution of baseline risk. To adjust for this, 
relative treatment effects, as defined above, were 
estimated as weighted averages of risk subgroup 
specific effects. Full details of the analytic methods 
are given in appendix II. 
STUDY SIZE REQUIREMENTS 
The protocol stated that trial treatments were to be 
evaluated in terms of the rates of recurrent ischaemia 
or myocardial infarction within 48 hours in patients 
without myocardial infarction at the start of trial 
medication. If it is assumed that this rate would be 
40<;,0 in placebo treated patients who were not 
already on f3 blockade, that nifedipine and meto-
prolol alone would reduce this rate to 20%, and that 
the combination would reduce this further to 10% 
(that is event rates of 40%, 20%, 20%, and 10% 
respectively), 70 patients per group are required for 
a 97% chance of obtaining a statistically significant 
(p < 0·05) result in a 4 x 2 continguency table x2 
test. 17 To allow for lower r!ltes and the possibility 
that only the combinat~on would be effective, we 
planned to study 150 patients per group. 
Results 
RECRUITMENT AND EXCLUSIONS 
Between 1 February 1981 and 30 October 1984, 668 
patients were enrolled. The median contribution per 
centre was 50 patients, ranging from seven (for a 
centre that participated only during the last nine 
months) to 144. Randomisation by centre resulted in 
balanced trial medication groups. 
Figure 1 shows that a violation of the admission 
protocol occurred in 131 patients; these cases were 
excluded. Another 22 patients classified as having 
pre-randomisation myocardial infarction were left 
out from trial medication assessment. In 82% of the 
515 remaining patients the treating physician's 
judgement on qualifying ST-T abnormalities or 
changes was independently confirmed by the 
Classification Committee. Figure 1 also shows the 
overall occurrence of relevant clinical events. All 
deaths were caused by myocardial infarction. 
l:'igure 2 shows the time of onset in 89 cases of 
non-fatal myocardial infarction within 48 hours of 
the start of trial medication. In 43 patients acute 
myocardial infarction was thought to have occurred 
before the start of trial medication despite cardiac 
enzyme concentrations being below twice the upper 
limit for normal at that time. Figure 2 also shows the 
time of first occurrence of a significant rise in enzyme 
concentrations and that of a new Q wave. 
Table 1 shows selected baseline characteristics in 
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668 Patients randomised 
131 protocol violations before start trial medication (some patients were excluded for more than one reason) 
22 last chest pain > 12 hours before 
49 exclusion criterion overlooked 
40 chest pain not treated as prescribed 
5 glyceryl trinitrate infusion started 
5 previous use of fl blockade not properly taken into account 
6 not pain free at start 
1 5 other reasons 
537 Patients with unstable angina as defined 
~22 (1 died) pre-randomisation myocardial infarction (MI 0 ) 
51 5 Patients available for assessment of trial medication effect 
l { 92 M1 48 (3 died within 48 hours, 1 died between 2-7 days) { 191 RI/MI•s 99 no Ml } 515 324 no RI/MI 48 48 20 Ml between 2-7 days (4 died) 
Fig 1 Exclusions from data analysis and overall distributions of outcome events. M10 , pre-randomisation 
myocardial infarction,- RI/Ml48 , recurrent ischaemia or myocardial infarction within 48 hours,- MJ48, 
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Fig 2 Timing of the onset of non-fatal myocardial infarction, the first signifiamt rise in enzyme concentration, and the 
appearance of Q waves for 89 cases of non-fatal myocardial infarction within 48 hours in 515 patients without enzymatic 
evidence of infarction at randomisation. The time of the onset of myocardial infarction was determined 
retrospectively by the Classification Committee from the complete clinical history. The upper dotted line represents the 
cumulative distribution of the time of onset of myocardial infarction-that is, it represents for each point in time after 
randomisation the total number of patients with an onset before that time. In 43 cases the onset was judged to have taken 
place before randomisarion; the upper line thus starts at 43. Similarly the middle broken line represents the cumulative 
distribution of the time of first rise in enzyme concentration to over twice the local upper limit of normal and the lower solid 
line the time of first appearance of a Q wave on the electrocardiogram. 
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Table 1 Baseline characteristics and corresponding outcome event rates 
RI/MI4s Ml4a 
All patients (515 = 100%) 191 (37%) 92(18%) 
Age: 
38(21%) <55 years (183 = 36%) 69(38%) 
55-65 years (248 = 48%) 92(37%) 40(16%) 
>65 years (84 = 16%) 30(36%) 14(17%) 
Sex: 
Male (387 = 75%) 149 (39%) 82(21 %) 
Female (128 = 25%) 42(33%) 10 (8%) 
History of myocardial infarction: 
No (340 = 66%) 134(39%) 68(20%) 
Yes (175 = 34%) 57(33%) 24(14%) 
History of angina > 4 weeks: 
No (308 = 60%) 116(38%) 61 (20%) 
Yes (207 = 40%) 75(36%) 31 (15%) 
Previous maintenance treatment with a [J blocker: 
No (338 = 66%) 121 (36%) 63 (19%) 
Yes (177 = 34%) 70(40%) 29(16%) 
Pain free interval: 
<1 hour (133 = 26%) 82(62%) 45(34%) 
1-3 hours (186 = 36%) 66(35%) 31 (17%) 
>3 hours (196 = 38%) 43(22%) 16 (8%) 
Baseline ECG: 
Not codable (20 =4%) 8(40%) 6(30%) 
No ST depression )'0·1mV (402 = 78%) 136(34%) 60(15%) 
ST depression ;;. 0·1 m V (93 = 18%) 47(51%) 26(28%) 
Comparison of pain ECG with baseline ECG: 
Not possible* (223 = 43%) 48(22%) 24(11%) 
Same ST coding (82 = 16%) 32(39%) 11(13%) 
More ST depressiont (159 = 31%) 87(55%) 45(28%) 
More ST elevationt (101 = 20%) 60(59%) 32(32%) 
Baseline risk for RI/MI4s::l: 
Low (303 =59%) 65(21%) 28 (9%) 
Medium (126 = 24%) 67(53%) 28(22%) 
High (86 = 17%) 59(69%) 36(42%) 
RI/MI4s, recurrent ischaemia or myocardial infarction within 48 hours; MI4s, myocardial infarction within 48 hours; ECG, electro-
cardiogram. 
*No pain observed after hospital admission or no (codable) pain free electrocardiogram available for comparison. 
tincluding 50 patients who had more ST depression as well as more ST elevation. 
tAs estimated from previous maintenance treatment with a f3 blocker, pain free interval, baseline electrocardiogram, and comparison of 
pain electrocardiogram with baseline electrocardiogram (see appendix II). 
relation to the defined outcome events. There were 
only small differences between the rates of recurrent 
ischaemia or myocardial infarction within 48 hours 
of the start of trial medication for respective catego-
ries of age, sex, history of coronary disease, and pre-
vious f3 blockade. Trial medication was started after 
a pain free interval of less than one hour in 26% of 
patients and in a further 36% after an interval of 
between one and three hours.. The length of this 
interval was strongly related to the rate of recurrent 
ischaemia or myocardial infarction within 48 hours: 
62% of patients who had a pain free interval of less 
than one hour developed recurrent ischaemia or 
myocardial infarction within 48 hours as opposed to 
22% of those in whom the pain free interval lasted 
more than three hours (table 1). The rate of recur-
rent ischaemia and myocardial infarction within 48 
hours was also related to the presence of ST depres-
sions > 0·1 m V on the baseline electrocardiogram. 
Patients without pain observed while in hospital had 
a lower event rate than those with pain. In those with 
pain the event rate was also related to the presence of 
changes in ST coding during pain. 
Of the baseline characteristics listed in table 1, 
previous use of f3 blockers, pain free interval before 
the start of trial medication, and ST coding of elec-
trocardiograms made during and after pain were 
retained in the logistic function for the estimation of 
the baseline risk for recurrent ischaemia or myo-
cardial infarction within 48 hours. Based on this 
estimation, 59% of patients were grouped as 
"low", 24% as "medium", and 17% as "high" risk. 
The observed rates were 21%, 53% and 69% 
respectively. The rate of myocardial infarction 
within 48 hours was also strongly related to this 
stratification. Appendix II gives full details of the 
logistic function. 
COMPARABILITY OF TRIAL MEDICATION 
GROUPS AND USE OF CONCOMITANT 
MEDICATION 
Table 2 shows the trial medication allocation. Of 338 
patients who<were not on previous maintenance 
treatment with a f3 blocker 84 were assigned to 
placebo, 89 to nifedipine, 79 to metoprolol, and 86 to 
the combination. Placebo was added to continued f3 
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Table 2 Disrriburion of baseline characreristics between trial medication groups 
No previous maintenance treatment with a Previous maintenance f3 blocker treatment with a f3 blocker 
All Placebo Nifedipine Meroprolol Combination Placebo Nifedipine 
Number of allocations 515 84 89 
Age: 
79 86 81 96 
<55 years 36~~ 40% 38% 41% 38% 31% 26% 55-65 years 48% 44% 49% 42% 42% 54% 56% 
>65 years 16% 15% 12% 18% 20% 15% 18% 
Sex: 
Male 75% 71% 74~~ 81% 73% 77% 75% 
Female 25% 29% 26% 19% 27% 23% 25% 
History of myocardial infarction: 
No 66% 73% 69% 73% 71% 49% 61% 
Yes 34% 27% 31% 27% 29% 51% 39o!o 
History of angina longer than 4 weeks: 
No 60% 69% 72% 76% 62% 46% 37% 
Yes 40% 31% 28% 24% 38% 54% 63% 
Previous maintenance treatment with 
a f3 blocker: 
No 66% 100% 100% 100% 100% 0% 0% 
Yes 34% 0% 0% 0% 0% 100% 100% 
Pain free interval: 
< 1 hour 26% 23% 33% 23% 27% 27% 23% 
1-3 hours 36% 27% 36% 47% 34% 35% 39% 
>3 hours 38% 50% 31% 30% 40% 38% 39% 
Baseline ECG: 
Not codable 4% 6% 3% 3% 5% 2% 4% 
No ST depression ;;.0·1mV 78% 76% 88% 87% 79% 63% 75% 
ST depression ;;.0·1mV 18% 18% 9% 10% 16% 35% 21% 
Comparison of pain ECG with 
baseline ECG: 
Not possible* 43% 46% 39% 33% 48% 42% 50% 
Same ST coding 16% 15% 19% 18% 14% 16% 14% 
More ST depressiont 31% 29% 30% 41% 26% 33~1o 28% 
More ST elevationt 20°/0 17'% 24% 19% 17% 22% 19% 
Baseline risk of RI/MI4s::j: 
Low 59% 67% 60% 66% 65% 42% 54% 
Medium 24% 26% 22% 29% 23% 22% 24% 
High 17% 7% 18% 5% 12% 36% 22% 
RI/MI4s, recurrent ischaemia or myocardial infarction within 48 hours; ECG, electrocardiogram. 
*No pain observed after hospital admission or no (codable) pain free electrocardiogram available for comparison. 
t Including 50 patients who had greater ST depression and greater ST elevation. 
tAs estimated from previous maintenance treatment with fJ blocker, pain free interval, baseline electrocardiogram, and comparison of 
pain electrocardiogram with baseline electrocardiogram (see appendix II). 
blocker treatment in 81 patients and nifedipine in 96. 
Table 2 also shows the baseline characteristics for 
each trial medication group separately. Baseline risk 
for recurrent ischaemia or myocardial infarction 
within 48 hours was distributed differently over the 
trial medication groups. Among patients not on pre-
vious maintenance treatment with a f3 blocker 18% 
of those allocated to nifedipine were high risk; for the 
other three trial medication groups this percentage 
ranged from 5% to 12%. The higher risk of the 
nifedipine group was due primarily to a relatively 
large proportion (33%) of patients in whom trial 
medication was started within one hour after the last 
attack of pain (a strong indicator of risk, table 1). In 







Use in relation to randomisation 
At randomisation + 6 h 
No previous maintenance treatment with a P blocker 
(n ~ 84) 100% 94% 
(n ~ 89) 100% 87% 
(n ~ 79) 100% 99% 
(n ~ 86) 100% 94% 
On continued maintenance treatment with a P blocker 
(n = 81) 100% 89% 
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Table 4 Outcome event rates in trial medication groups stratified for estimated baseline risk for recurrent ischaemia or 
myocardial infarction within 48 hours 
Mlo NoMio RI/MI•s MI.s Mr •• + Q 
No previous maintenance treatment with a fJ blocker 
Placebo: 
All patients 3 84 31 (37%) 13(15%) 9(11%) 
Low risk 56 13(23%) 3 (5%) 2 (4%) 
Medium risk 22 13(59%) 8(36%) 6(27%) 
High risk 6 5(83%) 2(33%) 1(17%) 
Nifedipine: 
All patients 4 89 42(47%) 25(28%) 14(16%) 
Low risk 53 15(28%) 8(15%) 4 (8%) 
Medium risk 20 14(70%) 6(30%) 4(20%) 
High risk 16 13(81%) 11 (69%) 6(38%) 
Metoprolol: 
All patients 4 79 22(28%) 13(16%) 6 (8%) 
Low risk 52 10 (19%) 6(12%) 2 (4%) 
Medium risk 23 9(39%) 5(22%) 3(13%) 
High risk 4 3(75%) 2(50%) 1(25%) 
Combination: 
All patients 7 86 26(30%) 12(14%) 7 (8%) 
Low risk 56 9(16%) 4 (7%) 3 (5%) 
Medium risk 20 12(60%) 5(25%) 2(10%) 
High risk 10 5(50%) 3(30%) 2(20%) 
On continued maintenance treatment with a f3 blocker 
Placebo: 
All patients 2 81 41(51%) 16(20%) 6 (7%) 
Low risk 34 8(24%) 3 (9%) 2 (6%) 
Medium risk 18 12(67%) 2(11%) 0 (0%) 
High risk 29 21(72%) 11(38%) 4(14%) 
Nifedipine: 
All patients 2 96 29(30%) 13(14%) 6 (6%) 
Low risk 52 10(19%) 4 (8%) 0 (0%) 
Medium risk 23 7(30%) 2 (9%) 2 (9%) 
High risk 21 12(57%) 7(33%) 4(19%) 
MI0 , pre-randomisation myocardial infarction; RI/MI48, recurrent ischaemia or myocardial infarction within 48 hours; MI4 s, myocardial 
infarction within 48 hours; MI•s + Q, myocardial infarction within 48 hours with subsequent Q wave formation. 
patients who were on continued f3 blockade the same 
was true for patients allocated to placebo, although 
to a lesser extent. 
Oral long acting nitrates had been given to 100 
patients at admission to hospital and were continued 
in 76%. Thus 439 patients did not receive oral long 
acting nitrates at randomisation. These drugs were 
later given, on indication, to 11% of these patients. 
Anticoagulants ( coumarins or heparin) were given to 
67%. At the start of the trial or during follow up 
14% received diuretics, 3% digitalis, and 3% plate-
let aggregation inhibiting drugs. Medication at 
hospital admission was not related to the risk of 
recurrent ischaemia or myocardial infarction within 
48 hours. 
Table 3 shows the percentage of patients still on 
trial medication 6, 12, and 48 hours after -random-
isation. At 48 hours the percentage of patients still on 
trial medication ranged from 63% of patients allo-
cated to nifedipine who were not on previous main-
tenance f3 blockade to 76% of patients allocated to 
placebo who were not on previous f3 blockade. The 
predominant reasons for discontinuation of trial 
medication were recurrent chest pain and diagnostic 
findings of myocardial infarction. In five patients the 
trial medication code was broken within 48 hours of 
randomisation. 
OUTCOME EVENT RATES IN TRIAL 
MEDICATION GROUPS AND RELATIVE EFFECTS 
OF TREATMENT 
Table 4 shows the number of pre-randomisation 
infarctions by trial medication group. Also shown 
are the outcome event rates for patients without pre-
randomisation infarction, both overall and according 
to stratum of baseline risk for recurrent ischaemia or 
myocardial infarction within 48 hours. The direc-
tions of the differences between the trial medication 
groups were consistent over the risk strata. In 
patients not on previous maintenance treatment with 
a f3 blocker who were treated with nifedipine both 
event rates were higher than the corresponding ones 
for those on placebo. This was also true for Q wave 
infarctions. On the other hand, in patients on meto-
prolol or on the combination, event rates tended to 
be lower than the rates for those on placebo. In 
patients who were already on a f3 blocker, the 
nifedipine group tended to have lower event rates 
than the placebo group. 
Table 5 gives the estimated relative effects 
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Table 5 Rate ratios with 95% confidence intervals for all trial medication comparisons 








No previous maintenance treatment with a f3 blocker 
1·15 (0·83, 1-64) 1·51 (0·87, 2·74) 
1·07 (0·54, 2·09) 
0·88(0·44, 1·74) 
0·74 (0·40, 1-31) 
0·56 (0·30, 0·99) 
0·79 (0·39, 1-62) 
0·76 (0·49, 1·16) 
0·80 (0·53, 1·19) 
0·66 (0·43, 0·98) 
0·68 (0·47, 0·97) 
1·06 (0·67, 1-70) 
Nifedipine/placebo 
On continued maintenance treatment with a f3 blocker 
0·68 (0·4 7' 0·97) 0·86 (0·45, 1·61) 
RI/MI4s, recurrent ischaemia or myocardial infarction within 48 hours; MI48, myocardial infarction within 48 hours. 
expressed as weighted averages of risk stratum 
specific rate ratios together with the 95% confidence 
intervals for all choices of index and reference trial 
medication. 
Discussion 
CLINICAL SPECTRUM OF UNSTABLE ANGINA 
DIAGNOSED AT ADMISSION TO CORONARY 
CARE UNIT 
According to one widely accepted definition patients 
who have recent onset (effort) angina, worsening 
angina, or angina at rest are classified as having 
unstable angina provided there are no signs of acute 
myocardial infarction. 18 It is generally recognised 
that the differential diagnosis of such cases may be 
difficult and that myocardial infarction may have 
already occurred or may be about to occur. The 
present trial reports clinical events and their timing 
in 537 patients in whom unstable angina was diag-
nosed at admission to the coronary care unit. 
This diagnosis was based on a combination of 
findings-angina at rest, evidence for causal myo-
cardial ischaemia, and absence of signs of acute myo-
cardial infarction such as persistent pain or charac-
teristic electrocardiographic signs (a subcategory of 
unstable angina as defined above). Not unexpectedly 
in 4% (22 out of 537, fig 1) there had already been 
myocardial infarction with an increase in enzyme 
concentrations. These cases of myocardial infarction 
could have been diagnosed immediately had labora-
tory measurements been immediately available. 
Within a week of the start of the trial myocardial 
infarction had occurred in 25% (22 + 92 + 20 out 
of 537, fig 1). Thus there is a considerable risk of 
myocardial infarction during this period. Similar 
percentages have been reported before 1 but the time 
of the onset of infarction (retrospectively determined 
from the complete clinical history) relative to the 
time when the diagnosis of unstable angina was made 
was not given. Figure 2 shows that the onset of myo-
cardial infarction was judged to have occurred before 
the start of trial medication in 43 cases and that there 
were 34 further cases within six hours of the start of 
the triaL Only few infarctions occurred later than six 
hours after the start of the triaL Thus so far as myo-
cardial infarction occurs in patients diagnosed as 
having unstable angina, its onset tends to cluster 
around the time of diagnosis. The clinical impli-
cations of this finding are considerable and it shows 
that treatment which aims at the prevention of 
progression to myocardial infarction will have a lim-
ited effect because in most cases it will come too late. 
Despite the high frequency of myocardial 
infarction, this trial supports the notion that the 
prognosis in patients with this type of unstable 
angina is good. Total one week mortality was only 
1·7% (9/537, fig 1). Our results indicate that the 
short term risk of recurrent ischaemia or myocardial 
infarction is primarily related to the interval since 
the last attack of pain on the one hand and to the 
presence of resting ST abnormalities and pain 
related ST changes on the other (table 1 and appen-
dix II). The first finding is understandable because 
by definition the condition of patients with a long 
interval between last pain attack and diagnosis has 
stabilised. The second finding accords with current 
views and previous findings on the relevance of 
electrocardiography in such patients. 1 - 3 19 20 
We did not attempt to relate the baseline risk of 
recurrent ischaemia or myocardial infarction within 
48 hours to findings at subsequent coronary angio-
graphy. Unless there are compelling reasons for an 
emergency procedure, catheterisation is generally 
only carried out a few days after hospital admission 
at the earliest. Thus in most patients catheterisation 
results are not relevant to the initial management. 
Does the clinical spectrum seen in the patients we 
studied in 1981-84 remain valid today? There does 
not seem to have been any major change in the initial 
clinical recognition of unstable angina and its 
differentiation from myocardial infarction or in the 
pharmacotherapeutic approach. On the other hand, 
emergency percutaneous transluminal coronary 
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angioplasty or bypass surgery are now increasingly 
offered, with good results. 21 It is unlikely, however, 
that the more general use of these procedures will 
have had any great effect on the clinical spectrum 
because such procedures are usually restricted to 
patients in whom chest pain persists despite maximal 
pharmacological treatment. In such cases angio-
plasty or bypass surgery may prevent the occurrence 
of myocardial infarction. Of the infarctions in the 
present trial only the later ones could have been 
prevented in this way, and there were only a few of 
these. 
EFFECTS OF TRIAL MEDICATION 
On the basis of an interim analysis enrolment in the 
present trial was discontinued (appendix I). This 
was because continuation of nifedipine monotherapy 
trial medication was considered to be unethical and, 
secondly, because there were only small differences 
between the other groups. The final data as 
presented here essentially accord with the interim 
data that led to this decision (tables 4 and 5, and 
appendix 1). 
Although the series is large, the trial medication 
groups are rather smalL In a randomised trial with 
small groups the results may indicate differences in 
the baseline risk between the groups. Table 2 shows 
that this was indeed the case. We used an approach 
developed for non-experimental epidemiological 
studies22 to impose risk stratification based on a 
composite logistic function of relevant baseline char-
acteristics on our study group and we have expressed 
trial medication effects as weighted averages of 
stratum specific rate ratios. This approach ensures 
that the estimation of trial medication effect becomes 
independent of the distribution of baseline risk in the 
groups that are compared. The use of 95% 
confidence intervals for the rate ratios so obtained 
provides a better indication of the statistical strength 
of evidence than the customary significance levels (p 
values). 23 
Patients with a pre-randomisation myocardial 
infarction are no longer at risk of the defined out-
come events. Therefore, we excluded these patients 
before we assessed the trial medication effects. To 
allow for effect analyses based on other principles the 
number of pre-randomisation infarctions is also 
given per treatment group (table 4). 
Of all the treatments studied only the addition of 
nifedipine to previous maintenance treatment with a 
f3 blocker was clearly beneficial. None of the other 
trial regimens came out as being unequivocally 
effective. Furthermore, there was a worrying trend 
towards an increased risk for myocardial infarction 
in patients assigned to nifedipine alone. What is the 
explanation for these findings? 
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We postulate that when nifedipine is given to 
patients whose condition has become unstable 
despite maintenance treatment with a f3 blocker 
coronary spasm may play a larger role than it does in 
patients not on f3 blockade. This would explain the 
efficacy of additional treatment with a coronary spas-
molytic agent such as nifedipine. 
We do not believe that the apparent lack of effect 
of the other trial medications is caused by the selec-
tion of already stabilised patients, which would lead 
to too few potential outcome events. The event rate 
of recurrent ischaemia or myocardial infarction 
within 48 hours was considerable and accorded with 
the a priori design assumptions. Nevertheless, the 
confidence intervals given in table five do not 
exclude the possibility that relevant trial medication 
effects were missed. We believe that the most likely 
explanation lies in the particular clinical situation 
that this trial was designed to examine. The trial 
design assumed that neither ischaemia nor necrosis 
was present after eligibility had been established. We 
realised that because there are no specific early elec-
trocardiographic signs of necrosis inclusion of some 
patients in whom myocardial infarction was already 
evolving would be unavoidable. Although we appre-
ciated that enzyme concentrations increase within 
hours of the onset of myocardial infarction, we 
decided to exclude patients from trial medication 
assessment only if enzymes were already 
significantly raised at randomisation. This was 
decided for two reasons. Firstly, if enzyme mea-
surements o brained after randomisation were used as 
a basis for exclusion the validity of comparisons 
between trial medications could be compromised. 
This would have occurred if any of the trial medica-
tions had affected the release of enzymes from necro-
tic myocardium rather than the amount of necrosis. 
Secondly, only enzyme measurements known at that 
time could be relevant to the formulation of treat-
ment guidelines based on the results of this triaL Of 
patients classified as having recurrent ischaemia or 
myocardial infarction within 48 hours and retained 
in the analysis, a considerable proportion (92 out of 
197, table 1) sustained a myocardial infarction, gen-
-erally before the start of trial medication or so soon 
thereafter that oral treatment could not be fully 
effective (fig 2). Thus an important fraction of the 
events on which effect estimation was based is 
unlikely to be affected by a preventive effect of trial 
medication, notwithstanding such an effect in 
another context. To be effective in this context a 
medication must not only prevent recurrent 
ischaemia or infarction in patients who are still at risk 
when treatment becomes effective but must also 
limit necrosis in those in whom the process of 
infarction has already progressed to the extent that 
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an otherwise detectable infarction would become 
undetectable by current conventional diagnostic 
methods. Neither nifedipine nor metoprolol are 
likely to meet these requirements. Nifedipine has not 
been shown to reduce infarct size when given to 
patients with myocardial infarction. 24 Animal 
experiments indicate that nifedipine does not protect 
the myocardium when given after onset of 
ischaemia. 25 Nor is the effect of f3 blockade on infarct 
size definitively known. 
The reason why nifedipine mono therapy increases 
the risk of progression to myocardial infarction can-
not be determined from our data. The nifedipine 
results may be a chance finding. On the other hand, 
they virtually exclude a major preventive effect of 
nifedipine used in this way for this indication. We do 
not believe that nifedipine's postulated influence on 
the release of enzymes26 explains this finding-there 
were more Q wave infarcts in the nifedipine mono-
therapy group than in the placebo group (table 4). 
Relative to placebo, nifedipine did not raise the heart 
rate substantially but it reduced blood pressure. It is 
possible therefore that the temporary rise in heart 
rate in combination with a decrease in blood pres-
sure, which has been observed before,27 plays a role. 
Nifedipine is generally accepted to be of particular 
value in patients with ST elevation during pain. A 
hundred and one patients had these features before 
entry (table 1). Subgroup analysis did not show that 
these patients especially benefited from nifedipine 
alone. 
COMPARISON WITH OTHER STUDIES 
In another trial for which patients were selected at 
hospital admission treatment with four 20 mg doses 
of nifedipine given over 24 hours was compared with 
placebo. 28 Eligibility for the trial, however, required 
more prolonged chest pain than in the present trial 
and patients with electrocardiographic evidence of 
acute infarction were not excluded. Patients were 
later stratified into either acute or threatened myo-
cardial infarction groups on the basis of the presence 
or absence of increased enzyme concentrations and 
Q waves at randomisation. The group with threat-
ened myocardial infarction resembled the patients 
that we studied. The rate of progression to myo-
cardial infarction, 75% after 24 hours, was much 
higher, however, probably because chest pain had 
been present for longer. The progression rate in the 
nifedipine and placebo groups was similar, as was 
enzymatic infarct size. The number of patients who 
were also treated with a f3 blocker was not reported, 
so direct comparison with our results is impossible. 
In another trial in patients diagnosed as having 
"threatened infarction" treatment with propranolol 
was compared with conventional treatment. 5 The 
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effect of propranolol resembled that of metoprolol in 
the present trial. 
Treatments in patients with unstable angina after 
enzyme concentrations were known to be normal 
have been studied in several trials with varying selec-
tion criteria. In one the addition of nifedipine to a 
standard regimen of propranolol and long acting 
nitrates reduced recurrent ischaemia during a three 
month follow up. 29 Nifedipine without concomitant 
f3 blockade was not studied. Another trial compared 
a conventional step-up regimen of long acting 
nitrates and propranolol with increasing dosages of 
nifedipine during a treatment period of 14 days. 30 
Overall there were no differences in recurrent 
ischaemia and 14°10 progressed to infarction in both 
groups. Because this trial did not have a placebo 
control group it is not possible to tell whether both 
regimens were equally effective or equally 
ineffective. In the subgroup of patients who were on 
maintenance treatment with propranolol the addi-
tion of nifedipine controlled pain more rapidly than 
did the addition of nitrates o~· an increase of the 
propranolol dose. On the other hand, in the sub-
group of patients who were not on maintenance 
propranolol the administration of propranolol or 
nitrates or both controlled pain more rapidly than 
did nifedipine. Our results accord with these 
findings. Moreover, they provide evidence for a pos-
itive effect of a particular f3 blocker in patients not 
already on such treatment compared with placebo 
and for a similar effect of nifedipine in patients 
already using a f3 blocker. 
CLINICAL IMPLICATIONS 
The present results confirm that with currently 
available diagnostic methods it is impossible to 
reliably differentiate unstable angina from evolving 
myocardial infarction at admission of a patient to a 
coronary care unit. Many of the patients with sus-
pected unstable angina have already sustained a 
myocardial infarction or are in the process of doing 
so. 
Initial management must take into account the 
possible presence of evolving myocardial infarction. 
The first management objective therefore becomes 
the reduction of the total number of infarcts even-
tually diagnosed among this subgroup of patients, 
irrespective of the precise time of onset relative to the 
start of treatment. To achieve this treatment must 
both reduce the size of evolving infarctions and pre-
vent those which are about to develop. 
Our results indicate that previous use of a f3 
blocker is an important consideration. They suggest 
that in patients not already on a f3 blocker, a f3 blocker 
is the treatment of first choice. The fixed combina-
tion of metoprolol and nifedipine had no additional 
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advantages. Patients with ST elevations during pain 
did not seem to benefit from nifedipine. Further-
more, nifedipine cannot be recommended as mono-
therapy because it was associated with a higher inci-
dence of myocardial infarction. On the other hand, 
patients whose condition has become unstable 
despite maintenance treatment with a f3 blocker can 
be expected to react favourably to the addition of 
nifedipine to a regimen of continued f3 blockade. 
We acknowledge with gratitude the leadership of the 
late Dirk Durrer, past chairman of the Executive 
Committee. 
Appendix I 
On 27 October 1984 the Policy Advisory Board was 
presented with the following interim classification 
results of 593 randomised patients who were 
included irrespective of protocol violations: 
Mlo 
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line risk, a logistic function was fitted to the data. 
This function relates the probability of recurrent 
ischaemia or myocardial infarction within 48 hours 
to a set of baseline characteristics X1, Xz, ... , Xk 
using the logistic function: 
{1 + exp [-(a+ b1X1 + bzXz + ... + bkXk)]} -!. 
CODING OF BASELINE CHARACTERISTICS 
As a general principle only indicator variables were 
used-that is variables that assume the value 1 if the 
property at issue is present and 0 if otherwise. 
ST depression and ST elevation (measured 0·08 
seconds after the J point) was scored according to the 
following categories: absent; < 0·5 mm; between 0·5 
and 1·0mm; between 1·0 and 2·0mm; between 2·0 
and 5·0 mm; > 5 mm. Maximum values were 
recorded for the following groups ofleads: (1) V2; (2) 
V3-V5; (3) II, III, aVF; (4) I, aVL, V6. Electro-
cardiographic characteristics were expressed in 
NoMio RI/Mhs 





7 86 30 (35° 0 ) 12(14° 0 ) 
26(27° 0 ) 
17 (19° 0 ) 
16 (18° 0 ) 
7 95 41(43° 0 ) 
6 89 28(31° 0 ) 
7 88 30 (34° 0 ) 
On continued maintenance treatment with a f3 blocker 
Placebo 
Nifedipine 
5 96 44(46° 0 ) 18(19°0 ) 
15 (14° 0 ) 3 104 35(34° 0 ) 
MI 0, pre-randomisation myocardial infarction; RI/MI 48 , recurrent ischaemia or myocardial infarction within 48 hours; Ml48, 
myocardial infarction within 48 hours. 
For myocardial infarction within 48 hours the 
nifedipine:placebo rate ratio was 2·0 with a 95% 
confidence interval (1·1, 3·6). The Policy Advisory 
Board recommended discontinuation of the trial on 
ethical grounds because of the observed adverse 
effect in the group on nifedipine alone and because 
the effects in the other groups were smaller than 
expected and would have required a much larger trial 
for adequate statistical power. 
This recommendation was accepted by the Execu-
tive Committee, which included the principal 
investigators of the participating centres. 
Measures to discontinue inclusion were put into 
effect immediately. 
Appendix II 
The baseline risk for recurrent ischaemia or myo-
cardial infarction within 48 hours is defined as the 
probability that recurrent ischaemia or myocardial 
infarction would occur within 48 hours given the 
patient's baseline characteristics and trial medication 
assignment to placebo. To estimate a patient's base-
terms of abnormalities present on the baseline elec-
trocardiogram and of changes in the pain electro-
cardiogram relative to the baseline electro-
cardiogram. We used separate codes to indicate that 
the baseline or the pain electrocardiogram was not 
available. The latter circumstance is of clinical rele-
vance because this would occur if the patient had 
arrived at the hospital after chest pain had subsided. 
VARIABLE SELECTION 
We used data on all patients to fit the logistic func-
tion. Variables indicating the patient's trial medica-
tion and pre-treatment with a f3 blocker were kept in 
the model all the time. 
Baseline characteristics were selected for inclusion 
in the model on the basis of their overall (statistical) 
contribution to prediction and on medical plau-
sibility. None of the characteristics related to the 
patient's history or medication before admission to 
hospital was selected. Only the interval since the last 
attack of chest pain and certain electrocardiographic 
characteristics proved to be predictive for recurrent 
ischaemia or myocardial infarction within 48 hours. 
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Table 6 Indicator variables (with coefficients and standard errors) retained in the logistic function of the baseline risk for 
recurrent ischaemia or myocardial infarction within 48 hours 
Indicator 
Pre-treatment with a [3 blocker 
Pain free interval < I hour 
Pain free interval between 1-3 hours 
Baseline ECG missing 
ST depression ~ 0·1 m V on baseline ECG 
Pain ECG absent 
More ST depression during pain than at baseline 













*Number of patients in whom the property considered was present. 
The baseline risk function was obtained by setting 
the variables representing the patient's actual trial 
medication to values representing treatment with 
placebo. 
Table 6 shows the variables that were eventually 
retained in the model with their coefficients and stan-
dard errors. 
STRATIFIED ANALYSIS 
Patients were ranked on the basis of their calculated 
baseline risk and were subsequently divided into 
three strata of low, medium, and high risk. The cut-
off points were chosen so that each stratum contained 
an equal number of patients in whom recurrent 
ischaemia or myocardial infarction within 48 hours 
had occurred. We calculated rate ratios as weighted 
averages of the stratum specific rate ratios for each 
trial medication comparison and for each variable of 
interest, 31 and thus adjusted for variability of the 
baseline risk. Confidence limits were calculated 
accordingly. 
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Samenvatting 
Patienten die een aanval van langdurige pijn op de 
borst in rust doormaken en medische hulp zoeken, 
worden in het algemeen naar een hartbewakingsaf-
deling doorverwezen wanneer de symptomen een 
acuut cardiaal lijden suggereren. De symptomen van 
deze patienten tonen een breed spectrum, dat varieert 
van een beeld dat karakteristiek is voor een zich 
ontwikkelend hartinfarct tot klachten van pijn op de 
borst die niet aan myocardischaemie gerelateerd 
lijken. Tussen deze uitersten kan het syndroom van 
onstabiele angina pectoris worden onderscheiden: 
angineuze pijn in rust, op basis van ischaemie van de 
hartspier waarbij geen (substantiele) necrose van 
hartspierweefsel lijkt op te (gaan) treden. 
In 1981 werd onder auspicien van het Inter-
universitair Cardiologisch Instituut Nederland de 
'Holland Interuniversity Nifedipinejmetoprolol Trial 
(HINT) opgezet. Doelstelling van dit gerando-
miseerde, dubbel-blinde en placebo-gecontroleerde 
onderzoek was nate gaan in welke mate de calcium-
antagonist nifedipine en de beta-receptor blok-
kerende stof metoprolol (alleen of in combinatie) 
nieuwe ischaemische episodes en de ontwikkeling van 
een hartinfarct voorkomen bij patienten die bij 
opname in het ziekenhuis vermoedelijk een episode 
van onstabiela angina pectoris doormaken. De 
klinische effectiviteit van deze stoffen bij deze indi-
catie was op dat moment slechts in beperkte mate 
onderzocht. Aan het onderzoek werd medewerking 
verleend door de acht cardiologische afdelingen die 
aangesloten zijn bij het Interuniversitair Cardio-
logisch Instituut Nederland en door een drietal 
afdelingen van grate niet-universitaire ziekenhuizen. 
Het onderzoek werd financieel mogelijk gemaakt 
door het Ministerie van Onderwijs via het Inter-
universitair Cardiologisch Instituut Nederland. 
Tevens werden subsidies ontvangen van Bayer 
GmbH, Duitsland en Hassle AB, Zweden. 
De eerste patient werd in het onderzoek opgeno-
men op I februari 1981. Op 30 oktober 1984 werd 
verdere voortzetting van het onderzoek gestaakt 
omdat tussentijdse gegevens de indruk wekten dat 
het risico op een hartinfarct hager was bij behande-
ling met nifedipine aileen in vergelijking met de ove-
rige behandelingen. De belangrijkste bevindingen van 
dit onderzoek werden in 1986 in het British Heart 
Journal gepubliceerd, welke publicatie als appendix 
aan dit proefschrift is toegevoegd. Dit proefschrift 
bevat een meer gedetailleerde rapportage van dit 
onderzoek. 
Begonnen wordt met een uiteenzetting van de 
pathofysiologie van onstabiele angina pectoris en een 
overzicht van vigerende opvattingen over behande-
ling. Het klinisch syndroom van onstabiele angina 
pectoris wordt meestal veroorzaakt door een plot-
seling optredende verminderde toevoer van zuur-
stofrijk bloed naar ( een gedeelte van) de hartspier. 
Een gedeeltelijke of tijdelijke afsluiting van een 
kranslagader ten gevolge van de vorming van een 
thrombus op de plaats van een breuk in een athero-
sclerotische plaque (a! dan niet in combinatie met 
vasoconstrictie) geldt als de meest waarschijnlijke 
oorzaak. In eerste instantie is het klinisch beleid erop 
gericht nieuwe aanvallen van pijn op de borst en de 
ontwikkeling van een hartinfarct te voorkomen. De 
behandeling bestaat uit bedrust, sedatie, en toedien-
ing van nitraten, beta-receptor blokkerende stoffen, 
calcium-antagonisten, of heparine (a! dan niet in 
combinatie). Op deze wijze wordt getracht het 
zuurstofverbruik en de zuurstofvoorziening van de 
hartspier in gunstige zin te belnvloeden. Wanneer een 
intensieve medicamenteuze behandeling niet voor-
komt dat zich nieuwe aanvallen van pijn op de borst 
voordoen, onstaat een indicatie voor spoedangio-
grafie (Hoofdstuk 1). 
De methodologische grondslagen van klinisch 
interventieonderzoek worden aan een beschouwing 
onderworpen. Een therapeutisch experiment (clinical 
trial) wordt gezien als een instrument om een 
behandelingseffect te meten. De methodologie van 
een therapeutisch experiment is een afgeleide van 
eisen van zuiverheid (accuracy) en precisie aan een 
meetinstrument. Een therapeutisch experiment wordt 
verder gezien als een experimenteel epidemiologisch 
onderzoek (Hoofdstuk 2). 
Ten behoeve van dit onderzoek werd onstabiele 
angina pectoris gedefinieerd als het optreden van 
angineuze pijn in rust die minstens 15 minuten aan-
hield, en die hetzij spontaan verdween of reageerde 
op glyceryl trinitraat (sublinguaal of een bolusin-
jectie) of een kleine dosis fentanyl. Indien een episode 
van pijn op de borst plaats vond in het ziekenhuis, 
was de aanwezigheid van ST-segment ofT-top ver-
anderingen in het electrocardiogram een vereiste voor 
toelating tot het onderzoek. Indien de pijn reeds 
verdwenen was voor opname in het ziekenhuis, kon 
de patient worden toegelaten bij aanwezigheid van 
een afwijkend electrocardiogram, tekenen van een 
eerder doorgemaakt hartinfarct, of angiografisch 
aangetoonde vernauwingen van de kranslagaderen. 
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Tot het onderzoek werden 668 patienten toegelaten. 
Een commissie stelde vast dat bij 131 patienten het 
toelatingsprotocol niet op de juiste wijze gevolgd was. 
Aangezien deze patienten geen onstabiele angina 
pectoris hadden volgens bovengenoemde criteria, 
werden ze van de verdere analyse uitgesloten. De 
overige 537 patienten vormen het HINT-cohort 
(Hoofdstuk 3). 
Patienten die bij opname niet reeds met een beta-
receptor b1okkerende stof werden voorbehande1d, 
werden behandeld met nifedipine-placebo en meto-
prolo1-p1acebo, nifedipine (6 x 10 mg/24 u) en meto-
prolol-placebo, nifedipine-placebo enmetoprolol (2 x 
100 mg/24 u), of de combinatie van beide actieve 
stoffen. Bij patienten die bij opname reeds met een 
beta-receptor blokkerende stof werden behande1d, 
werd naast voortzetting van deze behandeling nife-
dipine placebo of nifedipine (6 x 10 mg/24 u) als 
onderzoeksbehandeling ingesteld. Patienten die bij 
opname reeds werden behandeld met nifedipine, 
werden van het onderzoek uitgesloten. Patienten 
werden a-select (random) toegewezen aan een van 
bovengenoemde behandelingen. Deze werd vervol-
gens gedurende minstens 48 uur voortgezet, tenzij 
zich een contra-indicatie voordeed. Het effect van de 
behandelingen werd afgemeten aan het optreden 
van nieuwe ischaemische episodes (pijn op de borst 
met veranderingen in het electrocardiogram) of de 
ontwikke1ing van een hartinfarct (stijging van de 
hartenzymen) binnen de observatieperiode van 48 
uur. Een commissie bestaande uit drie ervaren cardio-
logen heeft voor iedere patient vastgesteld of en 
zo ja, welke van bovengenoemde gebeurtenissen zich 
hadden voorgedaan. De !eden van de commissie 
waren niet op de hoogte van de feitelijke behandeling. 
Bij 4% van de 537 patienten bleken de hartenzymen 
reeds verhoogd op het moment van randomisatie; 8% 
was bezig met het doormaken van een acuut hartin-
farct; 9% maakte een hartinfarct door binnen 48 uur; 
19% maakte binnen 48 uur een of meerdere nieuwe 
episodes van pijn op de borst (zonder infarcering) 
door; de overige 60% had een ongecompliceerd 
beloop over de eerste 48 uur. Onder patienten die 
bij opname niet reeds werden voorbehandeld met 
een beta-receptor blokkerende stof, deed zich een 
ischaemische episode of een hartinfarct voor bij 37% 
van 84 met placebo behande1de patienten; onder 
nifedipine bij 47% van 89 patienten; onder meto-
prolol bij 28% van 79 patienten; en onder gecombin-
eerde behandeling bij 30% van 86 patienten. Bij 
patienten die bij opname reeds voorbehandeld waren 
met een beta-receptor blokkerende stof, deed zich een 
ischaemische episode of een hartinfarct voor bij 51% 
van 81 met placebo behandelde patienten en bij 30% 
van 96 met nifedipine behandelde patienten. De 
gebeurtenissen die optraden, betroffen in de helft van 
de gevallen een hartinfarct en in de andere helft een 
aanval van pijn op de borst met ST-segment ofT-
top veranderingen (Hoofdstuk 4). 
Het effect van actieve medicatie werd (ten opzichte 
van placebo) uitgedrukt als de ratio van het per-
centage patienten waarbij een ischaemische episode 
of een harlinfarct was opgetreden onder actieve 
medicatie ten opzichte van placebo (het relatieve 
risico). Een relatief risico van I duidt op gelijke 
effectiviteit van de vergeleken stoffen, een waarde 
kleiner dan I op een gunstige werking van het actieve 
preparaat en een waarde groter dan 1 op een 
ongunstige werking. De onzekerheid in de schatting 
van het behandelingseffect werd aangegeven met het 
95%-betrouwbaarheidsinterval. Uit een multivariate 
analyse bleek dat het uitgangsrisico voor het optre-
den van een ischaemische episode of een hartinfarct 
hoofdzakelijk bepaald werd door de duur van de 
periode waarover de patient reeds pijnvrij was, en 
bepaalde electrocardiografische afwijkingen. Het 
uitgangsrisico voor het optreden van een ischae-
mische episode of een hartinfarct bleek ongelijk ver-
deeled over de behandelingsgroepen. Bij de schatting 
van behandelingseffecten werd hiervoor gecorrigeerd 
door middel van gestratificeerde analyse. Onder 
patienten die niet met een beta-receptor blokkerende 
stof waren voorbehandeld, was het (gecorrigeerde) 
relatieve risico I, 15 (0,83-1 ,64) voor nifedipine, 0, 76 
(0,49-1, 16) voor metoprolol, en 0,80 (0,53-1, 19) voor 
de combinatiebehandeling. (Deze relatieve risico's 
zijn ten opzichte van placebo; tussen haakjes staan 
95%-betrouwbaarheidsintervallen). Onder patienten 
die reeds met een beta-receptor blokkerende stof 
waren voorbehandeld, was het relative risico voor 
(toevoeging van) nifedipine 0,68 (0,47--(),97) 
(Hoofdstuk 5). 
De praktische uitvoering van het onderzoek wordt 
beschreven (Hoofdstuk 6), alsmede de gegevens en de 
overwegingen die een rol gespeeld hebben bij de 
voortijdige beeindiging van het onderzoek (Hoofd-
stuk 7). 
Bevindingen van andere recent gepubliceerde 
gerandomiseerde onderzoekingen naar het effect 
van beta-receptor blokkerende stoffen of calcium-
antagonisten bij patienten met klachten duidend op 
acute ischaemie van de hartspier worden aan een 
kritische beschouwing onderworpen. Speciale aan-
dacht wordt besteed aan de generalizeerbaarheid van 
de bevindingen naar klinisch herkenbare indicaties 
(Hoofdstuk 8). 
De bevindingen van HINT, tezamen met die van 
andere recent gepubliceerde onderzoekingen naar het 
effect van beta-receptor blokkerende stoffen bij 
patienten met een vermoedelijk hartinfarct, geven 
aan dat behandeling met metoprolol (of met andere 
beta-receptor blokkerende stoffen zoals atenolol) 
het klinisch beloop bij klachten duidend op acute 
ischaemie van de hartspier in beperkte mate in 
gunstige zin belnvloedt. De bevindingen van HINT, 
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tezamen met die van andere onderzoekingen, wijzen 
erop dat behandeling met nifedipine het klinisch 
beloop bij dezelfde indicatie niet in gunstige zin 
belnvloedt. Echter, wanneer het klinisch beeld van 
onstabiele angina pectoris ontstaan in rust zich ont-
wikkelt ondanks chronische behandeling met een 
beta-receptor blokkerende stof, lijkt toevoeging van 
nifedipine het klinisch beloop in gunstige zin te beln-
vloeden (Hoofdstuk 9). 
Het Engelstalige gedeelte van dit proefschrift zal in een supplement van het European Heart Journal worden gepubliceerd. 
De cardiologen S. G~lds.tein (Detroit), D. G. Julian (Newcastle upon Tyne), en H. Kulbertus (Luik) is gevraagd hun 
conclus1es mt de bevmdmgen van het HINT-onderzoek te verwoorden. Dit commentaar zal worden opgenomen in 
bovengenoemd supplement. 
Woorden van dank 
Het in dit proefschrift beschreven onderzoek is het 
resultaat van de inspanning van vele anderen naast 
de auteur. Ik wil allen die bijgedragen hebben tot de 
totstandkoming van dit werk bedanken. 
Een bijzondere plaats wordt hierbij ingenomen 
door de patienten die bereid geweest zijn dee! te 
nemen aan dit onderzoek. Ik hoop dat toekomstige 
patienten voordeel zullen hebben van hun hereid-
willige medewerking. 
Daarnaast dank ik het Interuniversitair Cardiolo-
gisch Instituut Nederland voor het opzetten van de 
infrastructuur waarin dit onderzoek kon worden 
uitgevoerd en het Thoraxcentrum te Rotterdam voor 
het creeren van de werkomgeving van waaruit het 
onderzoek kon worden gecoordineerd. 
Koos Lubsen heeft Ieiding gegeven aan de uitvoe-
ring van het onderzoek. Zander zijn voortdurende 
steun en stimulans zou dit proefschrift er niet geko-
men zijn. Zijn door Professor P. G. Hugenholtz 
gesteunde opvatting dat voor goed klinisch onder-
zoek een combinatie van klinische expertise en epi-
demiologisch/statistische deskundigheid een vereiste 
is, heeft geleid tot de totstandkoming van de afdeling 
klinische epidemiologie binnen het Thoraxcentrum. 
Dit proefschrift werd geconcipieerd vanuit dezelfde 
invalshoek. Het is een voorrecht betrokken geweest 
te zijn bij zijn wetenschappelijk werk. Ik heb daar 
vee! van geleerd en zeg hem daarvoor en voor de 
vriendschappelijke wijze waarop we samenwerkten, 
hartelijk dank. 
Maarten Simoons heeft een onmisbare rol vervuld 
zowel bij de uitvoering van het onderzoek als bij de 
totstandkoming van dit proefschrift. Vanaf mijn 
eerste schreden in het Thoraxcentrum hebben zijn 
positieve invloed en vertrouwen mij zeer gei:nspireerd. 
Naast zijn inbreng bij de verwerving van de beno-
digde klinisch cardiologische kennis was ook zijn 
scherpzinnige kritiek op methodologisch- epidemio-
logisch dogma van onschatbare waarde. 
De overige !eden van de promotie-commissie, Pro-
fessor P. G. Hugenholtz, Professor Dr F. L. Meijler 
en Professor Dr J. P. Vandenbroucke hebben het 
manuscript van commentaar voorzien. Hun opbou-
wende kritiek heb ik in hoge mate gewaardeerd. 
Verder ben ik vee! verschuldigd aan a! degenen die 
meegewerkt hebben aan de uitvoering van het 
onderzoek. De langdurige ondersteuning van de 
Wetenschappelijke Raad van het Interuniversitair 
Cardiologisch Instituut Nederland, voor deze gele-
genheid aangevuld met de hoofden van de dee!-
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nemende niet-universitaire klinieken, voor zowel het 
onderzoek als de voorbereiding van het proefschrift 
heb ik zeer op prijs gesteld. Het onderzoek werd 
begonnen onder het inspirerend voorzitterschap van 
wijlen Professor Dr D. Durrer en werd voltooid 
nadat Professor Dr F. L. Meijler deze taak had 
overgenomen. I thank the members of the Policy 
Advisory Board for improving the design and execu-
tion of the trial and for assuming the responsibilities 
of treatment monitoring. De bijdrage van de !eden 
van de classificatie-commissie kan aileen worden 
omschreven met het adjectief 'kolossaal'. Rapporten 
van een kleine 700 patienten (met in totaal ongeveer 
10.000 electrocardiogrammen) werden tot in de 
kleinste details beoordeeld. Ik heb de vriendschap-
pelijke en professionele atmosfeer tijdens de vaak 
langdurige avond- en weekendsessies zeer op prijs 
gesteld. Ik ben hen (en hun gezinsleden) zeer er-
kentelijk voor deze bijdrage. 
De medewerkers van het coordinatie-centrum heb-
ben, ieder op zijn of haar eigen wijze, bijgedragen 
aan de uitvoering van het onderzoek, waarvoor ik hen 
hartelijk bedank. Jurn Kerkkamp heeft een belang-
rijke bijdrage geleverd aan de coordinatie van het 
onderzoek en heeft het electrocardiografische en 
angiografische gegevensbestand opgebouwd. Ron 
van Domburg heeft de programmatuur voor de 
geautomatiseerde gegevensverwerking verzorgd. 
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